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Fetal and neonatal exposure to neurotoxicants
have adverse effects on neurodevelopment.
Early (small) effects of xenobiotics on the
brain could aggravate these effects during
development, creating a critical window for
neurotoxicity. However, the underlying
mechanisms are not well understood (Szpir
2006). Recently, a range of behavioral and
neurochemical effects have been described for
polychlorinated biphenyls (PCBs) (for review,
see Fonnum et al. 2006; Mariussen and
Fonnum 2006). Nowadays, the increasing
concentrations of the structurally related
polybrominated diphenyl ethers (PBDEs) in
the environment, human food chain, and
human tissues (Hites 2004) raise concern
about possible neurotoxic effects. In most
samples, 2,2´,4,4´-tetrabromodiphenyl ether
(BDE-47) is the predominant congener.
PBDEs are used as ﬂame retardants in a range
of products, including electronic equipment,
furniture, construction materials, and textiles.
Of concern is that children, at the age of
early brain development, accumulate BDE-47
more rapidly than adults because of their diet
(breast-feeding/relatively large intake) and
behavior (contact with house-dust) (Jones-
Otazu et al. 2005). Distribution studies show
that developing mice reach higher tissue con-
centrations of BDE-47 compared with adult
mice after identical dosing regimens (Staskal
et al. 2006). Behavioral studies have demon-
strated adverse neurodevelopmental effects on
learning and memory after neonatal BDE-47
exposure. Habituation capability in mice,
studied by scoring spontaneous behavior after
placement in a new environment, is reduced
and this effect is long-lasting and increases
with age (Eriksson et al. 2001). 
Recently, a proteomics approach was
used to investigate the effect of a single oral
dose of 12 mg (21.2 μmol)/kg body weight
(bw) 2,2´,4,4´,5-pentabromodiphenyl ether
(BDE-99) on brain protein levels in mice,
24 hr after exposure. Levels of striatal proteins
associated with neurodegeneration and neuro-
plasticity and of hippocampal proteins associ-
ated with metabolism and energy production
were found to be changed (Alm et al. 2006).
It is unclear whether such changes occur after
exposure to other congeners, and whether
these protein changes have functional conse-
quences.
The main objective of our study was to
gain insight in the mechanisms underlying
the observed effects of BDE-47 on learning
and memory (Eriksson et al. 2001). To this
purpose we have investigated N-methyl-D-
aspartate (NMDA)-dependent long-term
potentiation (LTP) in hippocampal slices
from animals exposed to a dose of BDE-47
known to induce behavioral aberrations.
NMDA-dependent LTP has been used as an
electrophysiologic substrate for learning and
memories for many years. This form of LTP
is induced by tetanic stimulation, strong
depolarization, and a large increase in intra-
cellular Ca2+ level (for review, see Lynch
2004; Malenka and Nicoll 1999; Soderling
and Derkach 2000). Paired pulse facilitation
(PPF), a form of short-lasting plasticity that
presumably reflects presynaptic function
(Xu-Friedman and Regehr 2004), was inves-
tigated to reveal possible presynaptic effects
of BDE-47. In additional ex vivo experi-
ments, we investigated protein expression
levels in the postsynaptic density (PSD) and
catecholamine release from chromaffin cells
to further reveal underlying mechanisms.
Acute effects of BDE-47 on intracellular
Ca2+ and catecholamine release of PC12 cells
have been studied in vitro to assess the
involvement of transient acute effects on
potential presynaptic targets. Our findings
provide a functional basis for previously
observed neurobehavioral changes (Eriksson
et al. 2001).
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BACKGROUND: Increasing environmental levels of brominated ﬂame retardants raise concern about
possible adverse effects, particularly through early developmental exposure. 
OBJECTIVE: The objective of this research was to investigate neurodevelopmental mechanisms
underlying previously observed behavioral impairments observed after neonatal exposure to poly-
brominated diphenyl ethers (PBDEs).
METHODS: C57Bl/6 mice received a single oral dose of 2,2´,4,4´-tetrabromodiphenyl ether
(BDE-47) on postnatal day (PND) 10 (i.e., during the brain growth spurt). On PND17–19, effects
on synaptic plasticity, levels of postsynaptic proteins involved in long-term potentiation (LTP), and
vesicular release mechanisms were studied ex vivo. We investigated possible acute in vitro effects of
BDE-47 on vesicular catecholamine release and intracellular Ca2+ in rat pheochromocytoma
(PC12) cells.
RESULTS: Field-excitatory postsynaptic potential (f-EPSP) recordings in the hippocampal CA1 area
demonstrated reduced LTP after exposure to 6.8 mg (14 µmol)/kg body weight (bw) BDE-47,
whereas paired-pulse facilitation was not affected. Western blotting of proteins in the postsynaptic,
triton-insoluble fraction of hippocampal tissue revealed a reduction of glutamate receptor subunits
NR2B and GluR1 and autophosphorylated-active Ca2+/calmodulin-dependent protein kinase II
(αCaMKII), whereas other proteins tested appeared unaffected. Amperometric recordings in chro-
mafﬁn cells from mice exposed to 68 mg (140 µmol)/kg bw BDE-47 did not reveal changes in cate-
cholamine release parameters. Modest effects on vesicular release and intracellular Ca2+ in PC12
cells were seen following acute exposure to 20 µM BDE-47. The combined results suggest a post-
synaptic mechanism in vivo.
CONCLUSION: Early neonatal exposure to a single high dose of BDE-47 causes a reduction of
LTP together with changes in postsynaptic proteins involved in synaptic plasticity in the mouse
hippocampus.
KEY WORDS: αCaMKII, brain growth spurt, developmental neurotoxicity, ﬁeld-EPSP recording,
hippocampal synaptic plasticity, postsynaptic density. Environ Health Perspect 115:865–870
(2007). doi:10.1289/ehp.9860 available via http://dx.doi.org/ [Online 5 February 2007]Materials and Methods
Animals and chemicals. Male C57Bl/6 mice
pups (litters culled to 5 pups each) with
mother (Harlan, Horst, the Netherlands) were
housed in a standard animal facility on a 12-hr
light/dark cycle with food and water ad libi-
tum. Animals were treated humanely and with
regard for alleviation of suffering. All experi-
mental procedures were performed according
to Dutch law and approved by the Ethical
Committee for Animal Experimentation of
Utrecht University.
Male C57Bl/6 mice received a single oral
dose of vehicle [1:10 (wt/wt) mixture of egg
lecithin (Sigma-Aldrich, Zwijndrecht, the
Netherlands) and peanut oil (Oleum arachidis)
(Sigma-Aldrich), sonicated with water to
obtain a 20% (wt/wt) fat:water emulsion] or
6.8 mg (14 μmol)/kg bw BDE-47 via a metal
gastric tube on postnatal day (PND) 10 for
ﬁeld-excitatory postsynaptic potential (f-EPSP)
recordings and brain protein analysis, or 68 mg
(140 μmol)/kg bw BDE-47 for amperometric
recordings of chromaffin cells (to investigate
presynaptic effects) at PND17–19. Experi-
mental groups consisted of mice from different
nests. 
BDE-47 was synthesized and purified
(~ 99%) at the Wallenberg laboratory of
Stockholm University. For oral dosing, BDE-47
was dissolved in the egg lecithin/peanut oil
mixture and sonicated with water to obtain a
20% (wt/wt) fat:water emulsion. 
Hippocampal slice preparation. On
PND17–19 (directly after brain growth
spurt), the animals were killed by decapitation
after inhalation anesthesia (isoflurane), and
the brain was rapidly dissected on ice. Hippo-
campal slices were prepared as described pre-
viously (Van der Heide et al. 2005). Brieﬂy,
transverse hippocampal slices (450 μm) were
cut in ice-cold carbogenated Mg2+-enriched
artiﬁcial cerebrospinal ﬂuid (ACSF) [contain-
ing NaCl (124 mM), KCl (3.3 mM),
KH2PO4 (1.2 mM), MgSO4 (2.6 mM),
CaCl2 (2.5 mM), NaHCO3 (20 mM), and
glucose (10 mM)] using a Leica VT1000 S
vibrotome (Leica Microsystems, Wetzlar,
Germany). The slices were allowed to stabilize
at room temperature in carbogenated ACSF
(MgSO4: 1.3 mM) for at least 1.5 hr. 
Extracellular recording of ﬁeld potentials.
We recorded f-EPSPs in the CA1 region of
hippocampal slices as previously described by
Van der Heide et al. (2005), with minor modiﬁ-
cations. Slices were superfused with carbo-
genated ACSF (~ 2 mL/min) in a recording
chamber at 30°C. A bipolar stainless steel stimu-
lation electrode (Ø 0.1 mm) was placed on the
afferent ﬁbers of the stratum radiatum of the
hippocampal CA1 region, as shown in a Nissl-
stained hippocampal slice in Figure 1A. f-EPSPs
were recorded with ACSF-filled glass micro-
electrodes using an Axoclamp-2B amplifier
(Axon Instruments, Foster City, CA, USA).
Data were digitized and stored using “Spike2”
software (Cambridge Electronic Design,
Cambridge, UK). 
Stimulation intensities for threshold and
maximum f-EPSPs were determined. Slices
with a maximum response amplitude of
≥ 1 mV were included in the experiment.
During baseline recording, half-maximum
f-EPSPs were evoked every 30 sec. After 15 min
baseline recording, LTP was induced with a
single tetanic stimulation (100 Hz, 1 sec) and
f-EPSPs were recorded for another 30 min.
PPF, with interstimulus intervals of 50, 100,
200, 500, and 1,000 msec, was recorded under
identical conditions as for LTP. 
For data analysis, we determined initial
slopes of the f-EPSPs (Figure 1B). For quantiﬁ-
cation of LTP, the slope was normalized
against the average f-EPSP slope during base-
line. Average relative increase of the slope was
determined 20–30 min after tetanic stimula-
tion as a measure for LTP and 0–7.5 min after
tetanic stimulation as a measure for post-
tetanic potentiation (PTP) in the individual
animals. To determine PPF, paired-pulse ratio
(PPR) was determined by dividing the slope of
the second average f-EPSP by the slope of the
ﬁrst average f-EPSP (n = 10). 
Western blotting analysis. We performed
Western blotting analysis as described previ-
ously by Gardoni et al. (2006), with minor
modifications. The triton-insoluble fraction
(TIF) was puriﬁed from blind samples of sin-
gle cortices and hippocampi of control (n =4 )
and BDE-47–exposed animals [6.8 mg
(14 μmol)/kg bw; n = 4] using a previously
validated biochemical fractionating method
(Gardoni et al. 2006), in the presence of pro-
tease inhibitors (CompleteTM; Roche
Diagnostics, Basel, Switzerland) and phos-
phatase inhibitors (Sigma, St. Louis, MO,
USA). Similar protein yield was obtained in
TIF purified from cortex (~ 200 μg) and
hippocampi (~ 50 μg) of both groups. Protein
composition of this preparation was tested for
the absence of presynaptic marker synapto-
physin (Gardoni et al. 2001) and enrichment
in the PSD proteins (Gardoni et al. 2006).
Samples (3 μg) were applied to SDS-PAGE
and electroblotted. For each TIF preparation
three independent western blotting experi-
ments were run. After blocking nonspecific
protein interactions with 10% albumin in Tris-
buffered saline (TBS), the nitrocellulose papers
were incubated for 2 hr at room temperature
with the primary antibodies: NR1 (1:1000;
Pharmingen, San Diego, CA, USA), NR2A
(1:1000; Zymed, San Francisco, CA, USA),
NR2B (1:1000; Zymed), GluR1 (1:1500;
Chemicon, Temecula, CA, USA), PSD-95
(1:2000; Afﬁnity BioReagents, Golden, CO,
USA), SAP97 (1:1000; StressGen, San Diego,
CA, USA), Ca2+/calmodulin-dependent 
protein kinase II (αCaMKII; 1:3000;
Chemicon), and p286-αCaMKII (1:1000;
Promega, San Luis Obispo, CA, USA) in 3%
albumin in TBS. After extensive rinsing in
TBS/0.1% Tween 20, the nitrocellulose
papers were incubated with horseradish perox-
idase–conjugated secondary antibodies.
Finally, the antigen–antibody complex was
revealed by enhanced chemiluminescence
(ECL; Amersham Biosciences, Little Chalfont,
UK). Quantiﬁcation was performed by means
of a Quantity-One computer-assisted imaging
system (Bio-Rad, Hercules, CA, USA).
Intracellular Ca2+ imaging. We investi-
gated acute effects of BDE-47 in vitro in
PC12 cells. PC12 cells were subcultured in
poly-L-lysine–coated glass-bottom cell culture
dishes (MatTek, Ashland MA, USA) at 37°C,
5% CO2 as described previously (Westerink
et al. 2000). We used the high-afﬁnity Ca2+-
responsive fluorescent dye Fura 2-AM
(Molecular Probes; Invitrogen, Breda, the
Netherlands) to measure the intracellular
Ca2+ concentration. PC12 cells were incu-
bated with Fura 2-AM (5 μM, 20 min at
room temperature) in saline containing CaCl2
(1.8 mM), glucose (24 mM), Hepes
(10 mM), KCl (5.5 mM), MgCl2 (0.8 mM),
NaCl (125 mM), and sucrose (36.5 mM) at
pH 7.3 (adjusted with NaOH). After incuba-
tion, the cells were washed with saline and left
at room temperature for 15 min to allow
intracellular deesterification of Fura 2-AM.
After deesteriﬁcation, the cells were placed on
the stage of an Axiovert 35M inverted micro-
scope (Zeiss, Göttingen, Germany) equipped
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Figure 1. f-EPSP recordings in the CA1 region of
hippocampal slices. (A) Placement of bipolar stimu-
lation electrode and ACSF-filled microelectrode in
CA1 region in a Nissl-stained hippocampal slice;
bar = 200 µm. (B) Representative f-EPSP recording.
For data analysis, the initial slope is determined
between dots.
A
Bwith a TILL Photonics Polychrome IV (TILL
Photonics GmBH, Gräfelfing, Germany).
Fluorescence evoked by 340 and 380 nm
excitation wavelengths (F340 and F380) was
collected at 510 nm with an Image SensiCam
digital camera (TILL Photonics GmBH). The
digital camera and polychromator were con-
trolled by imaging software (TILLvisION,
version 4.01), which was also used for data
collection and processing. The F340/F380
ratio, which is a qualitative measure for intra-
cellular Ca2+ concentration, was measured
every 20 sec during baseline. After 5 min
baseline recording, BDE-47 was bath-applied
to obtain final concentrations of 2 and
20 μM, and ratios were collected every 6 sec.
Maximum and minimum ratios were deter-
mined after 25 min recording by addition of
ionomycin (5 μM) and EDTA (17 mM) as a
control for experimental conditions.
Amperometry. We measured spontaneous
and K+-evoked catecholamine release using
carbon fiber microelectrode amperometry
from isolated chromafﬁn cells and PC12 cells
as described previously (Westerink and
Vijverberg 2002). Chromafﬁn cells from mice
exposed to vehicle or 68 mg (140 μmol)/kg
bw BDE-47 were isolated and cultured as
described previously (Westerink et al. 2006). 
PC12 cells were superfused with BDE-47
for 15 min to investigate acute effects on
vesicular catecholamine release. Recordings
were performed at room temperature. PC12
cells with high basal release (> 5 events/min)
or low evoked release (< 16 events/min) were
excluded for data analysis (3/25 cells). 
Statistical analysis. All data are presented
as mean ± SE. PC12 data were compared using
Student’s paired t-test. We ﬁrst compared the
LTP data using a two-way analysis of variance
(ANOVA) with post hoc Bonferroni testing
(Sigmastat software; Systat Software Inc,
Erkrath, Germany), followed by additional
unpaired t-tests to specify the effects on PTP
and LTP. We used unpaired Students’ t-test
for all other data.
Results
Pups exposed to BDE-47 did not differ in
body weight and relative thymus weight com-
pared with their unexposed littermates (data
not shown), indicating the absence of general
toxicity, treatment-dependent food competi-
tion, extensive immune suppression, and
stress. Additionally, visual inspection of the
brain slices of exposed pups did not show any
changes of general hippocampus morphology
(data not shown). 
Figure 2 shows the results from f-EPSP
recordings in the CA1 region of mouse hip-
pocampus for control and BDE-47–exposed
groups. No differences in stimulus–response
relation were seen. No effects were observed
on half-maximum f-EPSP slopes before LTP
induction (control: 682 ± 138 V/sec; BDE-47
exposed animals: 679 ± 92 V/sec). 
After tetanic stimulation, an immediate
large increase of the f-EPSP is apparent,
although the increase is signiﬁcantly lower in
the BDE-47–exposed group than in the con-
trol group. The increase of the f-EPSP during
the first 7.5 min post-tetanus is classified as
PTP. In the BDE-47–exposed mice, there
was signiﬁcantly less PTP (135 ± 9%) than in
the control mice (190 ± 17%) (p < 0.01)
(Figure 2). After PTP the f-EPSP size
decreases but stabilizes at a higher level than
baseline. This level of LTP is maintained for
at least 30 min. In the BDE-47–exposed
mice, LTP was signiﬁcantly lower (130 ± 7%)
than in the control group (165 ± 16%)
(p < 0.05). The signiﬁcance of these ﬁndings
was confirmed by two-way ANOVA with
post hoc Bonferroni testing. The trace inset
illustrates the enhancement of f-EPSPs after
tetanic stimulation. The cumulative probabil-
ity curve of LTP in the individual experiments
(Figure 2) indicates a shift to lower LTP values
in the BDE-47 group.
Figure 3 shows the effect of BDE-47 on
PPF at different interstimulus intervals. For
the 50-msec interstimulus interval, the PPR
was 1.98 ± 0.11% in the control group and
1.87 ± 0.15% in the BDE-47 group. For the
1,000-msec interstimulus interval, the PPR
was decreased to 1.16 ± 0.03% in the control
group and 1.08 ± 0.03% in the BDE-47
group. Insets show representative recordings
of PPF. No effects of BDE-47 on PPR were
detected. 
Because activation of NMDA receptors is
required for LTP, the reduction of LTP in
BDE-47–treated mice could reflect an alter-
ation of NMDA receptor-associated signaling
elements. Because the NMDA receptor com-
plex is enriched in the PSD, we used Western
blot analysis to measure protein levels of
NMDA receptor subunits and other PSD-
associated signaling proteins in total
homogenate and TIF, representing the PSD
compartment by Western blot analysis
(Gardoni et al. 2001). Protein composition of
this preparation was carefully tested for the
absence of presynaptic markers and enrich-
ment in PSD proteins (Figure 4A; Gardoni
et al. 2001). Representative Western blots for
all investigated proteins in hippocampal
homogenate and TIF are also shown in
Figure 4B. BDE-47 had no effects on protein
levels in cortical homogenate and TIF (data
not shown) and hippocampal homogenate
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Figure 2. Exposure to 6.8 mg (14 µmol)/kg bw BDE-47 reduces PTP (0–7.5 min after tetanus at t = 0) and LTP
(20–30 min) in hippocampal neurons in BDE-47–exposed mice (n = 8) compared with control mice (n = 5).
The upper left inset shows superimposed traces illustrating the enhancement of the f-EPSP by LTP induc-
tion. The bar diagram insets in the dashed frames show averages of data. The upper right inset shows the
cumulative probability (cum prob) curve of LTP in the individual experiments. 
*p < 0.05; **p < 0.01.
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)(Figure 4C). Figure 4C shows amounts of the
proteins in TIF of the hippocampus of
BDE-47–exposed mice compared with con-
trol mice. Signiﬁcant changes in protein levels
of NMDA receptor subunits NR1 and
NR2A, and NMDA receptor interacting pro-
teins PSD-95 and SAP97 were not detected.
However, protein levels of NMDA receptor
subunit NR2B (75 ± 2%) and α-amino-5-
hydroxy-3-methyl-4-isoxazole propionic acid
(AMPA) receptor subunit GluR1 (71 ± 4%)
were significantly reduced (p < 0.01). There
was a signiﬁcant decrease in the autophospho-
rylated-active form of αCaMKII (p286-
αCaMKII) to 65 ± 8% of control level
(p < 0.05), although total αCaMKII was not
changed.
In the experiments described above, post-
synaptic effects of BDE-47 are observed,
whereas presynaptic functional effects are not
detected. However, possible effects on pre-
synaptic mechanisms might remain unde-
tected at a dose of 6.8 mg (14 μmol)/kg bw
BDE-47. To ascertain the apparent absence of
presynaptic effects of BDE-47, we investigated
effects on catecholamine release in chromafﬁn
cells obtained from mice exposed to vehicle or
to a higher dose (68 mg (140 μmol)/kg bw) of
BDE-47. No changes were detected in the dif-
ferent parameters of vesicular catecholamine
release; that is, basal and high-K+ evoked
release frequency and vesicular release parame-
ters like quantal size (vesicle content), spike
amplitude, and 50–90% rise time (data not
shown).
Additional in vitro experiments were per-
formed in PC12 cells to investigate acute effects
of BDE-47 exposure on calcium homeostasis
and release mechanisms. Figure 5A shows the
average F340/F380 ratio in PC12 cells during
bath application of DMSO, 2 μM BDE-47,
and 20 μM BDE-47 normalized to baseline
(first 5 min). The higher concentration of
BDE-47 induced an increase in normalized
F340/F380 ratio (t = 12–24 min, p < 0.01).
To investigate whether the increase in intra-
cellular Ca2+ has functional consequences,
vesicular catecholamine release was also inves-
tigated (Figure 5B). The average number of
amperometrically recorded events of vesicular
release amounted to 1.9 ± 0.7 events/min (n =
9) in control experiments. During superfusion
with 20 μM BDE-47, the release frequency
was enhanced to 6.0 ± 1.7 events/min (n = 6;
p < 0.05), whereas superfusion with 2 μM
BDE-47 caused no detectable effect (1.2 ± 0.5
events/min; n = 7). BDE-47 had no effect on
release evoked by high-K+ depolarization of the
cells. Differences in vesicular release parameters
could not be detected (data not shown). 
Discussion
A broad spectrum of neurotoxicants (e.g.,
environmental pollutants such as metals, pesti-
cides, and PCBs) has been shown to cause a
reduction of habituation after neonatal expo-
sure (Eriksson et al. 1990, 1991; Eriksson and
Fredriksson 1991; Fredriksson et al. 1992).
However, from the behavioral effects it is difﬁ-
cult to deduce information about underlying
mechanisms.
In the present study, we found that neo-
natal exposure to BDE-47 causes developmen-
tal effects consisting of a reduction of PTP and
LTP, as well as speciﬁc reductions of key post-
synaptic proteins involved in glutamate recep-
tor signaling. Presynaptic parameters were not
affected ex vivo. In vitro experiments on PC12
cells show an increase in intracellular Ca2+ and
spontaneous vesicular release, only at the 
highest concentration BDE-47 (20 μM). The
combined results suggest that presynaptic
changes do not directly contribute to the
observed defect in synaptic plasticity.
The exposure to BDE-47 took place dur-
ing a period of rapid brain growth, which in
mice takes place during the ﬁrst 3–4 weeks of
life, reaching its peak around PND10
(Davison and Dobbing 1968). The multitude
and complexity of processes during this rapid
development makes the developing brain par-
ticularly vulnerable to the effects of xeno-
biotics, like the adverse effect of BDE-47 on
spontaneous behavior and habituation
(Eriksson et al. 2001). Interestingly, exposure
to BDE-47 does not affect performance in the
Morris water maze test (Eriksson et al. 2001),
commonly used as a learning task to detect
effects in the hippocampus. This suggests that
habituation is a more sensitive parameter for
BDE-47 effects in the hippocampus.
We observed a specific reduction of key
proteins in the PSD (i.e., GluR1, NR2B, and
p286-αCaMKII). Because no changes were
observed in total hippocampus homogenate,
the specific decrease in the PSD is therefore
attributed to changes in glutamate receptor
subunit trafficking or clustering in the PSD
instead of a reduced protein translation. 
A study in GluR1-knockout mice showed
that approximately 10% of the normal amount
Dingemans et al.
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Figure 4. Effects of 6.8 mg (14 µmol)/kg bw BDE-47 on levels of postsynaptic proteins in the hippocampus of control (Ctrl; n = 4) and BDE-47–exposed (n = 4) mice.
(A) Western blotting for NR2B, PSD-95, αCaMKII, and synaptophysin in homogenate (Hom) and TIF from hippocampus. (B) Representative Western blots of the inves-
tigated postsynaptic proteins in hippocampal homogenate (Hom) and TIF. (C) Relative amount of postsynaptic proteins in hippocampal TIF (representing the PSD).
*p < 0.05. **p < 0.01.
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of GluR1 is sufficient for LTP (Mack et al.
2001). Also, a GluR1-independent form of
LTP has been observed in juvenile GluR1-
knockout mice (Jensen et al. 2003). Therefore,
major effects on LTP as a consequence of the
observed reduction of AMPA subunit GluR1
by approximately 30% are not expected. 
The observed reduction of NR2B subunits
results in an increased NR2A/NR2B ratio.
The majority of NMDA receptors consist of
2 NR1 and 2 NR2A or 2 NR2B subunits.
NR2A-NMDA receptors gate smaller Ca2+
currents, have a lower afﬁnity for glutamate,
and desensitize faster than NR2B-NMDA
receptors (Kutsuwada et al. 1992). Therefore,
an increased NR2A/NR2B ratio is likely to
result in a higher threshold for LTP induction,
which could explain the reduction of PTP and
LTP. 
In mice exposed to BDE-47, the auto-
phosphorylated-active form of αCaMKII was
significantly reduced. Because CamKII
autophosphorylation is essential for hippo-
campal NMDA-dependent LTP (Giese et al.
1998), this speciﬁc effect may lead to reduced
synaptic plasticity resulting in behavioral
impairments.
To ascertain the absence of presynaptic
effects, we investigated neurotransmitter release
from chromafﬁn cells from BDE-47–exposed
[68 mg (140 μmol)/kg bw] mice. Because PPR
and chromaffin neurotransmitter release
remained unchanged after developmental
exposure to BDE-47, and because modest
acute effects on free intracellular Ca2+ and
spontaneous vesicular catecholamine release in
PC12 cells were only detected at a concentra-
tion of 20 μM BDE-47, we propose that presy-
naptic changes do not contribute considerably
to the observed functional defect in synaptic
plasticity. Based on tissue distribution data for
1 mg/kg bw 14C-BDE-47 orally given to
C57Bl/6 mice on PND10 (Staskal et al. 2006),
brain concentration at sacriﬁce after exposure
to 6.8 mg (14 μmol)/kg bw BDE-47 is esti-
mated to be 0.43–0.81 μM and the peak brain
concentration, reached 8 hr after exposure, is
estimated to be 1.1 μM. These estimated con-
centrations are at least one order of magnitude
lower than the lowest effective concentration in
the in vitro experiments described here. 
As with PCBs (for review, see Fonnum
et al. 2006), in vitro exposure to the commer-
cial penta-BDE mixture DE-71, which con-
tains (on a weight basis) 31.8% BDE-47
(Reistad and Mariussen 2005), affects several
other transmitter systems. Previous studies
reported cell death of cerebellar granule cells,
alterations of Ca2+ homeostasis in human
neutrophils and brain microsomes, and
arachidonic acid release and protein kinase C
translocation in cerebellar granule cells; inhi-
bition of dopamine reuptake in rat brain
synaptic vesicles has been reported after
in vitro exposure to DE-71 in the micromolar
range (2–20 μM) (Kodavanti and Ward
2005; Mariussen and Fonnum 2003; Reistad
et al. 2002; Reistad and Mariussen 2005).
Interestingly, addition of the NMDA receptor
antagonist MK801 protects cerebellar granule
cells against DE-71-induced cell death (Reistad
et al. 2006). No other effects of PBDEs on glu-
tamate receptors have yet been published. 
Pure (~ 99%) BDE-47, which has been
used in only a few experiments, has revealed
formation of reactive oxygen species in human
neutrophils and increased 3H-phorbol ester
binding in primary rat cerebellar granule neu-
rons, also at micromolar concentrations
(Kodavanti et al. 2005; Reistad and Mariussen
2005). The effects of BDE-47 in PC12 cells
reported here occur at concentrations in the
same order of magnitude. 
Effects on spontaneous motor activity and
habituation in mice have been described for
several lower and higher brominated diphenyl
ethers after a single oral dose of maximally
21 μmol/kg bw (Branchi et al. 2002, 2003;
Eriksson et al. 2001, 2002; Viberg et al.
2003a, 2003b, 2006). In rats, effects on
behavior have been observed after maternal
exposure to 10 mg (18 μmol)/kg bw BDE-99
at gestational days 10–18 and after oral expo-
sure to 30 mg/kg bw DE-71 at PND6–12
(Dufault et al. 2005; Lilienthal et al. 2006). 
In the 1990s, an association between
delayed human neurodevelopment and pre-
natal or early exposure to PCBs was reported
by cohort studies. These results were corrobo-
rated by experiments demonstrating the
developmental neurotoxicity of PCBs. The
observed interaction with the thyroid hormone
system is usually considered part of the under-
lying mechanism (for review, see Winneke
et al. 2002). For hazard characterization of
PCBs and the structurally related PBDEs, it is
relevant to investigate whether they induce
similar effects through similar mechanisms.
This is of particular importance because, in
neonatal mice, the effects of a combined dose
of PCB-52 and BDE-99 on spontaneous
motor behavior and habituation capability
appear to be additive or perhaps even synergis-
tic (Eriksson et al. 2006).
High human serum concentrations of
BDE-47 were measured in female inhabitants
of California by Petreas et al. (2003); the con-
centration of BDE-47 in serum ranged from
5 to 510 ng/g lipid weight, with a median of
16.5 ng/g lipid weight. High concentrations
(> 100 ng/g lipid weight) have also been
reported in Californian children (Fisher et al.
2006). The highest and median values corre-
spond (using average physiologic values) to
blood concentrations of approximately
11.5 nM and approximately 0.37 nM. Using
the tissue distribution data for 1 mg/kg bw
14C-BDE-47 (Staskal et al. 2006), the dose
used in the current study corresponds to an
estimated blood concentration of approxi-
mately 2.6 μM after 3 hr and to approximately
0.6 μM after 10 days (i.e., ~ 50–200 times
higher than in the worst, and ~ 1,600–7,000
times higher than in the median human situa-
tion described above). For risk assessment, the
difference between the animal dose level caus-
ing an adverse effect and the highest human
dose levels is relatively small, considering safety
factors for species extrapolation and intra-
species variability. Additional uncertainty
comes from the fact that humans are exposed
to multiple flame retardants over a lifetime.
Accumulation of BDE-47, as demonstrated in
primary rat cerebellar granule neurons and pri-
mary rat neocortical cells (Kodavanti et al.
2005; Mundy et al. 2004), is another reason
for concern about the neurotoxic potential of
PBDEs.
No tolerable daily intake is assigned to
PBDEs because sufficient data are not avail-
able. However, the limited toxicity data sug-
gest that adverse effects induced by exposure
to the more toxic congeners in rodents occur
at doses of at least 100 μg/kg bw per day
[Joint FAO/WHO Expert Committee on
Food Additives (JECFA) 2005]. The combi-
nation of quantitative molecular data with
functional neurophysiologic effects reported
here provides strong functional support for
the previously reported neurobehavioral
effects (Eriksson et al. 2001) and is essential
for characterization of the neurotoxic hazard
of brominated flame retardants, particularly
for rational risk assessment, which is required
in response to the general concern about the
vulnerability of the developing brain. 
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870 VOLUME 115 | NUMBER 6 | June 2007 • Environmental Health PerspectivesAlthough blood lead levels in the United
States and other industrialized nations have
declined over the past decades, pockets of
high lead exposure and widespread low-level
lead exposures still persist (Pirkle et al. 1994).
Moreover, a substantial proportion of the
population has had higher lead exposure from
leaded gasoline and other sources such as sol-
dered cans, paints, and tap water in the past
(Pirkle et al. 1994). The long-term conse-
quences of lead exposure include circulatory
diseases, kidney diseases, and neurologic dis-
orders (Cheng et al. 2001; Harlan 1988;
Hertz-Picciotto and Croft 1993; Hu et al.
1996a; Kopp et al. 1988; Lin et al. 2003;
Martin et al. 2006; Moller and Kristensen
1992; Nash et al. 2003; Pirkle et al. 1985;
Schwartz 1991, 1995; Tsaih et al. 2004).
Lead exposure has been associated with
increased blood pressure and hypertension in
cross-sectional as well as longitudinal studies
(Cheng et al. 2001; Harlan 1988; Hertz-
Picciotto and Croft 1993; Hu et al. 1996a;
Kopp et al. 1988; Martin et al. 2006; Moller
and Kristensen 1992; Nash et al. 2003; Pirkle
et al. 1985; Schwartz 1991, 1995). More
recently, there is evidence of increased mor-
tality from circulatory causes in individuals
with blood lead levels of 20–29 μg/dL in the
past (Lustberg and Silbergeld 2002).
However, the association between lead levels
and risk for future ischemic heart disease
(IHD) after controlling for potential con-
founders has not been established. The three
previous reports on the possible association
between lead levels and cardiovascular disease
found no such evidence (Kromhout 1988;
Moller and Kristensen 1992; Pocock et al.
1988). These reports used blood lead level as
a biomarker for lead exposure, which is now
known to poorly reﬂect the cumulative inter-
nal dose of lead. Instead, more recently, bone
lead has become the biologic marker of
choice to assess long-term lead exposure
(Landrigan 1991). With the development of
in vivo K X-ray fluorescence (KXRF), it is
now possible to safely and rapidly measure
bone lead in large-scale epidemiologic studies
(Landrigan and Todd 1994).
The objective of our study was to assess
the relationship of bone and blood lead levels
with risk for IHD (fatal and nonfatal) in a
longitudinal cohort of aging men.
Materials and Methods
Study population. Participants in our study
were from the Normative Aging Study
(NAS), a longitudinal study of aging estab-
lished by the Veterans Administration (now
Department of Veterans Affairs) in 1961 (Bell
et al. 1972). The study cohort initially con-
sisted of 2,280 community-dwelling men who
were health-screened from the Greater Boston
area; those with chronic medical conditions
such as heart disease, diabetes, cancer, peptic
ulcer, gout, recurrent asthma, bronchitis, or
sinusitis were excluded. Those with either sys-
tolic blood pressure > 140 mm Hg or diastolic
blood pressure > 90 mm Hg were also
excluded. The men were between 21 and 80
years of age (mean, 42 years) on entry into the
cohort. Participants subsequently returned for
examinations every 3–5 years during the fol-
low-up period. At each visit, extensive physical
examination, laboratory, anthropometric, and
questionnaire data were collected. 
Measurement of blood lead began in
1988 during each continuing regularly sched-
uled visit of the participant. Beginning in
September 1991, permission was sought from
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Lead Levels and Ischemic Heart Disease in a Prospective Study
of Middle-Aged and Elderly Men: the VA Normative Aging Study
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BACKGROUND: Lead exposure has been associated with higher blood pressure, hypertension, elec-
trocardiogram abnormalities, and increased mortality from circulatory causes. 
OBJECTIVE: We assessed the association between bone lead—a more accurate biomarker of chronic
lead exposure than blood lead—and risk for future ischemic heart disease (IHD).
METHODS: In a prospective cohort study (VA Normative Aging Study), 837 men who underwent
blood or bone lead measurements at baseline were followed-up for an ischemic heart disease event
between 1 September 1991 and 31 December 2001. IHD was defined as either a diagnosis of
myocardial infarction or angina pectoris that was confirmed by a cardiologist. Events of fatal
myocardial infarction were assessed from death certiﬁcates. 
RESULTS: An IHD event occurred in 83 cases (70 nonfatal and 13 fatal). The mean blood, tibia,
and patella lead levels were higher in IHD cases than in noncases. In multivariate Cox-proportional
hazards models, one standard deviation increase in blood lead level was associated with a 1.27 (95%
conﬁdence interval, 1.01–1.59) fold greater risk for ischemic heart disease. Similarly, a one standard
deviation increase in patella and tibia lead levels was associated with greater risk for IHD (hazard
ratio for patella lead = 1.29; 95% conﬁdence interval, 1.02–1.62). 
CONCLUSIONS: Men with increased blood and bone lead levels were at increased risk for future IHD.
Although the pathogenesis of IHD is multifactorial, lead exposure may be one of the risk factors. 
KEY WORDS: angina, epidemiology, myocardial infarction. Environ Health Perspect 115:871–875
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measurements. Consenting individuals
reported to the Ambulatory Clinical Research
Center of the Brigham and Women’s Hospital
in Boston. Of the 1,278 participants seen for
their regularly scheduled NAS visits from
1 September 1991 through 31 December
2001, our study included participants who
had information on either blood or bone lead
level and had at least one follow-up visit in
this time frame (n = 1,019). The major reason
given for nonparticipation in the bone lead
study was the inconvenience involved in mak-
ing a separate visit to our bone lead test facil-
ity. After excluding participants with a history
of IHD (myocardial infarction or angina)
before their year of baseline lead measurement
visit, the final data set for analysis included
837 participants. These 837 participants had
their baseline lead measurement done during
their first scheduled visit after September
1991. Approval for this study was obtained
from the Human Research Committees of
Brigham and Women’s Hospital and the
Department of Veterans Affairs Outpatient
Clinic. This study complied with all applicable
requirements of the United States (including
institutional review board approval), and all
participants gave written informed consent
before the study.
History and physical parameters. Each
NAS participant reported to the study center
in the morning after an overnight fast and
abstinence from smoking. At the start of the
visit, height and weight were measured with
the participant wearing only stockings and
undershorts. A complete medical history,
including identity and purpose of medica-
tions taken daily, was elicited by a physician.
A history of physician-diagnosed diabetes
mellitus and hypertension since the last visit
was also elicited. A participant was considered
as having a family history of hypertension if
either a parent or a sibling had hypertension.
The American Thoracic Society questionnaire
(Ferris 1978) was used to assess current smok-
ing and past history of smoking, and the
Food Frequency Questionnaire (Ward et al.
1994; Willett et al. 1988) was used to assess
alcohol consumption. 
The participants were asked about history
of heart disease since their last visit. Every
report of IHD event was reviewed by a board-
certiﬁed cardiologist, who was unaware of the
participant’s blood and bone lead levels. The
criteria for myocardial infarction and angina
pectoris were those used in the Framingham
Heart Study (Shurtleff 1974). A diagnosis
of myocardial infarction was defined by
unequivocal electrocardiographic changes
(i.e., pathologic Q waves), diagnostic
increases in serum glutamic-oxaloacetic
transaminase and lactic dehydrogenase, and
concurrent chest discomfort consistent with
myocardial infarction, or by autopsy. Angina
pectoris was diagnosed when the participant
reported recurrent chest discomfort that
lasted up to 15 min and was distinctly related
to exertion and relieved by rest or nitroglyc-
erin. Events of fatal IHD were assessed from
death certificates. Regular mailings to NAS
participants were used to maintain vital status
information, and death certificates were
obtained for all decedents. 
Immediately after the history was obtained,
blood pressure was measured using a standard
mercury sphygmomanometer with a 14-cm
cuff by a physician. With the subject seated for
at least 3 min, systolic blood pressure and ﬁfth-
phase diastolic blood pressure were measured
in each arm to the nearest 2 mm Hg. The
means of the right and left arm measurements
were used as each participant’s systolic and
diastolic blood pressures. 
Blood lead measurements. Blood samples
for lead measurement were taken in special
trace-metal-free tubes containing ethylenedi-
aminetetra-acetic acid, and sent to ESA
Laboratories, Inc. (Bedford, MA), for analy-
sis. After room temperature digestion with
nitric acid, the sample solution was cen-
trifuged and the supernatant was poured into
a sample cup. It was then analyzed by Zeeman
background-correlated flameless atomic
absorption (graphite furnace). The instru-
ment was calibrated after every 21 samples
with National Bureau of Standard Blood
Lead Standards materials (Gaithersburg,
MD). Ten percent of the samples were run in
duplicate; at least 10% of the analyses were
controls and 10% were blanks. A complete
calibration check was made after the last spec-
imen was analyzed. In tests on reference sam-
ples from the Centers for Disease Control and
Prevention (Atlanta, GA), the coefficient of
variation ranged from 8% for concentrations
< 10 to 30 μg/dL, to 1% for higher concen-
trations. In comparison to a National Bureau
of Standards (Gaithersburg, MD) target with
a known blood lead concentration of
5.7 μg/dL, 24 repeated measurements con-
ducted by ESA Labs using this method gave a
mean ± SD of 5.3 ± 1.23 μg/dL.
KXRF bone lead measurements. Bone lead
measurements were performed from each par-
ticipant’s mid-tibial shaft and patella with a
KXRF instrument (ABIOMED Inc, Danvers,
MA). The physical principles, technical speciﬁ-
cations, validation, and quality control proce-
dures of this (Burger et al. 1990; Hu et al.
1990, 1994) and other KXRF instruments
(Jones et al. 1987; Somervaille et al. 1985) are
described elsewhere. Because this instrument
provides a continuous unbiased point estimate
that oscillates around the true bone lead value,
negative point estimates are sometimes pro-
duced when the true bone lead value is close to
zero. An estimate of the uncertainty associated
with each instrument, derived from a good-
ness-of-ﬁt calculation of the spectrum curves
and equivalent to a single standard deviation, is
also provided. Although a minimum detectable
limit calculation of twice this value has been
proposed for interpreting an individual’s bone
lead estimate (Gordon et al. 1993), retention
of all point estimates makes better use of the
data in epidemiologic studies (Kim et al.
1995). As a standard quality-control procedure
of KXRF measurements, tibia and patella bone
lead measurements with uncertainty estimates
of > 10 μg/g and > 15 μg/g, respectively, of
bone mineral were excluded. For our study,
30-min measurements were taken at the mid-
shaft of the left tibia (representing cortical
bone) and at the left patella (representing tra-
becular bone), after each region was washed
with a 50% solution of isopropyl alcohol. The
KXRF beam collimator was sited perpendicular
to the bone surface for the tibia and 30 degrees
in the lateral direction for the patella.
Statistical analysis. We calculated univari-
ate statistics and examined them for cases and
noncases of IHD. We used chi-square or t-
tests to assess the difference across cases and
noncases. Blood and bone lead levels were
log-transformed because their distributions
were skewed. A value of 35 was added to tibia
and patella lead levels before log-transforma-
tion (Kim et al. 1995; Kosnett et al. 1994). 
We assessed the association between lead
levels and risk for subsequent development of
new IHD using Cox’s proportional hazards
models. The follow-up period started at the
time of baseline visit (after 1 September
1991) and lasted until the time of ﬁrst IHD
event or death from myocardial infarction,
whichever occurred ﬁrst. If the participant did
not have an IHD event, the follow-up period
ended on the date of last visit (before 31
December 2001) or 31 December 2001 (if
the participant had a visit after 31 December
2001). Because only the year of IHD event
was available, 31 December of the year in
which the event occurred was used to calcu-
late person-years for all incident cases. 
We selected possible confounders on the
basis of their biologic signiﬁcance and infor-
mation from previous studies. These covariates
included age, body mass index, education,
race, current smoking status, pack-years
smoked, alcohol intake (grams per day)
(Moller and Kristensen 1992; Pocock et al.
1988), history of diabetes mellitus and hyper-
tension (Barzilay et al. 1998; Castelli et al.
1989), family history of hypertension, dias-
tolic and systolic blood pressure, serum
triglycerides, serum high-density lipids, and
total serum cholesterol. Variables signiﬁcant at
the 0.10 level in univariate models were
included in ﬁnal multivariate models. Each of
the log-transformed lead biomarker variables
(blood lead, tibia lead, and patella lead) was
Jain et al.
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models. We also analyzed blood lead as a cate-
gorical variable (≥ 5 μg/dL, ≥ 10 μg/dL, and
≥ 15 μg/dL) and bone lead in tertiles. To check
for any residual or negative confounding, all
covariates were again added, one at a time, in
the final regression models. We performed a
sensitivity analysis for all ﬁnal regression mod-
els after excluding patients with diabetes melli-
tus (Barzilay et al. 1998; Castelli et al. 1989). 
Statistical analysis was performed using
SAS for UNIX (version 9.0; SAS Institute
Inc., Cary, NC). The authors had full access
to the data and take responsibility for its
integrity. All authors have read and agree to
the manuscript as written.
Results
A comparison of participants included in our
study with nonparticipants in the KXRF bone
lead study, within the same time frame,
revealed no significant differences with
respect to age, race, body mass index, alcohol
intake, smoking, a family history of hyperten-
sion, systolic and diastolic blood pressure, and
a history of diabetes mellitus or hypertension
(data not shown). A similar comparison of
participants included in our study with those
who did not return for a follow-up visit dur-
ing our study time frame also yielded no sig-
niﬁcant differences between the two groups. 
Of the 837 participants in our study, an
IHD event occurred in 83 cases (70 nonfatal
and 13 fatal). The mean age of noncases (65.9
± 7.3 years) was similar to that of cases (67.5 ±
6.5 years). The distribution of other covari-
ates—including known risk factors for IHD
such as smoking, alcohol intake, systolic and
diastolic blood pressures, a history of diabetes
mellitus or hypertension, serum triglycerides,
and total serum cholesterol—was also similar
among cases and noncases (Table 1). However,
the person-time contributed by noncases was
significantly longer than cases, because cases
were censored once an IHD event occurred. 
The mean blood, tibia, and patella lead
levels were higher in IHD cases than in non-
cases. When blood lead level was examined as
a categorical variable, the proportion of cases
with a blood lead level ≥ 5 μg/dL was signiﬁ-
cantly higher than noncases. When bone lead
was examined in tertiles, a higher proportion
of cases were in the highest tertile of tibia and
patella lead level compared with noncases (for
tibia lead: 38.1% cases compared with 32.7%
noncases; for patella lead: 49.2% cases com-
pared with 30.8% noncases) (data not shown). 
Age and serum high-density lipids were
associated with IHD in multivariate Cox pro-
portional hazards regression models such that
the risk for IHD increased with increasing age
and decreased with increasing serum high-
density lipids (Table 2). When assessed as
continuous variables, an increase in blood or
bone lead level was associated with higher risk
for an IHD event. As a categorical variable,
blood lead level ≥ 5 μg/dL had a hazard ratio
of 1.73 [95% confidence interval (CI),
1.05–2.87] for IHD compared with blood
lead level < 5 μg/dL. A dose response was not
noted when tibia and patella lead levels were
analyzed in tertiles and quartiles.
The inclusion of other covariates known
to be risk factors for coronary disease—such
as body mass index, alcohol consumption,
current smoking, pack-years, a diagnosis of
diabetes, a diagnosis of hypertension, blood
pressure, family history of hypertension, total
serum cholesterol, and total serum trigly-
cerides—in the final regression models did
not alter our findings on the association
between lead and IHD (data not shown).
Our results were also similar when partici-
pants with diabetes were excluded from the
analysis (data not shown). 
The correlation between blood and bone
lead levels was modest (correlation coefﬁcient
= 0.30 for tibia and blood lead, and 0.37 for
patella and blood lead). As expected, tibia and
patella lead levels were strongly correlated
with each other (correlation coefficient =
0.78). When blood lead and one of the bone
lead variables were assessed in regression mod-
els simultaneously, the individual effect esti-
mates of blood and bone lead were only
moderately attenuated. The hazard ratio for
log blood lead was 1.24 (95% CI, 0.80–1.93)
and for log patella lead was 2.62 (95% CI,
0.99–6.93) when these variables were assessed
together in a multivariate model. Similarly,
the hazards ratio for blood lead was 1.38
(95% CI, 0.89–2.13) and that for tibia lead
was 1.55 (95% CI, 0.44–5.53) when these
variables were included together in the model.
Discussion
The relationship between biomarkers of long-
term lead exposure and IHD has not been pre-
viously assessed. In a longitudinal study of
837 middle-aged and elderly men followed
from 1 September 1991 through 31 December
2001, we found that the risk of future IHD
increases signiﬁcantly with increasing bone and
blood lead levels, after adjusting for potential
confounders. 
The relationship of lead exposure with
hypertension and increased blood pressure has
been established in previous studies (Cheng
et al. 2001; Harlan 1988; Hertz-Picciotto and
Croft 1993; Hu et al. 1996a; Kopp et al. 1988;
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Table 1. Baseline characteristics of IHD cases and noncases, Normative Aging Study, 1991–2001.
Noncases (n = 754) Cases (nonfatal n = 70; fatal n = 13)
Characteristic Totala No. (%) Range Totala No. (%) Range
Age (years)*
< 60 754 162 (21.5) — 83 10 (12.1) —
60–69 754 378 (50.1) — 83 48 (57.8) —
≥ 70 754 214 (28.4) — 83 25 (30.1) —
Race**
White 747 734 (98.3) — 82 78 (95.1) —
Black 747 13 (1.7) — 82 4 (4.9) —
Current smoker 754 60 (8.0) — 83 4 (4.8) —
Pack-years (among smokers)b 528 29.7 ± 23.7 0.10 to 145.5 61 34.0 ± 30.4 0.20 to 110.0
Body mass index (kg/meter2)b 749 28.0 ± 3.8 16.7 to 51.3 82 28.4 ± 3.8 19.6 to 41.5
Serum triglycerides (mg/dL)b 743 151.2 ± 93.9 24.0 to 978.0 83 146.5 ± 60.9 49.0 to 340.0
Total serum cholesterol (mg/dL)b 753 230.5 ± 38.7 130.0 to 438.0 83 232.7 ± 32.6 158.0 to 297.0
Serum high-density lipids (mg/dL)b* 730 49.4 ± 13.3 21 to 131 83 45.8 ± 10.3 21.0 to 85.0
Alcohol intake (gm/day)b 737 13.3 ± 17.5 0.0 to 104.1 80 11.2 ± 14.6 0.0 to 67.0
Systolic blood pressure (mm Hg)b 753 134.9 ± 17.0 91.0 to 215.0 83 136.4 ± 18.6 103.0 to 186.0
Diastolic blood pressure (mm Hg)b 753 82.0 ± 9.3 51.0 to 122.0 83 81.5 ± 11.3 56.0 to 110.0
Diabetes 754 81 (10.7) — 83 9 (10.8) —
Hypertension 754 341 (45.2) — 83 42 (50.6) —
Family history of hypertension 635 277 (43.6) — 72 30 (41.7) —
Person time (years)b* 754 6.9 ± 2.3 1.8 to 10.4 83 3.8 ± 2.7 0.08 to 10.7
Blood lead (µg/dL)b 738 6.2 ± 4.3 0.0 to 35.0 80 7.0 ± 3.8 1.0 to 20.0
Blood lead* tertiles
< 5 µg/dL 738 306 (41.5) — 64 22 (27.5) —
5–9.9 µg/dL 738 329 (44.6) — 64 43 (53.8) —
≥ 10 µg/dL 738 103 (14.0) — 64 15 (18.8) —
Patella lead (µg/g)b* 487 30.6 ± 19.7 –10.0 to 165.0 63 36.8 ± 20.8 5.0 to 101.0
Patella lead (µg/g)b* tertiles
Tertile 1 487 13.9 ± 4.9 –10.0 to 20.0 63 15.3 ± 4.3 5.0 to 19.0
Tertile 2 487 27.1 ± 4.1 21.0 to 34.0 63 25.7 ± 3.8 21.0 to 33.0
Tertile 3 487 52.5 ± 20.7 35.0 to 165.0 63 53.3 ± 17.3 35.0 to 101.0
Tibia lead (µg/g)b 486 21.4 ± 13.6 –3.0 to 126.0 63 24.2 ± 15.9 –5.0 to 75.0
Tibia lead (µg/g)b tertiles
Tertile 1 486 10.2 ± 3.8 –3.0 to 15.0 63 10.1 ± 5.3 –5.0 to 15.0
Tertile 2 486 19.1 ± 2.3 16.0 to 23.0 63 19.8 ± 2.2 16.0 to 23.0
Tertile 3 486 35.5 ± 14.4 24.0 to 126.0 63 39.5 ± 14.9 25.0 to 75.0
aTotal n for the respective variable. bMean ± SD. *p < 0.05 for cases versus noncases. **p < 0.10 for cases versus noncases.Martin et al. 2006; Moller and Kristensen
1992; Nash et al. 2003; Pirkle et al. 1985;
Schwartz 1991, 1995). Furthermore, it has also
been reported that higher blood lead levels lead
to increased mortality from cardiovascular
causes (Lustberg and Silbergeld 2002).
However, only three previous investigations
have assessed the association between blood
lead levels and heart disease (Kromhout 1988;
Moller and Kristensen 1992; Pocock et al.
1988). Pocock et al. (1988) followed 7,371
men 40–59 years of age in Britain for 6 years,
to assess the relationship between blood lead
levels at baseline and IHD. Although mean
blood lead concentration was significantly
higher in cases (0.786 μmole/L) than in non-
cases (0.735 μmole/L), there was no evidence
that blood lead was associated with IHD after
controlling for potential confounders. Moller
and Kristensen (1992) studied the risk of fatal
and nonfatal coronary heart disease and cardio-
vascular disease in 1,050 participants after
14 years of follow-up. Their results were simi-
lar to those of Pocock et al. in that blood lead
was associated with increased risk for coronary
heart disease (relative hazard = 2.14; p = 0.003)
and cardiovascular disease (relative hazard =
1.58; p = 0.05) in an unadjusted analysis; but
the association disappeared when confounders
were adjusted for. Another smaller study (n =
141) by Kromhout (1988) in the Netherlands
found no association between blood lead and
coronary heart disease in univariate and multi-
variate analysis. However, only 26 participants
had coronary heart disease in their 8 years of
follow-up data. A recent case report described a
patient with angina (severe spontaneous chest
pain with S-T elevation) who had a normal
coronary angiogram and blood lead level of
33 μg/dL (Oneglia et al. 1998). The patient
was chelated with EDTA, and described to be
normal during follow-up. The authors hypoth-
esized that lead exposure was possibly involved
in endothelial dysfunction and coronary spasm
in this case.
It is likely that previous studies (Kromhout
1988; Pocock et al. 1988), although suggestive
of a relationship between lead exposure and
heart disease, did not find an association in
multivariate analysis because of differences in
study population. Another likely reason is that
blood lead was used as a biomarker for expo-
sure. Lead accumulates in the skeleton, with a
half-life of years to decades (Manton 1985;
Rabinowitz et al. 1976). Bone is a repository for
90–95% of lead in adults (Barry and Mossman
1970; Saltzman et al. 1990; Schroeder and
Tipton 1968). Previous studies have shown that
bone lead levels remain elevated despite declines
in blood lead. Therefore, bone lead may be the
biomarker of choice for measurement of long-
term lead exposure. Bone lead levels have been
found to be better predictors than blood lead
when assessing outcomes such as hypertension
and cognitive declines in a number of recent
studies (Cheng et al. 2001; Hu et al. 1996a;
Schwartz et al. 2000; Weisskopf et al. 2004).
There is evidence that lead is released from
bone stores, especially during increased bone
turnover (Rabinowitz 1991; Silbergeld 1991).
This may contribute to increased blood lead in
persons with increased bone lead or increased
bone turnover. 
Blood and bone lead were associated
with increased risk for IHD in our study.
Furthermore, the effect estimates of blood
and bone lead were not attenuated when
assessed simultaneously, suggesting that both
contribute independently to IHD. It is
unclear why tibia lead was not significantly
associated with IHD, although the direction
of association was consistent with our overall
findings. The stronger association of patella
lead with IHD is noteworthy in that the
patella is composed of trabecular bone and is
known to have higher turnover rates and con-
tribute more to blood lead than the cortical
bone represented by tibia lead (Hu et al.
1996b). Because bone lead may contribute to
blood lead, particularly in our aging cohort,
which has had greater historic environmental
exposures and higher rates of bone resorption,
the association of blood lead with IHD is
plausible. It is also likely that persons in the
general population with high blood lead levels
have historically had higher levels of lead. In
summary, blood lead level reﬂects acute expo-
sure from circulating lead, whereas bone lead
reﬂects chronic exposure as well as the major
internal source of circulating blood lead. Both
factors likely play a role in predicting risk for
IHD. We suggest that future studies look at
both blood and bone lead when assessing the
risk for IHD from lead exposure.
The pathogenesis of the association
between lead exposure and IHD can be
explained by two mechanisms: One is media-
tion through increase in blood pressure, which
has been previously associated with an increase
in risk for ischemic and coronary heart disease
(Khot et al. 2003; MacMahon et al. 1990;
Tibblin et al. 1975; Wojtczak-Jaroszowa and
Kubow 1989); and the other is by atherogenic
process. Atherosclerosis can result from lead
exposure by inhibition of cytochrome P-450,
leading to accumulation of lipids in vessel
walls. Lead exposure can also lead to inhibition
of superoxide dismutase, an oxygen radical–
scavenging enzyme, leading to an increase in
serum lipid peroxide (Moller and Kristensen
1992; Wojtczak-Jaroszowa and Kubow 1989).
Serum peroxide is a risk factor for vascular
disease and thrombus formation.
Although lead levels have declined in the
United States and other industrialized
nations, low-level lead exposures still persist,
and exposure from higher lead levels in the
past is likely. Because the pathogenesis of
IHD is chronic and takes years to develop,
the public health implications of cumulative
lifetime lead exposure in the general popula-
tion are likely being currently realized and
will continue in the near future. 
Our study was limited by the unavailability
of exact date of onset for the IHD event.
Therefore, 31 December of the year of IHD
diagnosis was used in person-time calculations.
However, it is unlikely that this would lead to
a differential bias by IHD status. Because our
study population included only men and had
very few minority participants, our results may
not be generalized to races other than white or
to women. Our study also had a limited
number of IHD events. Therefore, residual
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Table 2. Cox proportional hazards models for the association between biomarkers of lead level and IHD, Normative Aging Study, 1991–2001 [HR (95% CI)].
Model A Model B Model C Model D
Covariate Unadjusted (n = 787) (n = 787) (n = 532) (n = 531)
Age (years)
< 60 Reference Reference Reference Reference Reference
60–69 2.18 (1.10–4.32) 2.43 (1.19–4.97) 2.45 (1.20–5.03) 1.67 (0.77–3.64) 1.71 (0.78–3.76)
≥ 70 2.44 (1.16–5.10) 2.52 (1.15–5.49) 2.57 (1.18–5.61) 2.01 (0.83–4.84) 2.22 (0.91–5.42)
Black race 2.38 (0.87–6.49) 1.84 (0.58–5.90) 1.71 (0.53–5.53) 1.99 (0.61–6.45) 2.14 (0.66–6.94)
Serum high-density lipids (mg/dL) 0.97 (0.96–0.99) 0.97 (0.95–0.99) 0.97 (0.95–0.99) 0.98 (0.96–1.00) 0.98 (0.96–1.00)
Blood lead level ≥ 5 µg/dL 1.64 (1.00–2.68) 1.73 (1.05–2.87)* — — —
Blood lead level (µg/dL)a 1.40 (0.99–1.98) — 1.45 (1.01–2.06)* — —
Patella lead level (µg/g)a 3.27 (1.41–7.58) — — 2.64 (1.09–6.37)* —
Tibia lead level (µg/g)a 2.76 (0.94–8.12) — — — 1.84 (0.57–5.90)**
HR, hazard ratio; CI, conﬁdence interval. The hazard ratios and their statistical signiﬁcance for blood and bone lead were similar when other potential confounders such as smoking,
body mass index, alcohol consumption, blood pressure, family history of hypertension, and total serum cholesterol were included in the models.
aLogarithm of lead level. *p = 0.05;**p = 0.31.confounding unaccounted for in our analysis is
a possibility. This includes factors such as meas-
ures of socioeconomic status that are related to
lead levels. A lower socioeconomic status may
lead to inadequate health maintenance, thereby
increasing the risk for IHD. 
Conclusion
In summary, we found that men with
increased blood and bone lead levels were at an
increased risk for future IHD. Low-level lead
exposures in the recent past and higher past
exposures may contribute to the increased risk
for IHD. Although, the pathogenesis of IHD
is multifactorial, lead exposure may be one of
the risk factors for development of IHD. 
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Research
Obesity, insulin resistance, and type 2 diabetes
are interrelated metabolic disorders whose
prevalence has increased substantially in the
past two decades. Corresponding increases in
premature morbidity and mortality are
expected (Adams et al. 2006; Fujimoto 2000;
Haffner et al. 1998; Poirier et al. 2006;
Zimmet et al. 2001). Insulin resistance occurs
when increasing amounts of insulin are
required to correctly regulate transport of
plasma glucose into peripheral tissues.
Although the precise mechanism is unclear,
insulin resistance is commonly accompanied
by central (visceral) obesity, which, by elevat-
ing levels of free fatty acids in serum, may pro-
voke insulin resistance and disrupt lipid
metabolism. Initially, the beta cells of the pan-
creas can fully compensate for mild insulin
resistance by increasing insulin production. As
the disease progresses, beta cells decompen-
sate, resulting in elevated serum glucose levels
and the subsequent development of type 2
diabetes. 
Testosterone affects body fat distribution
and insulin sensitivity in men. Experimental
studies in males have shown that testosterone
administration reduces lipid uptake by intra-
abdominal fat (Mårin et al. 1996) and also
reduces visceral fat and improves insulin sensi-
tivity (Mårin 1995; Mårin et al. 1992, 1993).
A 2005 meta-analysis found that testosterone
administration reduces total fat mass (Isidori
et al. 2005). Men undergoing androgen depri-
vation therapy for prostate cancer have
increased serum glucose, total fat, and preva-
lence of metabolic syndrome (Braga-Basaria
et al. 2006; Shariﬁ et al. 2005). Epidemiologic
studies often support these findings (Ding
et al. 2006; Selvin et al. 2007), but sometimes
they do not (Oh et al. 2002). 
Humans are commonly exposed to man-
made chemicals that have the potential to
reduce androgen (e.g., testosterone) produc-
tion or function. One such class of chemicals
is phthalates, which are used in a variety of
products, including cosmetics, shampoos,
soaps, lubricants, pesticides, and paints; it is
also used as a softener of polyvinyl chloride.
More than 75% of the U.S. population has
measurable levels of several phthalate metabo-
lites in the urine (Silva et al. 2004). Unlike
polychlorinated biphenyls (PCBs) and dioxins,
phthalates are quickly metabolized and
excreted (Hauser and Calafat 2005). The half-
life of di(2-ethylhexyl)phthalate (DEHP), one
of the most widely used and studied phtha-
lates, is < 24 hr (Koch et al. 2004).
Phthalates are known antiandrogens in
experimental animal models, with consistent
results dating back several decades. Testicular
steroid hormone synthesis and reproductive
system development in males have been
adversely affected by exposure, especially
neonatal exposure, to certain phthalates,
including DEHP, di-butyl phthalate (DBP),
benzyl-butyl phthalate, and di-isononyl phtha-
late (Bell 1982; Fisher 2004; Parks et al. 2000).
Associations between certain phthalate
metabolites and antiandrogenic effects have
also been found in humans at much lower
exposure levels than those used in rodent
experiments. Suspected metabolites include
mono-benzyl phthalate (MBzP), mono-ethyl
phthalate (MEP), mono-isononyl phthalate
(MiNP), mono-methyl phthalate, and mono-
butyl phthalate (MBP). Urinary phthalate
metabolites in pregnant women have been
found to correlate with subtle genital changes
in their infant males (Swan et al. 2005), and
breast-milk phthalate metabolites have been
correlated with shifts in reproductive hor-
mones in infant males (Main et al. 2006).
Although fetuses and infants are thought
to be more susceptible to environmental
insult than adults, Duty et al. (2003) and
Hauser et al. (2006) found diminished sperm
quality associated with urinary phthalate
metabolites in adult males as well. If their
ﬁndings reﬂect true antiandrogenic effects of
phthalates or their metabolites at current
exposure levels, then one may reasonably pre-
dict that these exposures could increase the
prevalence of metabolic disorders that are
worsened by diminished androgen production
or function. 
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BACKGROUND: Phthalates impair rodent testicular function and have been associated with anti-
androgenic effects in humans, including decreased testosterone levels. Low testosterone in adult
human males has been associated with increased prevalence of obesity, insulin resistance, and diabetes. 
OBJECTIVES: Our objective in this study was to investigate phthalate exposure and its associations
with abdominal obesity and insulin resistance. 
METHODS: Subjects were adult U.S. male participants in the National Health and Nutrition
Examination Survey (NHANES) 1999–2002. We modeled six phthalate metabolites with prevalent
exposure and known or suspected antiandrogenic activity as predictors of waist circumference and
log-transformed homeostatic model assessment (HOMA; a measure of insulin resistance) using
multiple linear regression, adjusted for age, race/ethnicity, fat and total calorie consumption, physical
activity level, serum cotinine, and urine creatinine (model 1); and adjusted for model 1 covariates
plus measures of renal and hepatic function (model 2). Metabolites were mono-butyl phthalates
(MBP), mono-ethyl phthalate (MEP), mono-(2-ethyl)-hexyl phthalate (MEHP), mono-benzyl
phthalate (MBzP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono-(2-ethyl-5-
oxohexyl) phthalate (MEOHP). 
RESULTS: In model 1, four metabolites were associated with increased waist circumference (MBzP,
MEHHP, MEOHP, and MEP; p-values ≤ 0.013) and three with increased HOMA (MBP, MBzP,
and MEP; p-values ≤ 0.011). When we also adjusted for renal and hepatic function, parameter
estimates declined but all signiﬁcant results remained so except HOMA-MBP. 
CONCLUSIONS: In this national cross-section of U.S. men, concentrations of several prevalent
phthalate metabolites showed statistically significant correlations with abdominal obesity and
insulin resistance. If conﬁrmed by longitudinal studies, our ﬁndings would suggest that exposure to
these phthalates may contribute to the population burden of obesity, insulin resistance, and related
clinical disorders.
KEY WORDS: androgens, homeostatic model assessment, insulin resistance, obesity, phthalates.
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[Online 14 March 2007]In this study we examined the association
between phthalate exposure and two key
metabolic abnormalities associated with hypo-
androgenism: abdominal obesity and insulin
resistance. Although these conditions are
closely related, they represent key precursors—
alone or in combination—to the development
of type 2 diabetes and cardiovascular disease
(Janssen et al. 2004; Reaven 1988). Our
hypothesis was that increased phthalate expo-
sure would be associated with increased
abdominal obesity and insulin resistance.
Methods
Study population. We used data from the
1999–2002 National Health and Nutrition
Examination Survey (NHANES) for this
analysis. NHANES, conducted by the
National Center for Health Statistics (NCHS),
Centers for Disease Control and Prevention
(CDC), is a multistage, stratified, clustered
design that selects a representative sample of
the civilian, noninstitutionalized U.S. popula-
tion. Certain subgroups, such as older adults,
Mexican Americans, non-Hispanic blacks, and
low-income persons, were sampled at a higher
rate than other demographic groups, thus
necessitating the use of sample weights in
analysis. Data from NHANES subjects are
acquired through household interviews and
standardized examinations at mobile examina-
tion centers throughout the United States.
Detailed methods have been published else-
where (NCHS 2006b).
We limited our analysis to men > 18 years
of age with complete data for the measures
described below. Men on insulin, oral hypo-
glycemic agents, or sex hormone agonists/
antagonists were excluded because these
medications may affect the biological mecha-
nisms of interest. Men were also excluded
from the insulin resistance analyses if they
reported to NCHS that they failed to fast for
8–24 hr before collection of fasting blood
samples.
In NHANES 1999–2002, a random one-
third subsample was selected for urinary
phthalate metabolite measurements, and a
separate random, but overlapping, one-third
subsample was selected for fasting glucose and
insulin (used to compute insulin resistance)
measurements. Of the 5,094 adult men avail-
able in NHANES, 1,451 men had both
phthalate and obesity measurements for crude
analyses after exclusions. Of these men, 45%
(n = 651) also had fasting measurements.
Two of the phthalate metabolites, mono-(2-
ethyl-5-hydroxyhexyl) phthalate (MEHHP)
and mono-(2-ethyl-5-oxohexyl) phthalate
(MEOHP), were only available for the years
2001–2002, reducing sample size for these
metabolites by about half (waist circumfer-
ence, n = 781; insulin resistance, n = 344).
Missing data reduced sample sizes for fully
adjusted models (vs. crude) by 11% for waist
circumference and 4.5% for insulin resistance. 
Abdominal obesity. Waist circumference
was chosen as the best available measure of
abdominal obesity. As a predictor of insulin
resistance, waist circumference has been
found to be an equivalent and, in some cases,
a better measure than body mass index (Farin
et al. 2006; Janssen et al. 2004). Waist cir-
cumference was measured at the high point of
the iliac crest at minimal respiration to the
nearest 1 mm. 
Insulin resistance. We estimated insulin
resistance using HOMA (homeostatic model
assessment). HOMA is epidemiologically
practical, widely used, and correlates accept-
ably (R = 0.73–0.88) with the hyperinsuline-
mic-euglycemic clamp test, which is generally
considered to be the gold standard (Matthews
et al. 1985; Wallace et al. 2004). HOMA was
calculated from fasting plasma glucose and
insulin measures following the method of
Matthews et al. (1985):
HOMA = [fasting insulin (μU/mL) 
× fasting glucose (mmol/L)]/22.5. [1]
Plasma glucose was determined by an enzy-
matic reaction (Cobas Miras assay); plasma
insulin was determined using a radio-
immunoassay with the double-antibody batch
method. 
Phthalate exposure. Phthalate data were
collected in NHANES as urinary metabo-
lites—rather than unmetabolized phthalates
in serum—to eliminate contamination dur-
ing collection and analysis (Latini 2005).
Laboratory methods have been previously
described (Silva et al. 2004). Seven metabo-
lites were measured throughout the 4-year
period, with five additional metabolites
measured in 2001–2002 subjects only. For
measurements below the limit of detection
(LOD), the NCHS assigned a default value
of LOD divided by the square root of 2, a
method of handling nondetectable values
that produces reasonably nonbiased means
and SDs (Hornung and Reed 1990).
Of the seven phthalates with data for all
4 years, four (MBP, MEP, MiNP, MBP) are
suspected human antiandrogens based on exist-
ing human studies (Duty et al. 2003; Hauser
et al. 2006; Main et al. 2006; Swan et al. 2005).
Metabolites of DEHP, the most widely studied
antiandrogenic phthalate, were also of interest:
mono(2-ethylhexyl) phthalate (MEHP) because
it was available for all 4 years, and MEHHP
and MEOHP (2001–2002 only) because sec-
ondary DEHP metabolites are suspected to be
more biologically active (Koch et al. 2005;
Stroheker et al. 2005). MiNP was eliminated
from further consideration because its concen-
tration was < LOD in > 75% of subjects. In
NHANES 1999–2000, MBP represented both
mono-n-butyl phthalate and mono-isobutyl
phthalate, whereas in NHANES 2001–2002,
these metabolites were measured separately
(CDC 2005). In the present study, we
summed the two mono-butyl phthalate
metabolites in 2001–2002 data to permit
analyses of mono-butyl phthalates over the
4-year period.
Potential confounders. Covariates included
in our analyses were age, race/ethnicity, family
history of diabetes, dietary fat and caloric
intake, physical activity, income, renal func-
tion, hepatic function, and exposure to
tobacco smoke. Race/ethnicity was self-identi-
fied (white, black, Mexican American, other
Hispanic, and other/multiethnic). Family his-
tory of diabetes was dichotomous (yes, no).
Total dietary fat (continuous) and caloric
intake (continuous) were computed from a
24-hr recall dietary questionnaire. Two physi-
cal activity measures were included: moderate
to vigorous leisure activity (continuous; meta-
bolic equivalents/month) and video-based
(computer, video, TV) inactivity (categorical,
hours/day: 0, < 1, 1, 2, 3, 4, ≥ 5). Socio-
economic status was represented as a “poverty
income ratio,” a measure of income relative to
family size and compared to the federal
poverty threshold (categorical, percentage of
poverty threshold: < 100, 100–199, 200–299,
300–399, 400–499, > 500). The renal func-
tion measure was glomerular filtration rate
(GFR; continuous), estimated using the four-
variable equation from the Modification of
Diet in Renal Disease study (Levey et al.
1999), incorporating serum creatinine adjust-
ments per NCHS instructions (NCHS
2006c). Liver function was represented by ala-
nine aminotransferase (ALT; continuous) and
gamma glutamyl transferase (GGT; continu-
ous). Exposure to tobacco smoke was deter-
mined using serum cotinine (continuous).
Statistical analysis. For descriptive analy-
ses, we computed median and mean phthalate
metabolite levels, adjusting for urine concen-
tration by dividing metabolite measurements
by urine creatinine. These analyses were con-
ducted for the entire sample, and also strati-
ﬁed by race/ethnicity and age.
Linear regression analyses were performed
with HOMA (log-transformed) and waist cir-
cumference as outcome variables. Because sev-
eral phthalate metabolites are strongly
correlated, each urinary phthalate metabolite
was examined separately. Phthalate metabolite
concentrations were log-transformed to nor-
malize the data. Categorical analyses by expo-
sure quintiles were also performed.
We conducted crude analyses and two
adjusted analyses for each phthalate. Adjusted
model 1 includes covariates discussed below.
Adjusted model 2 includes these covariates,
plus GFR, ALT, and GGT. Model 1 was our
primary model because phthalates are known
to affect the liver (Bhattacharya et al. 2005;
Phthalates, waist circumference, and insulin resistance
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therefore, adjusting for liver function (model
2) could remove true effects. Model 2 is also
needed, however, because obesity can affect
liver function (Lawlor et al. 2005) and thus
alter phthalate metabolism. GFR had mini-
mal effect on results but was left in model 2
for completeness. 
Age and race/ethnicity are known con-
founders and were included in fully adjusted
models. Urine creatinine was included to cor-
rect for urine concentration, as recommended
by Barr et al. (2005). Because the relationship
between age and prevalence of metabolic syn-
drome (an outcome related to our outcomes)
appears curvilinear (Park et al. 2003), age2
was also included. Age, age2, urine creatinine,
and race/ethnicity were forced into all models
regardless of their influence on metabolite
regression coefﬁcients. Other covariates were
evaluated as possible confounders. 
Covariates whose removal caused metabo-
lite parameter estimates to change by ≥ 10%
were considered confounders and left in the
adjusted models (Greenland 1989). Food
intake (total fat and calories), serum cotinine,
and activity measures were confounders for
two or more metabolites, and were therefore
included as covariates. Family history of dia-
betes and poverty income ratio were not
important confounders and had many miss-
ing values; thus they were omitted. The sam-
ple size for the full regression model was
reduced by 11% for waist circumference and
4.5% for insulin resistance due to missing
data for one or more covariates.
To assess the contribution of phthalate
metabolites to the model fit, the percent
variation in the outcome measures explained
by each metabolite was calculated by comput-
ing the difference in adjusted R2 between the
full model with and without that metabolite.
To convert regression coefﬁcients to clini-
cally interpretable measures, we first com-
puted the absolute change in waist
circumference and log HOMA represented by
an increase in the significant (p ≤ 0.05) log
phthalate metabolites from the 10th to 90th
percentiles, then calculated this increase in
waist circumference and HOMA as a percent
of their medians:
[2]
[3]
where β is the regression coefﬁcient for each
individual metabolite.
We used SAS, version 9.1 (SAS Institute,
Cary, NC) for all statistical analyses.
Appropriate weight variables were used to
account for oversampling of special demo-
graphic groups in NHANES, and sampling
cluster variables were used for its complex
sampling design. Phthalate subsample weight
variables were used for both waist circumfer-
ence and HOMA analyses. Because we exam-
ined only the adult male subpopulation in the
NHANES data, we used subpopulation
methods as described by Graubard and Korn
(1996).
The use of weights associated with indi-
vidual NHANES subsamples may be inaccu-
rate when two subsamples that do not
completely overlap are used simultaneously
in an analysis (NCHS 2006a). Our waist cir-
cumference analyses used only one subsample
(phthalates) and are unaffected; however,
HOMA analyses used both fasting and
phthalate subsamples, which only overlap by
50%. Consequently, the use of phthalate
weights in our HOMA analyses could affect
validity of these ﬁndings. Nevertheless, use of
fasting subsample weights, phthalate weights,
and no weights did not substantially alter our
interpretation of the HOMA results, which
also demonstrated similar patterns as our
Percent change in HOMA (at median)
l
=
× exp β n nm e t a b o l i t e l nm e t a b o l i t e 90th percentile 1 () − 0 0th percentile
median HOMA
() ⎡ ⎣ ⎤ ⎦ {}
Percent change in waist circumference (at me edian)
ln metabolite l 90th percentile
=
× () − β n nm e t a b o l i t e
median wai
10th percentile () ⎡ ⎣ ⎤ ⎦
s st circumference
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Table 1. Mean median phthalate serum metabolite concentrations (µg/g creatinine): NHANES 1999–2002.a
4-Year 2-Year
MBP MBzP MEHP MEP MEHHP MEOHP
No. Mean ± SE (median) Mean ± SE (median) Mean ± SE (median) Mean ± SE (median) No. Mean ± SE (median) Mean ± SE (median)
All 1,443 33.8 ± 1.6 (21.2) 29.4 ± 2.7 (14.2)  11 ± 1.3 (3.8) 771 ± 66.7 (188.1) 780 65.8 ± 7.9 (19.6) 38.7 ± 4.5 (13.2)
By age (years)
19–35 469 36.1 ± 2.9 (23.9) 35.7 ± 6.0 (17.0) 12.8 ± 2.2 (5.1) 699.2 ± 117.2 (212.4) 253 77.5 ± 18.2 (22.1) 45.8 ± 9.9 (15.6)
36–50 386 31.0 ± 2.1 (21.4) 25.0 ± 1.8 (14.9) 13.4 ± 2.7 (3.9) 672.1 ± 130.3 (173.5) 219 68.9 ± 12.7 (20.1) 39.3 ± 8.2 (13.2)
51–65 284 33.4 ± 3.2 (18.3) 25.1 ± 4.3 (11.8) 7.1 ± 1.3 (2.5) 1017.5 ± 160.8 (208.7) 160 52.8 ± 14.4 (16.3) 32.1 ± 7.7 (11.6)
66–80 231 37.9 ± 5.7 (18.4) 25.9 ± 4.3 (11.3) 5.9 ± 1.0 (2.2) 933.7 ± 182.7 (139.1) 118 42.8 ± 17.5 (11.5) 26.0 ± 8.8 (7.5)
≥ 81  73 24.2 ± 2.9 (19.0) 49.6 ± 31.9 (12.1) 3.7 ± 0.7 (2.4) 503.7 ± 180.9 (94.8) 30 20.3 ± 4.9 (13.2) 13.5 ± 3.3 (8.3)
By ethnicity
Mexican American 335 33.1 ± 4.1 (23.2) 24.3 ± 3.3 (12.7) 8.6 ± 1.1 (4.0) 717.0 ± 82.2 (259.6) 161 34.0 ± 7.7 (15.6) 20.6 ± 4.2 (10.8)
Other Hispanic 75 39.7 ± 6.9 (24.2) 29.3 ± 4.1 (13.8) 14.9 ± 4.5 (6.9) 1347.3 ± 338.0 (292.1) 35 48.8 ± 17.3 (25.3) 30.0 ± 10.5 (15.9)
White 717 32.0 ± 1.9 (19.0) 28.5 ± 3.3 (14.0) 10.9 ± 1.8 (3.3) 703.1 ± 72.9 (158.8) 415 70.2 ± 11.8 (19.5) 41.9 ± 6.3 (13.1)
Black 271 45.6 ± 4.4 (31.7) 44.0 ± 9.4 (19.9) 13.4 ± 3.0 (5.3) 1086.5 ± 177.1 (362.6) 150 83.0 ± 24.7 (32.1) 42.5 ± 9.0 (18.7)
Other/multiethnic 45 28.7 ± 3.9 (28.1) 18.8 ± 2.8 (11.9) 5.0 ± .8 (3.8) 295.8 ± 65.6 (84.6) 19 14.7 ± 3.4 (12.3) 9.7 ± 2.1 (9.2)
a2001–2002 only for MEHHP and MEOHP.
Table 2. Association between waist circumference, HOMA (ln), and selected phthalate metabolites (ln):
NHANES 1999–2002.
Crude analysis Adjusted model 1a Adjusted model 2b
Outcome β (SE) p-Value β (SE) p-Value β (SE) p-Value
Waist circumference
1999–2002 (n = 1,451 crude, 1,292 adjusted)
MBP 1.39 (0.51) 0.011 0.98 (0.50) 0.059 0.79 (0.47) 0.106
MBzP 1.18 (0.47) 0.017 1.29 (0.34) 0.001 1.09 (0.36) 0.005
MEHP 0.24 (0.40) 0.550 0.62 (0.44) 0.170 0.53 (0.42)  0.217
MEP 0.95 (0.32) 0.005 0.77 (0.29) 0.013 0.66 (0.31) 0.041
2001–2002 (n = 781 crude, 696 adjusted)
MEHHP 1.82 (0.58) 0.007 1.71 (0.56) 0.008 1.65 (0.50) 0.005
MEOHP 2.00 (0.63) 0.006 1.81 (0.60) 0.009 1.79 (0.55) 0.005
HOMA (ln)
1999–2002 (n = 651 crude, 622 adjusted)
MBP 0.061 (0.024) 0.016 0.064 (0.024) 0.011 0.043 (0.023) 0.081
MBzP 0.059 (0.027) 0.037 0.079 (0.023) 0.002 0.061 (0.022) 0.009
MEHP 0.035 (0.023) 0.143 0.031 (0.025) 0.225 0.016 (0.024) 0.526
MEP 0.067 (0.021) 0.004 0.056 (0.020) 0.008 0.044 (0.021)  0.045
2001–2002 (n = 344 crude, 327 adjusted)
MEHHP 0.054 (0.029) 0.078 0.055 (0.028) 0.064 0.038 (0.023) 0.126
MEOHP 0.066 (0.031) 0.052 0.060 (0.032) 0.076 0.044 (0.027) 0.125
aAdjusted for age, age2, race/ethnicity, total fat and calorie intake, physical activity level, smoking exposure, and urine
creatinine. bAdjusted for model 1 covariates plus GFR, ALT, and GGT.waist circumference analyses. This suggests that
the use of two partially overlapping subsamples
did not signiﬁcantly impact our ﬁndings.
Results
Table 1 shows the median and mean phtha-
late levels in the U.S. population, overall and
stratiﬁed by age and race/ethnicity. Exposure
levels vary widely by phthalate metabolite,
with MEHP having the lowest concentration
among the six we analyzed, and MEP the
highest. Concentrations varied somewhat by
age, with greater median levels usually found
in younger age groups. For all phthalate
metabolites except MEHP, > 95% of subjects
were at ≥ LOD; for MEHP, 80% of subjects
were ≥ LOD. 
Concentrations also varied by race/ethnic-
ity. Blacks had higher levels of exposure than
whites and Mexican Americans for all phtha-
late metabolites. Mexican Americans had
somewhat higher levels than whites for MBP,
MEP, and MEHP.
Table 2 shows the regression results for
crude analysis (adjusting only for urinary
creatinine) and fully adjusted models. In the
adjusted model 1, increasing concentrations
of MBzP, MEHHP, and MEOHP were sta-
tistically significantly associated with greater
waist circumference, whereas concentrations
of MBP, MBzP, and MEP were signiﬁcantly
associated with increased log HOMA.
Adjusted model 2, which adjusted for renal
and hepatic function, showed declines in
parameter estimates, but all signiﬁcant results
remained so except HOMA-MBP.
Adjusted model 1 HOMA results gave
similar parameter estimates whether calculated
with phthalate or fasting subsample weights
(< 5% difference for analyses with signiﬁcant
p-values). For further verification, an
unweighted HOMA analysis was also con-
ducted (data not shown) with somewhat larger
changes in parameter estimates. However,
MBP, MEP, and MBzP were still signiﬁcantly
associated and MEHP was again not signifi-
cant. MEHHP and MEOHP gained signifi-
cance in the unweighted analysis.
Categorical dose–response analyses
demonstrated that the assumption of linearity
was not strongly violated, although the curves
appeared to level off, or perhaps decline, at
higher metabolite concentrations (Figure 1).
The contribution of phthalate metabolites
to model ﬁt is displayed in Table 3. Adjusted
R2 of the full model ranged from 15 to 20%
for both outcome measures. The addition of
significant phthalate metabolites explained
0.4–2.1% of outcome variability. Compared
with the overall explanatory power of the full
model, individual metabolites contributed
between 2.5 and 10.1% of the model ﬁt.
To convert regression coefﬁcients to clini-
cally interpretable measures, we computed the
Phthalates, waist circumference, and insulin resistance
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Figure 1. Fully-adjusted associations (adjusted model 1) between changes in outcomes and exposure
quintiles (quintile 1 is reference) for metabolites with significant/near-significant (p ≤ 0.10) continuous
regression coefﬁcients. Error bars indicate 95% conﬁdence intervals.
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represented by an increase in significant
phthalate metabolites from the 10th to 90th
percentiles in adjusted model 1. Waist cir-
cumference increased 3.9–7.8 cm (4.0–8.0%
of the 97.0-cm median) for four significant
metabolites: MEP (3.9 cm), MBzP (5.8 cm),
MEHHP (7.3 cm), and MEOHP (7.8 cm).
HOMA (at the 2.50 median) increased
1.3–1.4 (52–57% of median) in association
with three metabolites: MBP (1.3), MEP
(1.3), and MBzP (1.4).
Discussion
Obesity, insulin resistance, and diabetes have
increased substantially in prevalence over the
past three decades. Many plausible causes have
been described, such as perinatal exposures,
reduced physical activity, food marketing
strategies, poor city planning, and thrifty genes
(Ebbeling et al. 2002). However, if bioavailable
testosterone levels in American men have
declined considerably in recent years, as
recently reported by Travison et al. (2007),
then hypoandrogenism could be another con-
tributor to the epidemic of obesity and related
disorders. Hormonally active agents such as
phthalates could be one source of this decline
in testosterone level or, perhaps independently,
to a decline in androgen function.
In the present study, we found that the
log-transformed concentrations of several
phthalate metabolites were positively and sig-
nificantly correlated with abdominal obesity
(MBzP, MEHHP, MEOHP, MEP) and
insulin resistance (MBP, MBzP, MEP) in adult
U.S. males. Categorical analysis of these
metabolites by exposure quintiles yielded dose–
response curves consistent with this interpreta-
tion. Although wide conﬁdence intervals pre-
clude strong assertions, the HOMA analyses
curves suggest the inverted-U shaped, non-
monotonic dose–response sometimes seen with
hormonally active agents, including phthalates
(Andrade et al. 2006; Lehmann et al. 2004;
Takano et al. 2006; Welshons et al. 2003).
Adjustment for renal function had mini-
mal effect. Adjustment for liver function mod-
erated most associations but only eliminated
statistical significance for HOMA-MBP.
Whether this adjustment for liver function was
entirely appropriate is unclear, however.
Adjustment could be appropriate because obe-
sity can affect liver function, and thus may
alter phthalate metabolism. Conversely, adjust-
ing for liver function could falsely attenuate
real effects if phthalate exposure was partially
responsible for elevation of liver enzymes.
Among the DEHP metabolites available,
MEHP showed substantially weaker associa-
tions compared with the oxidative metabo-
lites MEHHP and MEOHP. This was not
unexpected because a recent study showed
MEHHP and MEOHP more active in ani-
mal models than MEHP (Stroheker et al.
2005). Further, MEHP has a shorter serum
half-life than these other DEHP metabolites,
thus reducing the correlation of MEHP
measurements with DEHP exposure (Koch
et al. 2005). 
To our knowledge, ours is the ﬁrst human
study to examine associations between phtha-
late metabolites and either abdominal obesity
or insulin resistance. In one animal study,
however, female rats exposed to DEHP were
found to have increased serum glucose and
decreased insulin, as well as thyroid and
adrenocortical dysfunction (Gayathri et al.
2004). However, the decreased insulin in that
study points to impaired beta cell function in
the pancreas, as found in type 1 diabetes or
later in the course of type 2 diabetes.
Like our study, others have found associa-
tions with outcomes that might follow from
antiandrogenic effects of MBP (Duty et al.
2003; Hauser et al. 2006; Main et al. 2006;
Swan et al. 2005) and MEP (Jönsson et al.
2005; Main et al. 2006; Swan et al. 2005),
and found no association with MEHP (Duty
et al. 2003; Hauser et al. 2006; Jönsson et al.
2005; Main et al. 2006; Swan et al. 2005).
Results for MBzP, MEHHP, and MEOHP
were less consistent. Assuming these associa-
tions represent true effects, differences
between our results and others could be due to
our larger sample sizes and increased power.
Phthalates might also affect adult males differ-
ently than fetuses, or they may interact
directly with energy balance or glucose
metabolism pathways in addition to anti-
androgenic effects. 
In our study, individual phthalate expo-
sures only explained ≤ 2.1% of the variability
of our outcomes (abdominal obesity and
insulin resistance). The full model, however,
explained only 15–20%, despite including the
well-accepted covariates of age, race/ethnicity,
fat and calorie intake, activity levels, and smok-
ing. In part, this demonstrates the difﬁculty of
predicting the presence of this complex, multi-
factorial clinical syndrome. In addition,
humans are exposed to multiple phthalates
simultaneously and in combination with other
potential environmental toxicants that may
add together to produce adverse effects. For
example, PCBs, dioxins, and organochlorine
pesticides have also been associated with dia-
betes prevalence in adult humans (Lee et al.
2006; Rylander et al. 2005). Combinations of
phthalates and other potential antiandrogens
have been shown in animal models to act in a
dose-additive manner (Gray et al. 2006;
Hotchkiss et al. 2004); in humans, Hauser
et al. (2005) found greater than additive effects
between MBP and PCB-153 on semen quality.
Although individual phthalate exposures in
humans are generally asserted to be below the
no observed effect level (NOEL), combina-
tions of man-made estrogenic chemicals, indi-
vidually below NOEL concentrations, have
been shown to exert considerable effect in a
yeast reporter gene assay using the human
estrogen receptor-α (Rajapakse et al. 2002). 
Estrogenic exposures might also add to
antiandrogenic exposures; some authors have
found the estradiol/testosterone (total) ratio
correlated more strongly with fasting glucose
and insulin than testosterone (free or total) or
estradiol alone (Phillips et al. 2003). Among
xenoestrogens, bisphenol A (currently unmea-
sured in NHANES) would be important to
investigate because it has recently been shown
to affect insulin production in mouse pancre-
atic beta cells in a manner similar to that of
estrogen (Alonso-Magdalena et al. 2006).
Our findings should be considered in
light of several important limitations. First, as
a cross-sectional study, this design cannot
examine changes over time. Second, HOMA
is a static measure of insulin resistance, unlike
the hyperinsulinemic–euglycemic clamp,
which limits its ability to detect abnormalities
in insulin secretion or peripheral glucose dis-
posal. This may have reduced our ability to
observe associations. Third, NHANES
1999–2002 contains no measures of sex hor-
mones, gonadotropins, or sex hormone-bind-
ing globulin in men, which limits our ability
to examine the mechanism of action proposed
in this study. Fourth, our HOMA analyses
are less generalizable to the population
because specially calculated sample weights
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Table 3. Outcome variation explained by and contribution to fit of phthalate metabolites significantly
(p ≤ 0.05) associated with one or both outcome measures (adjusted model 1).
Adj R2 of full model Adj R2 of full model Outcome variation  Model contribution 
with metabolite without metabolite explained by metabolite (%)a of metabolite (%)b
Waist circumference
MBzP 0.1587 0.1517 0.7 4.4
MEHHP 0.2042 0.1837 2.1 10.0
MEOHP 0.2043 0.1837 2.1 10.1
MEP 0.1556 0.1517 0.4 2.5
HOMA (ln)
MBP 0.1650 0.1575 0.8 4.5
MBzP 0.1748 0.1575 1.7 9.9
MEP 0.1727 0.1575 1.5 8.8
Adj, adjusted. 
a(R2
with metabolite – R2
without metabolite) × 100%. b[(R2
with metabolite – R2
without metabolite)/R2
with metabolite] × 100%.for the combined use of phthalate and fasting
subsamples are not available.
Fifth, our study was restricted to adult
males. Children and adolescents were
excluded from our study because fasting glu-
cose and insulin were not available in
NHANES 1999–2002 for subjects < 12 years
of age, and because in adolescents, hormone
levels vary greatly with stage of puberty.
Women were excluded due to the high degree
of premenopausal fluctuations in sex hor-
mones and the change in risk profile at
menopause. Also, women appear to respond
differently than men to low testosterone levels;
in women, low testosterone has been associ-
ated with reduced prevalence of obesity,
insulin resistance, and diabetes (Ding et al.
2006; Kalish et al. 2003; Oh et al. 2002). An
analysis of the adult women in this data set
indeed gave dissimilar results from men
(results not shown) and deserves further study. 
Sixth, the one-time spot urine samples
used in this study are limited measures of
long-term exposure to phthalates. If phthalates
are exerting antiandrogenic effects, one might
expect this effect to manifest over months to
years. No study has yet examined the correla-
tion between a spot urine phthalate measure-
ment and year-long exposure patterns. Hauser
et al. (2004b), however, found that a single
spot urine predicted the highest tercile of
phthalate exposure over 3 months with sensi-
tivities from 0.56 to 0.67 and specificities
from 0.83 to 0.87 among the phthalates in
our study. Hauser et al. also noted that urine
creatinine may not be the best way to correct
for variation in urine dilution, and that spe-
ciﬁc gravity (unavailable in NHANES) may be
a better approach. These flaws in exposure
classification also reduced our ability to
observe associations.
Seventh, people with obesity or insulin
resistance may be exposed to more phthalates
than people who do not have these conditions.
A few Food and Drug Administration–licensed
medications incorporate phthalates to modify
drug delivery (Schettler 2006), and this expo-
sure can sometimes be quite large (Hauser
et al. 2004a). Because people with disease are
also more likely to take medications, some of
the associations we have observed, particularly
with MBP and MEP (metabolites of DBP and
diethyl phthalate), may be falsely strengthened
through reverse causality. Adjustment for this
possible confounder would be difﬁcult, how-
ever. Phthalates are considered inert ingredi-
ents, and we are not aware of a comprehensive
database of inert ingredients for prescription
and over-the-counter medications, herbals, and
vitamins.
The present study has several important
strengths, based primarily on strengths of
NHANES data. Our sample was large,
nationally representative, and multiethnic.
Biomarkers were used for both exposures and
outcomes, and a number of relevant covariates
could be controlled.
Although we based our study on the
premise that phthalates are acting as anti-
androgens, the relationships between phtha-
late metabolites, abdominal obesity, and
insulin resistance may be complicated by
other mechanisms. For example, phthalates
can act as thyroid hormone receptor antago-
nists (Sugiyama et al. 2005). Some phthalate
metabolites are also known to interact with
peroxisome proliferator–activated receptors
(PPARs), which are not only important regu-
lators of lipid and glucose homeostasis (Evans
et al. 2004) but also mediate some effects of
phthalates on testicular and hepatic function
(Corton and Lapinskas 2005; Lapinskas et al.
2005). Activation of PPARs appear to have
generally beneficial effects on lipid and glu-
cose homeostasis, though medications that
activate PPARγ improve insulin sensitivity
while simultaneously increasing nonvisceral
fat mass (Semple et al. 2006). 
Several research paths would help deter-
mine the importance of our ﬁndings. Animal
studies conducted in human exposure ranges,
as well as human cross-sectional studies, could
explore the capacity of combinations of hor-
monally active agents to create metabolic dis-
turbances such as those we have examined
here. Studies similar to ours could be extended
to women, children, and adolescents, or to
related conditions such as metabolic syndrome.
Measurement of sex hormones, unavailable for
males in NHANES 1999–2002, might suggest
possible mechanisms. Examination of lipid
effects could help tease out PPAR contribu-
tions. Ultimately, longitudinal studies will be
required to provide more deﬁnitive answers.
In conclusion, in this large national cross-
sectional sample, several phthalate metabolites
showed statistically signiﬁcant positive corre-
lations with abdominal obesity and insulin
resistance in adult U.S. males. If conﬁrmed by
longitudinal studies, these associations would
suggest that phthalates, a widely used family
of chemicals, may contribute to the preva-
lence of obesity, insulin resistance, and related
clinical disorders. Because phthalates are
rapidly metabolized, unlike PCBs and other
persistent organic contaminants, such conﬁr-
mation could prompt effective actions to
reduce phthalate exposure in the population. 
REFERENCES
Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-
Barbash R, et al. 2006. Overweight, obesity, and mortality
in a large prospective cohort of persons 50 to 71 years old.
N Engl J Med 355(8):763–778.
Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A.
2006. The estrogenic effect of bisphenol A disrupts pan-
creatic β-cell function in vivo and induces insulin resis-
tance. Environ Health Perspect 114:106–112.
Andrade AJ, Grande SW, Talsness CE, Grote K, Chahoud I. 2006.
A dose-response study following in utero and lactational
exposure to di-(2-ethylhexyl)-phthalate (DEHP): non-monot-
onic dose-response and low dose effects on rat brain aro-
matase activity. Toxicology 227(3):185–192.
Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL,
Pirkle JL. 2005. Urinary creatinine concentrations in the U.S.
population: implications for urinary biologic monitoring
measurements. Environ Health Perspect 113:192–200.
Bell FP. 1982. Effects of phthalate esters on lipid metabolism in
various tissues, cells and organelles in mammals. Environ
Health Perspect 45:41–50.
Bhattacharya N, Dufour JM, Vo MN, Okita J, Okita R, Kim KH.
2005. Differential effects of phthalates on the testis and
the liver. Biol Reprod 72(3):745–754.
Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M,
Egan J, et al. 2006. Metabolic syndrome in men with prostate
cancer undergoing long-term androgen-deprivation therapy.
J Clin Oncol 24(24):3979–3983.
CDC (Centers for Disease Control and Prevention). 2005. Third
National Report on Human Exposure to Environmental
Chemicals. Available: http://www.cdc.gov/exposurereport/
[accessed 20 December 2006].
Corton JC, Lapinskas PJ. 2005. Peroxisome proliferator-activated
receptors: mediators of phthalate ester-induced effects in
the male reproductive tract? Toxicol Sci 83(1):4–17.
Ding EL, Song Y, Malik VS, Liu S. 2006. Sex differences of endoge-
nous sex hormones and risk of type 2 diabetes: a systematic
review and meta-analysis. JAMA 295(11):1288–1299.
Duty SM, Singh NP, Silva MJ, Barr DB, Brock JW, Ryan L, et al.
2003. The relationship between environmental exposures to
phthalates and DNA damage in human sperm using the neu-
tral comet assay. Environ Health Perspect 111:1164–1169.
Ebbeling CB, Pawlak DB, Ludwig DS. 2002. Childhood obesity:
public-health crisis, common sense cure. Lancet
360(9331):473–482.
Evans RM, Barish GD, Wang YX. 2004. PPARs and the complex
journey to obesity. Nat Med 10(4):355–361.
Farin HM, Abbasi F, Reaven GM. 2006. Body mass index and
waist circumference both contribute to differences in
insulin-mediated glucose disposal in nondiabetic adults.
Am J Clin Nutr 83(1):47–51.
Fisher JS. 2004. Environmental anti-androgens and male repro-
ductive health: focus on phthalates and testicular dys-
genesis syndrome. Reproduction 127(3):305–315.
Fujimoto WY. 2000. The importance of insulin resistance in the
pathogenesis of type 2 diabetes mellitus. Am J Med
108(suppl 6a:)9S–14S.
Gayathri NS, Dhanya CR, Indu AR, Kurup PA. 2004. Changes in
some hormones by low doses of di (2-ethyl hexyl) phthalate
(DEHP), a commonly used plasticizer in PVC blood storage
bags & medical tubing. Indian J Med Res 119(4):139–144.
Graubard BI, Korn EL. 1996. Survey inference for subpopulations.
Am J Epidemiol 144(1):102–106.
Gray LE Jr, Wilson VS, Stoker T, Lambright C, Furr J, Noriega N,
et al. 2006. Adverse effects of environmental antiandrogens
and androgens on reproductive development in mammals.
Int J Androl 29(1):96–104. 
Greenland S. 1989. Modeling and variable selection in epidemio-
logic analysis. Am J Public Health 79(3):340–349.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. 1998.
Mortality from coronary heart disease in subjects with type
2 diabetes and in nondiabetic subjects with and without
prior myocardial infarction. N Engl J Med 339(4):229–234.
Hauser R, Calafat AM. 2005. Phthalates and human health.
Occup Environ Med 62(11):806–818.
Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. 2004a.
Medications as a source of human exposure to phthalates.
Environ Health Perspect 112:751–753.
Hauser R, Meeker JD, Duty S, Silva MJ, Calafat AM. 2006.
Altered semen quality in relation to urinary concentrations
of phthalate monoester and oxidative metabolites.
Epidemiology 17:682–691.
Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM. 2004b.
Temporal variability of urinary phthalate metabolite levels
in men of reproductive age. Environ Health Perspect
112:1734–1740.
Hauser R, Williams P, Altshul L, Calafat AM. 2005. Evidence of
interaction between polychlorinated biphenyls and phtha-
lates in relation to human sperm motility. Environ Health
Perspect 113:425–430.
Hornung RW, Reed LD. 1990. Estimation of average concentra-
tion in the presence of nondetectable values. App Occup
Environ Hyg 5:46–51.
Hotchkiss AK, Parks-Saldutti LG, Ostby JS, Lambright C, Furr J,
Phthalates, waist circumference, and insulin resistance
Environmental Health Perspectives • VOLUME 115 | NUMBER 6 | June 2007 881Stahlhut et al.
882 VOLUME 115 | NUMBER 6 | June 2007 • Environmental Health Perspectives
Vandenbergh JG, et al. 2004. A mixture of the “antiandro-
gens” linuron and butyl benzyl phthalate alters sexual dif-
ferentiation of the male rat in a cumulative fashion. Biol
Reprod 71(6):1852–1861.
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori
A, et al. 2005. Effects of testosterone on body composition,
bone metabolism and serum lipid profile in middle-aged
men: a meta-analysis. Clin Endocrinol (Oxf) 63(3):280–293.
Janssen I, Katzmarzyk PT, Ross R. 2004. Waist circumference
and not body mass index explains obesity-related health
risk. Am J Clin Nutr 79(3):379–384.
Jönsson BA, Richthoff J, Rylander L, Giwercman A, Hagmar L.
2005. Urinary phthalate metabolites and biomarkers of repro-
ductive function in young men. Epidemiology 16(4):487–493.
Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. 2003.
Association of endogenous sex hormones and insulin
resistance among postmenopausal women: results from
the Postmenopausal Estrogen/Progestin Intervention Trial.
J Clin Endocrinol Metab 88(4):1646–1652.
Koch HM, Bolt HM, Angerer J. 2004. Di(2-ethylhexyl)phthalate
(DEHP) metabolites in human urine and serum after a single
oral dose of deuterium-labelled DEHP. Arch Toxicol
78(3):123–130.
Koch HM, Bolt HM, Preuss R, Angerer J. 2005. New metabo-
lites of di(2-ethylhexyl)phthalate (DEHP) in human urine
and serum after single oral doses of deuterium-labelled
DEHP. Arch Toxicol 79(7):367–376.
Lapinskas PJ, Brown S, Leesnitzer LM, Blanchard S,
Swanson C, Cattley RC, et al. 2005. Role of PPARα in medi-
ating the effects of phthalates and metabolites in the liver.
Toxicology 207(1):149–163. 
Latini G. 2005. Monitoring phthalate exposure in humans. Clin
Chim Acta 361(1–2):20–29.
Lawlor DA, Sattar N, Smith GD, Ebrahim S. 2005. The associa-
tions of physical activity and adiposity with alanine amino-
transferase and gamma-glutamyltransferase. Am J
Epidemiol 161(11):1081–1088.
Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, et al.
2006. A strong dose-response relation between serum
concentrations of persistent organic pollutants and dia-
betes: results from the National Health and Examination
Survey 1999–2002. Diabetes Care 29(7):1638–1644.
Lehmann KP, Phillips S, Sar M, Foster PM, Gaido KW. 2004.
Dose-dependent alterations in gene expression and
testosterone synthesis in the fetal testes of male rats
exposed to di (n-butyl) phthalate. Toxicol Sci 81(1):60–68.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,
et al. 1999. A more accurate method to estimate glomerular
filtration rate from serum creatinine: a new prediction
equation. Ann Intern Med 130(6):461–470.
Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN,
Chellakooty M, et al. 2006. Human breast milk contamination
with phthalates and alterations of endogenous reproductive
hormones in infants three months of age. Environ Health
Perspect 114:270–276.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. 1985. Homeostasis model assessment: insulin
resistance and beta-cell function from fasting plasma glu-
cose and insulin concentrations in man. Diabetologia
28(7):412–419.
Mårin P. 1995. Testosterone and regional fat distribution. Obes
Res 3(suppl 4):609S–612S.
Mårin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A,
et al. 1993. Androgen treatment of abdominally obese men.
Obes Res 1(4):245–251.
Mårin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G,
et al. 1992. The effects of testosterone treatment on body
composition and metabolism in middle-aged obese men.
Int J Obes Relat Metab Disord 16(12):991–997.
Mårin P, Lönn L, Andersson B, Odén B, Olbe L, Bengtsson BA,
et al. 1996. Assimilation of triglycerides in subcutaneous
and intraabdominal adipose tissues in vivo in men: effects
of testosterone. J Clin Endocrinol Metab 81(3):1018–1022.
NCHS (National Center for Health Statistics). 2006a. Current
NHANES Web Tutorial. Available: http://www.cdc.gov/
nchs/tutorials/currentnhanes/index.htm [accessed
29 January 2007].
NCHS (National Center for Health Statistics). 2006b. National
Health and Nutrition Examination Survey. Available: http://
www.cdc.gov/nchs/nhanes.htm [accessed 1 November
2006].
NCHS (National Center for Health Statistics). 2006c. Note for
Correction of Serum Creatinine for NHANES III, NHANES
1999–2000, 2001–2002 and 2003–2004. Available: http://www.
cdc.gov/nchs/data/nhanes/nhanes_03_04/general_%20note_
for_serum_creatinine.pdf [accessed 17 January 2007].
Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. 2002.
Endogenous sex hormones and the development of type 2
diabetes in older men and women: the Rancho Bernardo
study. Diabetes Care 25(1):55–60.
Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR,
Heymsﬁeld SB. 2003. The metabolic syndrome: prevalence
and associated risk factor findings in the US population
from the Third National Health and Nutrition Examination
Survey, 1988–1994. Arch Intern Med 163(4):427–436.
Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR,
Barlow NJ, et al. 2000. The plasticizer diethylhexyl phtha-
late induces malformations by decreasing fetal testos-
terone synthesis during sexual differentiation in the male
rat. Toxicol Sci 58(2):339–349.
Phillips GB, Jing T, Heymsﬁeld SB. 2003. Relationships in men
of sex hormones, insulin, adiposity, and risk factors for
myocardial infarction. Metabolism 52(6):784–790.
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX,
et al. 2006. Obesity and cardiovascular disease: patho-
physiology, evaluation, and effect of weight loss: an
update of the 1997 American Heart Association Scientiﬁc
Statement on Obesity and Heart Disease from the Obesity
Committee of the Council on Nutrition, Physical Activity,
and Metabolism. Circulation 113(6):898–918.
Rajapakse N, Silva E, Kortenkamp A. 2002. Combining xeno-
estrogens at levels below individual no-observed-effect
concentrations dramatically enhances steroid hormone
action. Environ Health Perspect 110:917–921.
Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance
in human disease. Diabetes 37(12):1595–1607.
Rusyn I, Peters JM, Cunningham ML. 2006. Modes of action
and species-specific effects of di-(2-ethylhexyl)phthalate
in the liver. Crit Rev Toxicol 36(5):459–479.
Rylander L, Rignell-Hydbom A, Hagmar L. 2005. A cross-sectional
study of the association between persistent organochlorine
pollutants and diabetes. Environ Health 4:28; doi:10.1186/
1476-069X-4-28 [Online 29 November 2005].
Schettler T. 2006. Human exposure to phthalates via consumer
products. Int J Androl 29(1):134–139. 
Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG,
et al. 2007. Androgens and diabetes in men: results from
the Third National Health and Nutrition Examination
Survey (NHANES III). Diabetes Care 30(2):234–238.
Semple RK, Chatterjee VK, O’Rahilly S. 2006. PPARγ and human
metabolic disease. J Clin Invest 116(3):581–589. 
Sharifi N, Gulley JL, Dahut WL. 2005. Androgen deprivation
therapy for prostate cancer. JAMA 294(2):238–244.
Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP,
et al. 2004. Urinary levels of seven phthalate metabolites in
the U.S. population from the National Health and Nutrition
Examination Survey (NHANES) 1999–2000. Environ Health
Perspect 112:331–338.
Stroheker T, Cabaton N, Nourdin G, Régnier JF, Lhuguenot JC,
Chagnon MC. 2005. Evaluation of anti-androgenic activity
of di-(2-ethylhexyl)phthalate. Toxicology 208(1):115–121.
Sugiyama S, Shimada N, Miyoshi H, Yamauchi K. 2005.
Detection of thyroid system-disrupting chemicals using
in vitro and in vivo screening assays in Xenopus laevis.
Toxicol Sci 88(2):367–374.
Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM,
et al. 2005. Decrease in anogenital distance among male
infants with prenatal phthalate exposure. Environ Health
Perspect 113:1056–1061.
Takano H, Yanagisawa R, Inoue K, Ichinose T, Sadakane K,
Yoshikawa T. 2006. Di-(2-ethylhexyl) phthalate enhances
atopic dermatitis-like skin lesions in mice. Environ Health
Perspect 114:1266–1269.
Travison TG, Araujo AB, O’Donnell AB, Kupelian V, McKinlay JB.
2007. A population-level decline in serum testosterone lev-
els in American men. J Clin Endocrinol Metab 92(1):196–202.
Wallace TM, Levy JC, Matthews DR. 2004. Use and abuse of
HOMA modeling. Diabetes Care 27(6):1487–1495.
Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM,
vom Saal FS. 2003. Large effects from small exposures. I.
Mechanisms for endocrine-disrupting chemicals with
estrogenic activity. Environ Health Perspect 111:994–1006.
Zimmet P, Alberti KG, Shaw J. 2001. Global and societal implica-
tions of the diabetes epidemic. Nature 414(6865):782–787.Environmental Health Perspectives • VOLUME 115 | NUMBER 6 | June 2007 883
Research
Persistent organic pollutants (POPs) are
organic chemical compounds that are highly
toxic, persist in the environment, bioaccumu-
late in fatty tissues of living organisms, travel
long distances, and naturally flow toward
colder climates (Abelsohn et al. 2002).
Humans are generally exposed to POPs
through their food supply (Abelsohn et al.
2002). 
Whether the exposure to endocrine disrup-
tors such as POPs at current background envi-
ronmental levels is harmful to human health
has become a matter of intense debate, politi-
cally and scientiﬁcally (Kaiser 2000). However,
we recently reported striking associations of
serum concentrations of several POPs with
diabetes in a random sample of the general
population with background exposure to
POPs (Lee et al. 2006b). In a recent editorial
(Lee et al. 2006a), we discussed that selection
of a reference group with a known very low
exposure is critical in the estimation of POPs-
associated risks. This is because risks of several
POPs-associated conditions appear to increase
substantially even within a narrow range of low
POPs concentrations, not detectable without
substantial blood volume. Thus, epidemiologic
studies on POPs in the general population
could identify strong associations that might
have been missed in previous epidemiologic
studies in people exposed to high concentra-
tions of selected POPs that used the general
population as the reference group, as if its sub-
stantial range of exposure had uniform risk. 
In the present study we hypothesized that
background environmental exposure to POPs
is also involved in pathogenesis of arthritis.
Among the various subtypes of arthritis,
rheumatoid arthritis (RA) and osteoarthritis
(OA) are the two most common in the gen-
eral population (Abyad and Boyer 1992). RA
is an autoimmune disease in which an as yet
unknown trigger results in a chronic inﬂam-
matory process affecting the synovial mem-
brane of the joints (Gabriel 2001), while OA
is often thought to result from natural aging
processes on the joint surfaces (Sharma et al.
2006). Although much is known about the
pathophysiology of these conditions at a cel-
lular level, there is considerably less informa-
tion about the etiology of RA and OA in
general population studies.
Endocrine disruptors such as POPs
markedly influence the immune system
(Ahmed 2000), which could increase the
risk of autoimmune diseases such as RA. In
addition, beyond the negative effects of
increased weight bearing caused by obesity,
metabolic change due to adipose tissue has
recently been proposed as one underlying
mechanism of osteoarthritis (Dumond et al.
2003). Because POPs stored in adipose tissue
can be related to differentiation, metabolism,
and function in adipose tissue (Mullerova
and Kopecky 2006), POPs could be involved
in the relation between obesity and OA.
Furthermore, the relations of POPs with
arthritis may be different depending on sex
because endocrine disruptors such as POPs
may exert their effects through sex hormone-
related receptors (Crews et al. 2000). 
The population-based National Health and
Nutrition Examination Survey (NHANES)
1999–2002 measured background concentra-
tions of a variety of POPs. This survey also
obtained self-report of clinical diagnosis of
history of arthritis and subtypes of arthritis.
Although the validity of report of all types of
arthritis combined is high, validity of the sub-
type of arthritis based on questionnaire has
been reported to be low (Star et al. 1996).
Given this fact, the predominance of RA and
OA among all arthritis types, and our
hypothesis that jointly involved RA and OA,
we primarily focused our investigation on the
association between serum concentrations of
POPs and prevalence of all arthritis and fur-
ther analyzed by the subtype of arthritis. 
Materials and Methods
The 1999–2002 NHANES conducted by the
National Center for Health Statistics (NCHS)
of the Centers for Disease Control and
Prevention (CDC) was designed to be nation-
ally representative of the noninstitutionalized
U.S. civilian population on the basis of a com-
plex, multistage probability sample. Details of
the NHANES protocol and all testing
Address correspondence to D.R. Jacobs Jr., University
of Minnesota, Division of Epidemiology, School of
Public Health, 1300 South 2nd St., Suite 300,
Minneapolis, MN 55454 USA. Telephone: (612)
624-4196. Fax: (612) 624-0315. E-mail: jacobs@
epi.umn.edu 
This study was supported in part by the Brain
Korea 21 project in 2007.
The authors declare they have no competing
ﬁnancial interests.
Received 7 November 2006; accepted 20 February
2007.
Positive Associations of Serum Concentration of Polychlorinated Biphenyls
or Organochlorine Pesticides with Self-reported Arthritis, Especially
Rheumatoid Type, in Women
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BACKGROUND: Persistent organic pollutants (POPs) can influence the immune system, possibly
increasing the risk of rheumatoid arthritis (RA). In addition, as metabolic change due to obesity has
been proposed as one mechanism of osteoarthritis (OA), POPs stored in adipose tissue may be also
associated with OA. 
OBJECTIVE: Our goal in this study was to examine associations of background exposure to POPs
with arthritis among the general population.
DESIGN: We investigated cross-sectional associations of serum POPs concentrations with the preva-
lence of self-reported arthritis in 1,721 adults ≥ 20 years of age in the National Health and
Nutrition Examination Survey 1999–2002. 
RESULTS: Among several POPs, dioxin-like polychlorinated biphenyls (PCBs) or nondioxin-like
PCBs were positively associated with arthritis in women. After adjusting for possible confounders,
odds ratios (ORs) were 1.0, 2.1, 3.5, and 2.9 across quartiles of dioxin-like PCBs (p for trend
= 0.02). Corresponding ﬁgures for nondioxin-like PCBs were 1.0, 1.6, 2.6, and 2.5 (p for trend
= 0.02). Organochlorine (OC) pesticides were also weakly associated with arthritis in women. For
subtypes of arthritis, respectively, RA was more strongly associated with PCBs than was OA. The
adjusted ORs for RA were 1.0, 7.6, 6.1, and 8.5 for dioxin-like PCBs (p for trend = 0.05), 1.0, 2.2,
4.4, and 5.4 for nondioxin-like PCBs (p for trend < 0.01), and 1.0, 2.8, 2.7, and 3.5 for OC pesti-
cides (p for trend = 0.15). POPs in men did not show any clear relation with arthritis. 
CONCLUSIONS: The possibility that background exposure to PCBs may be involved in pathogenesis
of arthritis, especially RA, in women should be investigated in prospective studies. 
KEY WORDS: arthritis, persistent organic pollutants, pesticides, polychlorinated biphenyls, rheuma-
toid arthritis. Environ Health Perspect 115:883–888 (2007). doi:10.1289/ehp.9887 available via
http://dx.doi.org/ [Online 20 February 2007]procedures are available elsewhere (NCHS
2006a, 2006b). Serum concentrations of bio-
logically important POPs or their metabolites
were measured in subsamples of the
NHANES 1999–2002 (NCHS 2005). The
study protocol was reviewed and approved by
the CDC institutional review board; addi-
tionally, informed written consent was
obtained from all subjects before they took
part in the study.
The NHANES standardized home
interview was followed by a detailed physical
examination in a mobile evaluation clinic or
the participant’s home (NCHS 2006a, 2006b).
Information about existing medical conditions
was collected using questionnaires. Venous
blood samples were collected and shipped
weekly at –20°C. POPs were measured by
high-resolution gas chromatography/high-
resolution mass spectrometry using isotope
dilution for quantiﬁcation. All of these analytes
were measured in approximately 5 mL serum
using a modiﬁcation of the method of Turner
et al. (1997). Ability to detect low POPs con-
centrations was greater in those participants
who provided a larger aliquot. The POPs were
reported on a lipid-adjusted basis using con-
centrations of serum total cholesterol and
triglycerides. 
Although 49 POPs were measured in
both NHANES 1999–2000 and 2001–2002,
to avoid bias in estimation among those
below the limit of detection (LOD) we
selected the 19 POPs for which at least
60% of study subjects had concentrations
> LOD; 3 polychlorinated dibenzo-p-dioxins
(PCDDs), 3 polychlorinated dibenzofurans
(PCDFs), 4 dioxin-like polychlorinated
biphenyls (PCBs), 5 nondioxin-like PCBs,
and 4 organochlorine (OC) pesticides. A total
of 1,721 study participants were ≥ 20 years of
age with information available on serum con-
centrations of the 19 selected POPs. 
For each POP, subjects with serum con-
centrations < LOD were regarded as the refer-
ence group, and subjects with detectable
values were categorized into quartiles by cutoff
points of 25th, 50th, and 75th values. To
yield a cumulative measure (which would pro-
vide a cumulation of risk across POPs with
similar chemical and physical properties) of 3
PCDDs, we summed the rank of 3 POPs that
belong to the PCDDs. The summary values
were categorized into quartiles by cutoff points
of 25th, 50th, and 75th values. We categorized
and cumulated POP subclasses similarly for the
3 PCDFs, the 4 dioxin-like PCBs, the 5 non-
dioxin-like PCBs, and the 4 OC pesticides. For
example, a subject had rank 0 for all POPs with
serum concentrations < LOD. For other POPs
with a detectable level, the participant was
ranked accordingly. Thus, depending on the
sum of ranks of the several POPs belonging to
the speciﬁc POP subclass under consideration,
the subject could be in the lowest quartile or in
a higher quartile; however, if all POPs in the
subclass were nondetectable, the subject would
be placed in the lowest quartile. We chose the
current approach because there is no scientiﬁc
rationale for summing within the POP sub-
classes to create broader exposure categories. 
Participants were considered to have
prevalent arthritis if they answered “yes” to the
following question: “Has a doctor or other
health professional ever told you that you had
arthritis?” They were further asked about the
type of arthritis. We used logistic regression
models to calculate multivariate-adjusted odd
ratios (ORs) and 95% confidence intervals
(CIs). All analyses were performed separately
in men and women. Adjusting variables were
age (years), race/ethnicity, poverty income
ratio (continuous), body mass index (BMI;
continuous), and cigarette smoking (never,
Lee et al.
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Table 1. Age-adjusted Spearman correlation coefﬁcientsa between ﬁve categories of lipid-adjusted POPs
(3 PCDDs, 3 PCDFs, 4 dioxin-like PCBs, 5 nondioxin-like PCBs, and 4 OC pesticides) with demographic or
health behavior factors by sex.
Dioxin-like Nondioxin-like  OC 
Characteristic PCDDs PCDFs PCBs PCBs pesticides
Males 
Age 0.53** 0.35** 0.65** 0.69** 0.72**
Race NS 0.07* NS NS –0.29**
Poverty income ratio  NS NS 0.10** 0.10** –0.17**
BMI 0.24** 0.14** 0.15** NS 0.18**
Current smoker  –0.14** NS –0.13** NS NS
Females 
Age 0.60** 0.52** 0.76** 0.73** 0.78**
Race –0.10** 0.08* 0.08* 0.10** –0.35**
Poverty income ratio  NS 0.07* 0.09** 0.12** –0.16**
BMI NS NS NS –0.17** NS
Current smoker  –0.19** NS NS 0.09** NS
NS, not signiﬁcant. For race, white = 1, and others = 0. For current smoker, current = 1, and others = 0.
aBefore calculating correlation coefﬁcients, detectable values of each POP were individually ranked, and the rank order
of the individual POPs in each subclass were summed to arrive at the subclass value; all nondetectable values were
ranked as 0. *p < 0.05. **p < 0.01.
Table 2. Adjusteda OR (95% CI) of prevalence of arthritis by quartiles of PCDDs, PCDFs, dioxin-like PCBs, non-
dioxin-like PCBs, and OC pesticides in males and females.b
Analyte < 25th  25th to < 50th 50th to < 75th ≥ 75th ptrend
Males
PCDDs
Cases/participants (no.) 17/191 35/193 47/193 65/192
Adjusted OR (95% CI) Referent  1.5 (0.8–2.9) 1.6 (0.8–3.1) 1.4 (0.7–2.8) 0.48 
PCDFs
Cases/participants (no.) 30/192 29/192 43/193 62/192
Adjusted OR (95% CI) Referent 0.7 (0.4–1.2) 0.9 (0.5–1.6) 1.1 (0.6–1.9) 0.52 
Dioxin-like PCBs
Cases/participants (no.) 16/192 32/192 47/193 69/192
Adjusted OR (95% CI) Referent 1.3 (0.6–2.5) 1.1 (0.6–2.3) 1.3 (0.6–2.8) 0.56
Nondioxin-like PCBs
Cases/participants (no.) 12/192 24/192 72/193 56/192
Adjusted OR (95% CI) Referent 1.2 (0.5–2.6) 3.3 (1.6–6.9) 1.5 (0.7–3.4) 0.23
OC pesticides
Cases/participants (no.) 14/192 28/192 43/193 62/192
Adjusted OR (95% CI) Referent 1.1 (0.5–2.3) 1.5 (0.7–3.2) 1.2 (0.5–2.7) 0.72
Females
PCDDs
Cases/participants (no.) 28/238 54/238 62/238 106/238
Adjusted OR (95% CI) Referent 1.4 (0.8–2.5) 1.0 (0.6–1.9) 1.3 (0.7–2.4) 0.67
PCDFs
Cases/participants (no.) 31/237 52/239 63/238 104/238
Adjusted OR (95% CI) Referent 1.2 (0.7–2.1) 0.9 (0.5–1.6) 1.3 (0.8–2.3) 0.51
Dioxin-like PCBs
Cases/participants (no.) 11/237 36/239 91/238 112/238
Adjusted OR (95% CI) Referent 2.1 (1.0–4.5) 3.5 (1.7–7.4) 2.9 (1.3–6.5) 0.02
Nondioxin-like PCBs
Cases/participants (no.) 16/238 34/238 89/238 111/238
Adjusted OR (95% CI) Referent 1.6 (0.8–3.1) 2.6 (1.3–5.1) 2.5 (1.2–5.2) 0.02
OC pesticides
Cases/participants (no.) 19/238 37/238 73/238 121/238
Adjusted OR (95% CI) Referent 1.2 (0.6–2.3) 1.3 (0.7–2.6) 1.8 (0.9–3.9) 0.09
aAdjusted for age, race, poverty income ratio, BMI, and cigarette smoking. bDetectable values of each POP were individu-
ally ranked, and the rank orders of the individual POPs in each subclass were summed to arrive at the subclass value; all
nondetectable values were ranked as 0. former, or current). We substituted median
values of noncases for missing BMI or poverty
income ratio in 83 subjects; exclusion of these
individuals did not change any conclusions. 
We performed all statistical analyses with
SAS 9.1 (SAS Institute Inc., Cary, NC, USA)
and SUDAAN 9.0 (Research Triangle
Institute, Research Triangle Park, NC, USA).
Estimates of main results were calculated
accounting for stratification and clustering
(Korn and Graubard 1991), adjusting for age,
race and ethnicity, and poverty income ratio
instead of using sample weights; this adjust-
ment is a good compromise between effi-
ciency and bias (Graubard and Korn 1999;
Korn and Graubard 1991). Because results
were very similar with SAS 9.1 and SUDAAN
9.0, we present the results based on SAS 9.1.
Results
The sample of 1,721 participants was 44.7%
male, 47.7% white, and 16.9% current
smokers. Mean ± SD for age was 49.2 ±
19.0 years (range 20–85 years). Table 1 shows
the associations of ﬁve subclasses of POPs with
demographic or health behavior factors. Age
was the strongest and most important corre-
late of serum concentrations of all five sub-
classes of POPs in both sexes, with correlation
coefﬁcients ranging from 0.35 to 0.72. White
subjects had lower concentrations of OC pes-
ticides in both sexes and lower PCDDs in
females, but higher concentrations of PCDFs
and PCBs. Those with higher income had
lower concentrations of OC pesticides but
higher PCBs. Males with higher BMI tended
to have higher concentrations of most POPs;
however BMI was not associated with POPs
among females, except in the inverse associa-
tion with nondioxin-like PCBs. Current
smokers tended to have lower concentrations
of most POPs. After adjusting for age, we
found positive pairwise correlations among
serum concentrations of the ﬁve subclasses of
POPs with correlation coefﬁcients from 0.24
to 0.73 in men and 0.19 to 0.77 in women.
Women had higher serum concentrations of
all five subclasses of POPs with age-adjusted
correlation coefﬁcients with sex of 0.22–0.34. 
There were 414 prevalent self-reported
arthritis cases (164 men and 250 women):
93 RA, 116 OA, 37 other types of arthritis,
and 168 unspecified arthritis cases. Neither
PCDDs nor PCDFs were associated with
arthritis in either sex. However, women who
had higher concentrations of dioxin-like PCBs
or nondioxin-like PCBs showed a higher risk
of prevalence of arthritis (Table 2). After
adjusting for age, race/ethnicity, poverty
income ratio, BMI, and smoking, ORs were
1.0, 2.1, 3.5, and 2.9 across quartiles of
dioxin-like PCBs (p for trend = 0.02).
Corresponding figures for nondioxin-like
PCBs were 1.0, 1.6, 2.6, and 2.5 (p for trend
= 0.02). OC pesticides were weakly associated
with the prevalence of arthritis among women;
PCBs, OC pesticides, and rheumatoid arthritis
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Table 3. Adjusteda OR (95% CI) of prevalence of arthritis by categories of speciﬁc POPs belonging to dioxin-like PCBs, nondioxin-like PCBs, and OC pesticides in
females.
Detectableb
Analyte Nondetectable < 25th  25th to < 50th 50th to < 75th ≥ 75th ptrend
Dioxin-like PCBs
2,4,4´,5-Tetrachlorobiphenyl (PCB-74)
Cases/participants (no.) 20/334 26/151 53/158 7/154 81/155
Adjusted OR (95% CI) Referent 2.1 (1.1–4.1) 2.9 (1.5–5.6) 3.4 (1.8–6.7) 3.2 (1.5–6.7) < 0.01 
2,3´,4,4´,5-Pentachlorobiphenyl (PCB-118)
Cases/participants (no.) 21/306 27/162 47/161 74/161 81/162
Adjusted OR (95% CI) Referent 1.6 (0.8–3.1) 2.1 (1.1–3.9) 3.0 (1.6–5.8) 2.2 (1.1–4.5) 0.01
3,3´,4,4´,5-Pentachlorobiphenyl (PCB-126)
Cases/participants (no.) 26/174 25/193 32/195 70/196 97/194
Adjusted OR (95% CI) Referent 0.9 (0.4–1.6) 0.7 (0.4–1.3) 1.3 (0.7–2.3) 1.4 (0.8–2.7) 0.07
3,3´,4,4´,5,5´-Hexachlorobiphenyl (PCB-169)
Cases/participants (no.) 26/221 15/183 47/183 76/183 86/182
Adjusted OR (95% CI) Referent 0.7 (0.3–1.4) 1.4 (0.8–2.6) 1.6 (0.9–3.0) 1.6 (0.8–3.1) 0.08
Nondioxin-like PCBs
2,2´,3,4,4´,5-Hexachlorobiphenyl (PCB-138)
Cases/participants (no.) 26/233 17/180 52/179 73/181 82/179
Adjusted OR (95% CI) Referent 0.9 (0.4–1.8) 1.6 (0.9–2.9) 1.7 (1.0–3.1) 1.3 (0.7–2.5) 0.21
2,2´,4,4´,5,5´-Hexachlorobiphenyl (PCB-153)
Cases/participants (no.) 20/199 12/188 50/188 83/189 85/188
Adjusted OR (95% CI) Referent 0.7 (0.3–1.5) 1.7 (0.9–3.3) 2.3 (1.2–4.4) 1.6 (0.8–3.2) 0.06
2,2´,3,3´,4,4´,5-Heptachlorobiphenyl (PCB-170)
Cases/participants (no.) 24/344 36/152 47/152 70/152 73/152
Adjusted OR (95% CI) Referent 2.9 (1.6–5.3) 1.9 (1.0–3.6) 2.9 (1.4–5.6) 2.7 (1.3–5.6) 0.03
2,2´,3,4,4´,5,5´-Heptachlorobiphenyl (PCB-180)
Cases/participants (no.) 16/234 21/179 48/179 76/181 89/179
Adjusted OR (95% CI) Referent 1.4 (0.7–2.9) 2.1 (1.1–4.2) 2.7 (1.3–5.7) 2.7 (1.2–6.0) < 0.01
2,2´,3,4´,5,5´,6-Heptachlorobiphenyl (PCB-187)
Cases/participants (no.) 33/396 35/137 46/141 67/140 69/138
Adjusted OR (95% CI) Referent 1.9 (1.1–3.3) 1.9 (1.0–3.4) 2.8 (1.5–5.1) 2.2 (1.1–4.3) 0.01
OC pesticides
p,p´-Dichlorodiphenyldichloroethane
Cases/participants (no.) 0/0 31/236 44/240 84/239 91/237
Adjusted OR (95% CI) Referent 0.9 (0.5–1.6) 1.1 (0.6–2.0) 1.0 (0.5–1.8) 0.93 
Oxychlordane
Cases/participants (no.) 11/185 17/191 51/192 67/192 104/192
Adjusted OR (95% CI) Referent 1.1 (0.5–2.6) 2.6 (1.2–5.4) 2.0 (0.9–4.5) 3.1 (1.3–7.1) < 0.01
trans-Nonachlor
Cases/participants (no.) 5/104 20/210 47/215 75/212 103/211
Adjusted OR (95% CI) Referent 1.4 (0.5–4.0) 2.0 (0.7–5.6) 2.4 (0.9–6.8) 2.2 (0.8–6.6) 0.07
β-Hexachlorocyclohexane
Cases/participants (no.) 17/225 24/181 58/182 74/182 77/182
Adjusted OR (95% CI) Referent 1.0 (0.5–1.9) 1.7 (0.8–3.4) 1.5 (0.7–3.1) 1.4 (0.6–3.2) 0.37
aAdjusted for age, race, poverty income ratio, BMI, and cigarette smoking. bFor each POP, subjects with serum concentrations < LOD were regarded as the reference group. adjusted ORs were 1.0, 1.2, 1.3, and 1.8 (p for
trend = 0.09) (Table 2). We also performed
analyses adjusting for sex (males and females
in one model); adjusted ORs for dioxin-like
PCBs were 1.0, 1.6, 2.1, and 2.0 (p for trend
= 0.02) and those for nondioxin-like PCBs
were 1.0, 1.4, 3.0, and 2.1 (p for trend
< 0.01). However, we found little association
among males (Table 2), and we observed sig-
niﬁcant p-values for sex interaction: 0.03 for
dioxin-like PCBs and 0.04 for nondioxin-like
PCBs. When the study subjects were stratiﬁed
by age (< 50 and ≥ 50 years) or obesity (BMI
< 30 and ≥ 30), the associations were similar
to those in Table 2. Most specific POPs
belonging to the subclasses of dioxin-like and
nondioxin-like PCBs and OC pesticides were
positively associated with arthritis among
women (Table 3). 
For subtypes of arthritis among women,
RA (n = 93) was more strongly associated
with dioxin-like PCBs, nondioxin-like PCBs,
or OC pesticides than was OA (n = 116)
(Table 4). The adjusted ORs (by quartile) for
RA were 1.0, 7.6, 6.1, and 8.5 for dioxin-like
PCBs (p for trend = 0.05), 1.0, 2.2, 4.4, and
5.4 for nondioxin-like PCBs (p for trend
< 0.01), and 1.0, 2.8, 2.7, and 3.5 for OC
pesticides (p for trend = 0.15). Adjusted ORs
for unspecified arthritis subtype (n = 168)
were weaker than those of RA but stronger
than those of OA (Table 4), as we expected
because these cases were likely a mixture of
mostly RA and OA.
In all analyses, we also considered possible
confounding by self-reported weight loss in
the 1 year or in the 10 years before examina-
tion, because weight loss has been reported to
increase serum concentrations of POPs
(Chevrier et al. 2000). However, the adjust-
ment for weight loss did not materially change
the results (data not shown). Additionally, we
investigated the associations after excluding
subjects with diabetes or cardiovascular dis-
eases, but the results were not different (data
not shown). 
Discussion
In the present study, background exposure to
some kinds of POPs was positively associated
with arthritis among women. Especially,
among the two most common subtypes of
arthritis, RA showed much stronger associa-
tions with POPs than did OA, and those
associations were of intermediate strength in
those with unspecified arthritis type. The
validity of self-reported RA is low (Star et al.
1996). However, because subjects did not
know their serum levels of POPs and because
their exposure to POPs was mainly due to
background exposure, nondifferential misclas-
sification is the most likely consequence of
reduced reliability, leading to attenuated
strength of association. In this case, null asso-
ciations could be falsely negative; however,
the clear positive associations among women
would not be explained by the low validity of
RA. In spite of the cross-sectional design, our
ﬁndings are biologically plausible; this is the
first study in the general population with
background exposure to POPs. Whether low-
dose environmental exposure to POPs in
humans could be harmful is one of the most
controversial issues in the ﬁeld of toxicology
(Kaiser 2000; Safe 2000; Welshons et al.
2003). However, few epidemiologic studies
have been carried out for POPs in the general
population, even in a cross-sectional design.
The absence of epidemiologic studies in the
general population is understandable given
the cost of measuring of a variety of POPs
and the substantial amount of serum required
for their measurement.
Endocrine disruptors such as POPs
markedly influence the immune system
(Ahmed 2000), but the possibility that the
human immune system may respond to a low
concentration of POPs has not been studied
speciﬁcally. However, one might infer such an
immune response even to the exposure to the
background exposure to POPs on the basis of
associations of POPs with diabetes in the gen-
eral population, which we have reported in
this same data set (Lee et al. 2006b). Among
the POPs examined in the present study,
PCBs were most strongly associated with RA,
and the associations did not differ depending
on chemical and physical properties of speciﬁc
PCBs (dioxin-like or nondioxin-like).
Interestingly, the known decreasing concentra-
tions of PCBs appear to be consistent with
decreasing secular trends of RA over several
recent decades in the United States (Alamanos
et al. 2006; Doran et al. 2002). 
The different associations between PCBs
and RA by sex we report here may be biologi-
cally plausible because sex hormones appear
to play an important role as modulators of
autoimmune disease onset and perpetuation,
as in the case of RA (Cutolo et al. 2002).
Generally, steroid hormones are implicated in
the immune response, with estrogens as
enhancers at least of the humoral immunity
and androgens, progesterone, and glucocorti-
coids as natural immunosuppressors (Cutolo
et al. 2002). Thus, different effects of PCBs
by sex may be also possible because endocrine
disruptors such as POPs may exert some of
their toxicologic effects through sex hor-
mone–related receptors (Crews et al. 2000;
Ulbrich and Stahlmann 2004).
Until now, reports of the effects of PCBs
on immune function have focused primarily
on immunosuppression, with changes in both
humoral and cellular immunity (Fernlof et al.
1997; Kimbrough and Krouskas 2001; Lu
Lee et al.
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Table 4. Adjusteda OR (95% CI) of prevalence of RA, OA, or unspeciﬁed arthritis by categories of dioxin-like
PCBs, nondioxin-like PCBs, or OC pesticides in females.b
Outcome/analyte < 25th  25th to < 50th 50th to < 75th ≥ 75th ptrend
RA
Dioxin-like PCBs
Cases/participants (no.) 2/228 16/219 17/164 26/152
Adjusted OR (95% CI) Referent 7.6 (1.7–34.4) 6.1 (1.2–29.7) 8.5 (1.6–44.5) 0.05
Nondioxin-like PCBs
Cases/participants (no.) 4/226 9/213 21/710 27/154
Adjusted OR (95% CI) Referent 2.2 (0.6–7.4) 4.4 (1.3–15.2) 5.4 (1.4–20.3) < 0.01
OC pesticides
Cases/participants (no.) 4/223 13/214 19/184 25/142
Adjusted OR (95% CI) Referent 2.8 (0.8–8.9) 2.7 (0.7–9.8) 3.5 (0.9–14.0) 0.15
OA
Dioxin-like PCBs
Cases/participants (no.) 3/229 12/215 28/175 33/159
Adjusted OR (95% CI) Referent 1.9 (0.5–7.2) 2.0 (0.5–7.6) 1.6 (0.4–6.4) 0.97
Nondioxin-like PCBs
Cases/participants (no.) 4/226 12/216 30/179 30/157
Adjusted OR (95% CI) Referent 1.6 (0.5–5.3) 1.7 (0.5–5.8) 1.2 (0.3–4.5) 0.90
OC pesticides
Cases/participants (no.) 4/223 12/213 22/187 38/155
Adjusted OR (95% CI) Referent  1.4 (0.4–4.6) 1.3 (0.4–5.2) 2.1 (0.6–8.2) 0.21
Unspeciﬁed arthritis
Dioxin-like PCBs
Cases/participants (no.) 5/231 8/211 38/185 44/170
Adjusted OR (95% CI) Referent 1.2 (0.4–3.9) 3.8 (1.3–11.2) 2.9 (0.9–9.3) 0.06
Nondioxin-like PCBs
Cases/participants (no.) 7/229 9/213 36/185 43/170
Adjusted OR (95% CI) Referent  1.2 (0.4–3.3) 2.8 (1.0–7.4) 2.8 (1.0–8.3) 0.03
OC pesticides
Cases/participants (no.) 8/228 10/209 24/188 53/172
Adjusted OR (95% CI) Referent 0.8 (0.3–2.3) 1.0 (0.4–2.8) 1.6 (0.6–4.6) 0.14
aAdjusted for age, race, poverty income ratio, BMI, and cigarette smoking. bDetectable values of each POP were individu-
ally ranked, and the rank orders of the individual POPs in each subclass were summed to arrive at the subclass value; all
nondetectable values were ranked as 0. PCBs, OC pesticides, and rheumatoid arthritis
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and Wu 1985; Nakanishi et al. 1985;
Svensson et al. 1994; Van Den Heuvel et al.
2002; Weisglas-Kuperus et al. 2000). Studies
on specific clinical correlates have suggested
increased prevalence of middle ear (Dewailly
et al. 2000; Weisglas-Kuperus et al. 2000)
and other bacterial infections (Tsuji 2000).
Limited information exists on the potential
effects of PCBs on autoimmunity. Most epi-
demiologic studies on autoimmunity have
measured cellular or humoral immunologic
function, such as numbers in lymphocyte
subpopulations, in vitro lymphocyte response,
plasma cytokine levels, or autoantibodies.
However, the results have not been consis-
tent. Although some studies have reported
positive associations (Daniel et al. 2001;
Langer et al. 2002), other studies failed to do
so (Schoenroth et al. 2004; Tsuji 2000; Tsuji
et al. 1999; Yu et al. 1998). 
In addition to PCBs in the present study,
we found that some pesticides were positively
associated with RA among women. Previous
studies on the association between pesticides
and RA have been inconsistent. Several epi-
demiologic studies have reported increased
RA or increased prevalence of antinuclear
antibody among farmers (Lundberg et al.
1994; Olsson et al. 2004; Rosenberg et al.
1999), but others did not (De Roos et al.
2005). Interpretation of previous studies may
be limited because the exposure assessment
was based on questionnaires about exposure
to pesticides rather than on direct measure-
ment of pesticide concentrations in blood. 
We were able to evaluate the associations
of arthritis with a variety of POPs by taking
advantage of the NHANES public use data set.
In most epidemiologic studies until now, only
a limited set of POPs were evaluated. This
approach is sensible when the focus is on occu-
pational or accidental exposure to specific
POPs. However, in the study of general popu-
lations with background exposure to a mixture
of POPs, it may be very important to measure
a variety of POPs, because the associations of
POPs with health outcomes may differ
depending on the speciﬁc types of POPs in the
exposure and the fact that POPs may interact
with each other.
Although the strength of association with
OA was weaker than with RA, OA still
appeared to be associated with some POPs
among women. Recently, metabolic factors
related to obesity, such as secretion of leptin,
have been linked with the onset and progres-
sion of OA (Dumond et al. 2003). Thus,
POPs may be involved in the pathogenesis of
OA because POPs stored in adipose tissue can
cause metabolic disturbances, including over-
secretion of leptin (Mullerova and Kopecky
2006). Leptin also plays a key role in a host of
autoimmune inﬂammatory conditions such as
RA (Otero et al. 2006).
The present study has several limitations.
First, the cross-sectional study design in
NHANES does not allow inferences to be
drawn regarding temporality of events and
the causality between POPs and arthritis.
Second, misclassification bias is possible
because some subjects with a higher POP
value but a lower sample volume could be
classiﬁed in the reference group, or vice versa.
Such misclassiﬁcation would be nondifferen-
tial if sample volume is unrelated to the pres-
ence of arthritis. Third, as discussed above,
the validity of self-reported RA is low (Star
et al. 1996) even though it may be also associ-
ated with nondifferential misclassification,
leading to attenuated strength of association.
In the present study, serum concentrations
of both dioxin-like and nondioxin-like PCBs
were positively and possibly nonlinearly asso-
ciated with arthritis among women. The rela-
tions were stronger with RA than with OA.
These results raise the possibility that back-
ground exposures to some POPs may be
involved in the pathogenesis of autoimmune
diseases such as RA in women. To confirm
these relationships, further study in a prospec-
tive cohort study would be necessary.
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37:1855–1865. Use of groundwater has reduced the morbidity
and mortality from waterborne disease in
Bangladesh and helped the country achieve
self-sufficiency in cereal production through
dry-season irrigation (Ahmad 2001; Gill et al.
2003). However, the shallow groundwater
aquifer of this region is highly contaminated
with naturally occurring arsenic from dissolved
minerals and ores. In a national survey con-
ducted by the British Geological Survey and
the Department of Public Health Engineering,
Bangladesh (BGS and DPHE 2001), 27% of
the shallow tube wells exceeded the Bangladesh
drinking water standard of 50 μg/L, exposing
an estimated 33 million people to potentially
dangerous levels of As in their drinking water.
Chronic exposure to As increases the risk for
As-induced diseases such as noncancerous skin
lesions, bronchitis, hepatomegaly, neuropathy,
peripheral vascular diseases (e.g., gangrene),
cardiovascular disease, skin cancer, lung can-
cer, and bladder cancer (Chen and Ahsan
2004; Chowdhury et al. 2000; Mazumder
2003; McLellan 2002; Smith et al. 1998).
Although there is no question that con-
sumption of As-contaminated drinking water
is the most important route of exposure in
Bangladesh, little research has focused on
food as an additional source of exposure in
spite of evidence that rice, a dietary staple,
can accumulate As when grown in contami-
nated environments. Studies have shown that
irrigation with As-contaminated water can
lead to elevated As concentrations in rice-
paddy soil, as well as in the rice root, stalk,
and grain (Duxbury et al. 2003; Meharg and
Rahman 2003; Norra et al. 2005). Market
basket studies that analyze individual food
items also found that As concentrations in
commonly consumed vegetables are directly
correlated with the As concentration in irriga-
tion water (Alam et al. 2003). Furthermore,
cooking with As-contaminated water can be
an additional source of exposure because rice
absorbs twice its weight in water when
cooked (Bae et al. 2002).
To more fully understand the relative
contribution of food and drinking water to
ingested As dose, we conducted a duplicate
diet study in Pabna district, located north of
Dhaka in central Bangladesh. We targeted
female heads of households because they are
responsible for all food preparation; they also
represent a potentially susceptible sub-
population because there is mounting evi-
dence that As is transmitted to the fetus (Jin
et al. 2006) and can inﬂuence child neurode-
velopment (Wasserman et al. 2004; Wright
et al. 2006). 
Methods
Participant selection. Forty-seven women who
had previously taken part in a longitudinal
study investigating As exposure and biomarker
response, and who identiﬁed themselves as the
primary food preparer in the family were
invited to participate in this study (Kile et al.
2005). All women agreed to participate, and
informed consent was obtained. Two sam-
pling periods were scheduled for 3 consecutive
days in winter (January–March 2004) and for
3 consecutive days in summer (June–August
2004). Participants received compensation
(US$9) after each sampling period. The insti-
tutional review boards at Harvard School of
Public Health and Dhaka Community
Hospital approved the protocol for this study. 
Food samples. Participants were instructed
to save duplicate portions from each meal in
separate polypropylene resealable bags.
Researchers visited each participant after the
midday and evening meals to collect samples,
which were kept refrigerated until processing.
Each evening, individual portions were
weighed in order to determine dietary intake
rates. The portions from each participant were
then homogenized into a 24-hr composite sam-
ple (n = 282) using a blender. Homogenized
samples were aliquotted into polyethylene tubes
and frozen at –4°C and shipped on dry ice.
Field blanks, composed of 50 mL Milli-Q
18.2 Ω analytical grade water (Millipore
Corporation, Billerica, MA, USA), were col-
lected after every eighth sample. For the ﬁeld
blanks, the water underwent the same homoge-
nization process as the food samples and was
preserved with reagent grade nitric acid
(Merck, Darmstadt, Germany) to a pH of < 2.
Composite samples were subjected to micro-
wave acid digestion with nitric acid and ana-
lyzed for total As using dynamic reaction cell
inductively coupled plasma-mass spectrometry
(ICP-DRC-MS) with oxygen as the cell gas
(Model 6100 DRC; PerkinElmer, Norwalk,
CT, USA). This analytical method detects As
oxide species (75As16O+) at mass 91 and avoids
argon chloride interference (Bollinger and
Schleisman1999). Indium was added as an
internal standard upstream of the nebulizer.
The average limit of detection (LOD) was
0.07 μg As/L. The average ﬁeld blank (± SD)
contained 0.03 ± 0.07 μg As/L, with only six
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Dietary Arsenic Exposure in Bangladesh
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BACKGROUND: Millions of people in Bangladesh are at risk of chronic arsenic toxicity from drinking
contaminated groundwater, but little is known about diet as an additional source of As exposure. 
METHODS: We employed a duplicate diet survey to quantify daily As intake in 47 women residing
in Pabna, Bangladesh. All samples were analyzed for total As, and a subset of 35 samples were
measured for inorganic arsenic (iAs) using inductively coupled plasma mass spectrometry equipped
with a dynamic reaction cell. 
RESULTS: Median daily total As intake was 48 µg As/day [interquartile range (IQR), 33–67) from
food and 4 µg As/day (IQR, 2–152) from drinking water. On average, iAs comprised 82% of the
total As detected in dietary samples. After adjusting for the estimated inorganic fraction, 34% [95%
conﬁdence interval (CI), 21–49%] of all participants exceeded the World Health Organization’s
provisional tolerable daily intake (PTDI) of 2.1 µg As/kg-day. Two of the 33 women who used a
well with < 50 µg As/L exceeded this recommendation. 
CONCLUSIONS: When drinking water concentrations exceeded the Bangladesh drinking water stan-
dard of 50 µg As/L, ingested water was the dominant source of exposure. However, as drinking
water As concentrations decrease, the relative contribution of dietary As sources becomes more
important to ingested dose. The combined intake from both diet and drinking water can cause
some individuals to exceed the PTDI in spite of using a tube well that contains < 50 µg As/L.
KEY WORDS: arsenic, Bangladesh, dose, duplicate diet, food, intake, water. Environ Health Perspect
115:889–893 (2007). doi:10.1289/ehp.9462 available via http://dx.doi.org/ [Online 20 February 2007]ﬁeld blanks exceeding the average LOD. Each
sample was analyzed five times, and the
reported total As value was corrected for any As
detected in the method blank and ﬁeld blank.
Four samples had corrected total As concentra-
tions below the averaged method LOD of
0.07 μg/L and were assigned half the LOD.
Samples were digested in 14 batches, with
each batch containing a method blank, certi-
fied rice flour [standard reference material
(SRM) 1568A; National Institute of Standards
and Technology (NIST), Gaithersburg, MD,
USA] and certified dogfish liver sample
(DOLT-2; National Research Council,
Ottawa, Ontario, Canada). The average per-
cent recovery (± SD) was 102.2 ± 7.9% for
SRM 1568A and 93.0± 7.1% for DOLT-2.
We used SRM 1643e (Trace Elements in
Water; NIST) to validate instrument perfor-
mance. The average percent recovery for
SRM 1643e was 101.7 ± 5.8%. Additionally,
10% of the samples were randomly chosen
for replicate analysis and were analyzed on
separate days in the laboratory. The average
percent difference in As concentrations
detected in replicate samples was 4.0%. 
Thirty-ﬁve samples representing a range of
drinking water exposures were analyzed by
Brooks Rand (Seattle, WA, USA) for total As
and inorganic arsenic (iAs). This served as an
interlaboratory validation for total As and also
allowed for the estimation of the iAs fraction
in composite dietary samples. Three samples
partially thawed during shipping; however, it
is unlikely that this brief warming inﬂuenced
As speciation because it lasted < 24 hr. Brooks
Rand extracted the 35 samples for total As
and iAs following modifications of U.S.
Environmental Protection Agency (EPA)
methods 1638 (U.S. EPA 1995b) and 1632
(U.S. EPA 1995a), respectively. For total As,
samples were closed-vessel oven-bomb diges-
ted with concentrated nitric acid and analyzed
by ICP-DRC-MS. For total iAs, sample
aliquots were extracted with hydrochloric acid
and the pH adjusted to 1.5 before analysis.
The comparison between laboratories for total
As was good, with an interlaboratory percent
difference of 14.6 ± 19.1%. 
The quality control at Brooks Rand
included method blanks, certified dogfish
muscle tissue (DORM-2; National Research
Council, Canada), dogfish liver tissue
(DOLT-3; National Research Council,
Canada), and certiﬁed lobster hepatopancreas
(TORT-1; National Research Council,
Canada), spiked reference material, and
matrix spikes at concentrations > 10 times the
native sample concentration. The percent
recovery for DORM-2, DOLT-3, and
TORT-1 was 93%, 87%, and 103% respec-
tively. The average percent recovery (± SD)
for total As from two spiked certiﬁed material
samples, run in triplicate, was 92.6 ± 7.3%
and the average recovery for iAs was 96.8
± 11.9% and 91.5 ± 4.5%. Water (SRM 1640
and SRM 1643e; NIST) was used to validate
instrument performance; the percent recoveries
for SRM 1640 and SRM 1643e were 112%
and 102%, respectively. All quality assurance
met the laboratory’s acceptance criteria. The
method LODs for total As and iAs were 0.013
and 0.003 μg/g, respectively. All samples were
above the LODs.
Drinking water. All women reported hav-
ing their own tube well and using it for all
water for drinking and cooking purposes.
Participants were provided with two 4-L poly-
ethylene containers and instructed to place an
identical quantity of water in the containers
immediately after drinking a glass of water in
order to determine drinking water intake rates.
However, the concentration of As in each par-
ticipant’s tube well was estimated using water
samples collected as part of a larger, longitudi-
nal biomarker study in which water samples
were collected for 3 consecutive days every
3 months (Kile et al. 2005). Data from 2004,
representing 12 samples per participant and
overlapping the time frame of this duplicate
diet study, were used to establish an average
annual drinking water As concentration for
each participant. Total As was measured by
Environmental Laboratory Services (North
Syracuse, NY, USA) using ICP-MS following
U.S. EPA method 200.8 (U.S. EPA 1994). 
Quality control criteria included analyz-
ing Plasma CAL#1 Multi-Element QC
Standard (SCP Science, Baie D’Urfè,
Quebec, Canada). The average percent recov-
ery (± SD) was 96.7 ± 3.4%. Additionally,
10% of the samples were randomly chosen
for replicate analysis, with the average percent
difference in As concentrations of 0.2%.
Twenty-one households had drinking water
As concentrations below the 1-μg/L LOD
and were assigned half the LOD. 
Statistical analysis. We recorded the
weight of each duplicate meal portion (grams
wet weight) and the volume of drinking water
(milliliters) collected in a 24-hr period as the
daily dietary intake rate and drinking water
intake rate, respectively. Descriptive statistics
were calculated, including mean ± SD. We cal-
culated daily total As intake from food (micro-
grams per day) for each participant using the
total wet weight of food consumed each day
multiplied by the total As concentration meas-
ured in the corresponding 24-hr composite
sample (micrograms per gram wet weight). We
multiplied the annual average total As concen-
tration in each participant’s tube well by the
total volume of water consumed each day to
determine daily total As intake from water
(micrograms per day) from drinking water.
The daily total As intake was the sum of daily
total As intake from food and drinking water.
Dividing each participant’s daily As intake by
their body weight determined the daily total As
dose (micrograms per kilogram per day).
Medians and interquartile range (IQR; 75th
percentile – 25th percentile) were reported for
all exposure outcomes.
Because drinking water As concentrations
were positively skewed, they were subsequently
transformed to their common logarithms. We
used generalized estimating equations (GEE)
employing an exchangeable working correla-
tion structure to evaluate seasonal and daily
differences in As concentrations in food com-
posite samples and dietary and drinking water
intake rates. We used two regression tech-
niques, GEE and median regression, to exam-
ine the relationship between As-contaminated
drinking water and dietary As intake, which
approximates the effect of preparing and cook-
ing food with contaminated water. The
median regression technique, which is robust
to outliers, estimated standard errors using the
resampling method while taking into account
repeated measures (Parzen et al. 1994).
We estimated the iAs fraction using diet
samples with both total As and iAs measured
by the same laboratory. The average iAs frac-
tion was then multiplied by the average total
As dose from food and summed with the
daily As dose from drinking water in order to
estimate the amount of iAs ingested. We then
compared these values with the World Health
Organization’s (WHO) provisional tolerable
daily intake recommendations (WHO 1985).
We report the proportion of participants
whose average daily iAs dose exceeded the
WHO’s PTDI of 2.1 μg/kg-day along with
exact conﬁdence intervals (CIs). All statistics
were computed using SAS for Windows,
Kile et al.
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Table 1. Physical and demographic characteristics of the 47 female participants.
Characteristic Percent of population Mean ± SD Range
Age (years) 36.6 ± 8.6 20–65
Body mass index 22.5 ± 3.5 15.1–30.3
Years using tube well 31.9 ± 7.8 11–54
Years using current tube well 8.7 ± 6.1 1–20
Marital status
Married 94
Widowed 6
Occupation
Homemaker 96
Factory worker 2
Ofﬁce worker 2version 9.1(SAS Institute Inc., Cary, NC,
USA) except the median regression analysis
which was conducted in R, version 2.0.1 (R
Foundation for Statistical Computing 2006).
Results
The participant’s physical and demographic
characteristics are presented in Table 1. The
median drinking water concentration for the
47 tube wells sampled was 1.6 μg/L (range,
< 1–450 μg/L). Overall, 60% were below the
WHO’s 10-μg/L drinking water standard
(WHO 1985), and 70% were below the
Bangladesh drinking water standard of 50 μg/L
(BGS and DPHE 2001). On average, partici-
pants consumed 1,636 g food (wet weight) and
2,676 mL water per day. Participants con-
sumed signiﬁcantly more food in winter (1,700
± 338 g wet weight) than in summer (1,571 ±
324 g wet weight), but no seasonal difference
was detected in the concentration of As in the
composite food samples. The number of serv-
ings collected did not vary significantly over
the course of the study. Also, we did not ﬁnd a
significant difference in the amount of food
collected within each season. No seasonal or
daily difference was observed in the drinking
water intake rate.
The frequency of each food type collected
in the duplicate diet study is shown in Table 2.
Vegetables and rice were the most commonly
consumed food items. Rice, the dietary staple,
was present in 91% of all collected meals, with
405 g (wet weight) consumed in an average
serving. Vegetables were present in 94% of all
meals collected, with an average serving size of
72 g wet weight. Freshwater ﬁsh was the most
commonly consumed protein. Pabna is far
enough inland that seafood is not readily avail-
able in the local markets, and no participants
reported eating either seafood or shrimp dur-
ing this study period. Furthermore, all partici-
pants reported purchasing their food at local
markets. These items would most likely be
produced domestically, if not locally. However,
this data was not collected.
The distribution of total dietary As intake
and dose were heavily skewed, driven by the
overwhelming contribution from contami-
nated drinking water for the upper 25th per-
centile of the population (Figure 1). When
drinking water As concentrations decreased,
the relative contribution of As from dietary
sources increased. Background dietary total As
intake for the population, calculated using the
dietary exposures for the participants with no
detectable As in their drinking water, was
46 μg/day or 0.91 μg/kg-day. For all partici-
pants, the combined median daily total As
intake from both food and drinking water was
68 μg/day (IQR, 191 μg/day). The median
daily total As intake from food only was
48 μg/day (IQR, 34 μg/day) and drinking
water only was 4 μg/day (IQR, 150 μg/day). 
A subset of 35 samples (12% of the total
sample collected) analyzed for both total As
and iAs were used to estimate the iAs fraction
in the 24-hr dietary composite samples. The
average inorganic fraction (± SD) in dietary
samples was 82.1 ± 13.9%. Linear regression
showed that iAs explained 90% of the variabil-
ity in total As measurements. To estimate the
daily iAs dose, all dietary doses were adjusted
by the inorganic fraction before being added
to the drinking water doses because it is
assumed that all As present in drinking water
is in the inorganic form. These values were
compared to the WHO’s iAs PTDI of
2.1 μg/kg-day (WHO 1985). Overall, 34%
(95% CI, 21–49%) of all participants had an
average daily dose that exceeded this recom-
mended limit. Of the four women who used
tube wells containing 10–50 μg As/L, two
exceeded the PTDI. For women who used a
tube well containing < 10 μg As/L, diet was
the only substantial source of ingested As.
Using both GEE and median regression
models, we found a significant association
between the concentration of As in a given
household’s drinking water and the total As
concentration measured in their food
(Figure 2). This likely reflects the effect of
cooking and preparing food with As-contami-
nated water. The median regression model
provided the best fit to the average dietary
total As intake, as indicated by the smaller SE.
This model estimated that dietary total As
exposure increased by 0.5 μg/day (95% CI,
0.2–0.7 μg/day) for every 10% increase in
drinking water As concentration. 
Dietary arsenic exposure
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Table 2. Frequency of food types collected in the duplicate diet study. 
Winter Summer Total
[No. (%)] [No. (%)] [No. (%)]
Grains
Rice 393 (35.0) 390 (33.7) 783 (34.3)
Bread 32 (2.9) 43 (3.7) 75 (3.3)
Proteins
Fish (all freshwater) 139 (12.4) 95 (8.2) 234 (10.3)
Meat (poultry, beef, goat) 27 (2.4) 21 (1.8) 48 (2.1)
Egg 21 (1.9) 22 (1.9) 43 (1.9)
Fruits and vegetables
Vegetables 436 (38.8) 374 (32.4) 810 (35.5)
Fruit 1 (0.1) 80 (6.9) 81 (3.6)
Pulses/legumes 65 (5.8) 94 (8.1) 159 (7.0)
Others
Condiments (sugar, salt) 3 (0.3) 11 (1.0) 14 (0.6)
Fried snacks 2 (0.2) 4 (0.4) 6 (0.3)
Butter 0 (0) 1 (0.1) 1 (0.0)
Dessert (sweet noodles) 2 (0.2) 7 (0.6) 9 (0.4)
Dairy
Milka 3 (0.3) 14 (1.2) 17 (0.8)
A total of 432 meals were collected for each season, with 864 meals collected in total from 47 participants.
aWas not included in the 24-hr composite or analyzed for As.
< 1 1–10 11–50 51–100 101–200 > 200
1,300
1,170
1,040
910
780
650
520
390
260
130
0
D
a
i
l
y
 
i
n
t
a
k
e
 
(
μ
g
/
d
a
y
)
Tube well As concentration (μg/L)
Drinking water As
Dietary As
Figure 1. Distribution of average daily As intake (µg/day) from both drinking water and dietary sources for
all 47 participants sorted by tube well As concentration.It is interesting to note that only one par-
ticipant was diagnosed with As-induced skin
lesions (melanosis, leukomelanosis, and hyper-
keratosis of the palms and soles). This 38-year-
old woman reported using the same tube
well—one with an average As concentration of
360 μg/L—for the past 12 years. She had the
highest observed average daily total As intake
(1231.3 μg/day) and subsequent average daily
total As dose (25.7 μg/kg-day). However,
another participant with no visible As-induced
skin lesions had a higher well concentration.
This reinforced the notion that interindividual
differences in ingestion rates and duration of
exposure are an important contributing factor
in exposure assessments.
Discussion
In Bangladesh, groundwater provides 95% of
the drinking water and approximately 71%
of the agricultural irrigation water (Fazal
et al. 2001). The shallow aquifer beneath
Bangladesh is contaminated with naturally
occurring As, and chronic As exposure is wide-
spread throughout the country. Arsenic expo-
sure from drinking contaminated water has
received the most attention, primarily because
of the high As concentrations detected but also
because of the circumstances that generated the
current As crisis. In the 1970s, tube wells were
installed to switch the population from micro-
bially contaminated surface water to ground-
water to decrease the morbidity and mortality
from waterborne disease. It was not until
20 years later that the public became aware
that these relatively shallow tube wells could be
contaminated with As, thus introducing a new
health burden on the community. 
We observed a median daily total As dose
of 1.3 μg/kg-day, whereas the median daily
total As dose from drinking water and diet
was 0.08 μg/kg-day and 1.0 μg/kg-day,
respectively. These exposure estimates reﬂect
the As contamination in our study area and
the relative distribution of As-contaminated
water. National groundwater surveys show
that As concentrations in approximately 27%
of tube wells exceed the Bangladesh drinking
water standard of 50 μg/L and 51% exceed
the WHO drinking water recommendation
of 10 μg/L (BGS and DPHE, 2001). We
observed a similar distribution in the present
study, with 30% of the tube wells containing
> 50 μg/L and 40% containing > 10 μg/L.
Our exposure assessment suggested that when
tube well concentrations were > 50 μgL, water
was the dominant route of exposure. However,
if the observed distribution of contaminated
tube wells is representative, then drinking As-
contaminated water will be the dominant
route of exposure for only one-third of the
population. Dietary sources of As, on the
other hand, will be the most important route
of exposure for the remaining two-thirds of
the population. Therefore, it is important to
further understand the health risks associated
with this route of exposure.
The average daily total As intake calcu-
lated in the present study was 174 μg/day,
which is considerably lower than the
515 μg/day estimated in an earlier study for
an adult Bangladeshi (Watanabe et al. 2004).
This discrepancy could be due to regional dif-
ferences in As contamination or from
methodologic differences between the two
study designs, because the Watanabe study
employed a market basket technique to esti-
mated food-derived exposure and we used a
duplicate diet methodology that analyzed As
in cooked, ready-to-eat food. Duplicate diet
studies are considered to be more accurate at
estimating personal exposures because they
account for the individual’s water source, the
type and quantity of food items consumed,
and the agricultural conditions under which
the food is cultivated (WHO 1985). It is
important to note that the estimates derived
from duplicate diet studies depend on the
dietary habits of the participants and may not
be generalizable to other populations. Because
we collected dietary data from women only,
the results may not be generalizable to men
because gender influences the intrafamilial
distribution of food in Bangladeshi house-
holds, with men eating on average, 40% more
cereals, 26% more tubers, 29% more pulses,
and 57% more vegetables than women
(Hassan and Ahmad 1982). Thus, it is possi-
ble that adult males may have higher As expo-
sures than women. 
In the present analysis, 34% (95% CI,
21–49%) of the participants ingested iAs con-
centrations in excess of the WHO’s recom-
mended daily allowance of 2.1 μg/kg-day
(WHO 1985). If drinking water contained
> 50 μg As/L, water was the dominant route
of exposure. However, the combined intake
from food and drinking water was sufﬁciently
high that two women who used a well con-
taining 10–50 μg/L exceeded this recom-
mended daily allowance. This provides
evidence that the current Bangladesh drinking
water standard of 50 μg/L might not be pro-
tective of public health when all routes of
exposure are considered. The sources of As in
the diet are likely to be from rice and vegeta-
bles cultivated in As-contaminated environ-
ments because these are the two types of food
items most commonly consumed. However,
we also observed that food preparation mod-
estly contributed to dietary As intake, which
has been observed in experimental settings
(Bae et al. 2002). However, it is important to
recognize that the present study is small, and
further studies will be required before deter-
mining the source of dietary As and whether
the exposure estimates computed for this pop-
ulation are generalizable to other regions in
Bangladesh.
It is also important to recognize that the
fraction of iAs in food items varies widely
(Schoof et al. 1999). We estimated that the
average iAs concentration comprised 82% of
the total As detected in a subset of the dietary
samples. This is similar to values reported by
Smith et al. (2006) who reported that iAs
made up 87% of the total As measured in rice
and 96% of the total As measured in vegeta-
bles commonly consumed in Bangladesh.
Our estimated inorganic fraction is slightly
lower, but we computed the inorganic frac-
tion in homogenized 24-hr dietary samples
rather than individual food items. Also, the
absorbed dose that influences toxicity
depends on the solubility of the iAs during
gastrointestinal digestion, which is poorly
understood and varies with food type. 
Biomarker studies provide evidence that
dietary sources contribute to internal dose.
Studies that have looked at both urinary and
toenail As concentrations found that the
relationship between these biomarkers and
drinking water As concentrations are non-
linear at low drinking water As concentrations
but become linear as drinking water As con-
centrations increase (Karagas et al. 2000; Kile
et al. 2005; Watanabe 2001). It is therefore
likely that the added exposure from dietary
sources explains the observed nonlinearity in
these relationships.
Bangladesh is developing rapidly and has
become dependent upon groundwater as a
source of drinking and irrigation water. While
providing safe drinking water to exposed indi-
viduals must remain a public health priority,
it is also important that irrigation policies are
reviewed, because this analysis clearly demon-
strates an elevated background exposure from
dietary sources. In accordance with the
Kile et al.
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Figure 2. Average dietary As intake (µg/day) plotted
against the logarithm of drinking water As (µg/L).
The mean and median regressions were obtained
from the model Y = (α + β) × (log10 X + ε), where
either the mean or median of ε is zero. For the
median regression line, α = 40.5 and β = 11.6; for the
mean regression line, α = 46.0 and β = 19.5. Shaded
areas represent 1 SE around each regression line.recently adopted national policy for As miti-
gation, which acknowledges that As in
groundwater used for irrigation may also have
an effect on the food chain, preference should
be given to surface water for irrigation where
appropriate (Bangladesh Government 2004).
Furthermore, it is important to continue to
monitor the food chain because continued use
of As-contaminated irrigation water is likely to
increase the probability and magnitude of
dietary As intake.
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Research
The single largest source of chemical exposure
on military bases of the North Atlantic Treaty
Organization (NATO) is jet propulsion
fuel 8 (JP-8), which is the preferred fuel for
both aircraft and military vehicles in NATO
countries. JP-8 comprises many aromatic
hydrocarbons, including benzene and naph-
thalene, and aliphatic hydrocarbons such as
nonane and decane (McDougal et al. 2000).
Exposures to JP-8 can occur during spills,
transportation and storage of the fuel, as well
as during fueling, general maintenance and
operation of aircraft and military vehicles,
fueling of military tent heaters, and cleaning
and degreasing of parts with the fuel. 
Since JP-8 can enter the body via both
inhalation and dermal contact, the assessment
of occupational exposures to fuel constituents
can be difficult. Personal sampling of JP-8
vapors provides information about inhalable
levels but not about dermal exposure levels.
Similarly, sampling the exposed skin provides
information about dermal but not about
inhalable levels. Conversely, the collection of
end-exhaled breath concentrations provides
an integrated estimate of uptake via both
inhalation and dermal contact (Egeghy et al.
2003; Pleil et al. 2000) but cannot determine
the relative contributions of the two exposure
routes to the internal dose. Through statistical
evaluation of levels of naphthalene in air,
breath, and skin, measured in the U.S. Air
Force personnel during fuel maintenance pro-
cedures, both inhalation and dermal exposures
to JP-8 were demonstrated to contribute to the
internal dose (Chao et al. 2006). However,
because of the respiratory protection used in
that population, it was difﬁcult to determine
the relative contributions of dermal and
inhalation exposures to the systemic levels of
JP-8 components.
Physiologically based toxicokinetic
(PBTK) modeling is an effective tool for
quantifying the absorption, distribution,
metabolism, and elimination of chemicals.
PBTK models have been developed for vari-
ous components of JP-8, notably naphthalene
and decane (Perleberg et al. 2004; Quick and
Shuler 1999; Willems et al. 2001). The
model developed by Quick and Shuler
(1999) focused on the disposition of naph-
thalene in ﬁve compartments representing the
lungs, liver, fat, rapidly perfused tissues, and
slowly perfused tissues and relied on in vitro
data to calibrate kinetic constants. Willems
et al. (2001) refined the Quick and Shuler
(1999) model by using kinetic constants
derived from in vivo data from laboratory
animal experiments performed by the
National Toxicology Program. They observed
that a diffusion-limited PBTK model was nec-
essary to characterize the toxicokinetic behav-
ior of naphthalene in rats and mice. Perleberg
et al. (2004) developed a PBTK model using
decane as a chemical marker of JP-8. Data for
calibration and validation of this model were
derived from an animal study in which rats
were exposed for 4 hr to decane vapor at three
different concentrations (1,200, 781, or 273
ppm). Their final model consisted of flow-
limited compartments for liver and lung, and
diffusion-limited compartments for brain,
bone marrow, fat, skin, and spleen. The
model predicted the time course of decane in
tissue and blood from low-level exposures to
decane vapor.
Because the PBTK models mentioned
above did not examine the uptake via skin, we
developed a PBTK model that included both
inhalation and dermal routes of exposure.
Naphthalene was chosen as the surrogate for
JP-8 exposure because it is abundant in JP-8,
is readily absorbed into blood, and is only a
minor component in confounding sources of
exposure such as cigarette smoke and gasoline
exhaust (Rustemeier et al. 2002; Serdar et al.
2003). We expanded on the structure of a
data-based compartmental model that was
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PBTK Modeling Demonstrates Contribution of Dermal and Inhalation Exposure
Components to End-Exhaled Breath Concentrations of Naphthalene
David Kim,1 Melvin E. Andersen,2 Yi-Chun E. Chao,1 Peter P. Egeghy,1* Stephen M. Rappaport,1 and 
Leena A. Nylander-French1
1Department of Environmental Sciences and Engineering, School of Public Health, The University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina, USA; 2CIIT Centers for Health Research, Research Triangle Park, North Carolina, USA
BACKGROUND: Dermal and inhalation exposure to jet propulsion fuel 8 (JP-8) have been measured
in a few occupational exposure studies. However, a quantitative understanding of the relationship
between external exposures and end-exhaled air concentrations has not been described for occupa-
tional and environmental exposure scenarios.
OBJECTIVE: Our goal was to construct a physiologically based toxicokinetic (PBTK) model that
quantitatively describes the relative contribution of dermal and inhalation exposures to the end-
exhaled air concentrations of naphthalene among U.S. Air Force personnel.
METHODS: The PBTK model comprised five compartments representing the stratum corneum,
viable epidermis, blood, fat, and other tissues. The parameters were optimized using exclusively
human exposure and biological monitoring data.
RESULTS: The optimized values of parameters for naphthalene were a) permeability coefﬁcient for
the stratum corneum 6.8 × 10–5 cm/hr, b) permeability coefﬁcient for the viable epidermis 3.0 ×
10–3 cm/hr, c) fat:blood partition coefﬁcient 25.6, and d) other tissue:blood partition coefﬁcient
5.2. The skin permeability coefﬁcient was comparable to the values estimated from in vitro studies.
Based on simulations of workers’ exposures to JP-8 during aircraft fuel-cell maintenance opera-
tions, the median relative contribution of dermal exposure to the end-exhaled breath concentration
of naphthalene was 4% (10th percentile 1% and 90th percentile 11%).
CONCLUSIONS: PBTK modeling allowed contributions of the end-exhaled air concentration of
naphthalene to be partitioned between dermal and inhalation routes of exposure. Further study of
inter- and intraindividual variations in exposure assessment is required to better characterize the
toxicokinetic behavior of JP-8 components after occupational and/or environmental exposures.
KEY WORDS: dermal, exposure assessment, inhalation, jet fuel, naphthalene, physiologically based
toxicokinetic model. Environ Health Perspect 115:894–901 (2007). doi:10.1289/ehp.9778 avail-
able via http://dx.doi.org/ [Online 14 February 2007]used to quantify the absorption, distribution,
and elimination of jet fuel components (Kim
et al. 2006b). Data from a study of controlled
dermal exposure in humans were used to opti-
mize the parameters in the PBTK model (Kim
et al. 2006a). The optimal PBTK model,
combined with exposure and biomarker data
from ﬁeld studies (Chao et al. 2005; Egeghy
et al. 2003), was used to quantify the relative
contributions of dermal and inhalation expo-
sures to end-exhaled breath concentrations of
naphthalene among U.S. Air Force personnel.
Materials and Methods
Laboratory study of dermal exposure to JP-8.
We conducted a laboratory study to quantify
the dermal absorption and penetration of JP-8
components across human skin in vivo (Kim
et al. 2006a). Approval for this study was
obtained from the Ofﬁce of Human Research
Ethics (School of Public Health, The
University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina). Written
informed consents were received from all
study volunteers. The study consisted of
10 volunteers (5 females and 5 males) recruited
for this study. Exposures were conducted in an
exposure chamber. One forearm was placed
palm up inside the exposure chamber, and two
aluminum application wells were pressed
against the skin and sealed for the duration of
the experiment (0.5 hr). At the end of the
0.5-hr exposure period, the exposed sites were
tape-stripped 10 times with adhesive tape
strips. Tape strips were used to quantify the
mass of naphthalene in successive layers of the
stratum corneum. Both tape-strip and blood
samples were analyzed by gas chromatogra-
phy–mass spectrometry (GC-MS). The time
course of naphthalene in blood for all study
volunteers showed considerable interindivid-
ual variability. For example, the time course
for a 23-year-old Caucasian male with a body
mass index (BMI) of 25 kg/m2 was very dif-
ferent from that of a 24-year-old Caucasian
female with a BMI of 22 kg/m2. For the male
volunteer, the maximum concentrations in
blood (Cmax) occurred shortly after the end of
exposure (tmax ≈ 30 min), with a value of
0.8 ng/mL. The Cmax for the female volunteer
occurred at tmax ≈ 60 min, with a value of
0.3 ng/mL. In either case, the concentrations
in blood at t > 0 min did not return to base-
line levels. 
Field study of dermal and inhalation
exposures to JP-8. Exposure data were obtained
from the assessment of dermal and inhalation
exposures to JP-8 in the personnel at six U.S.
Air Force bases in the continental United
States (Chao et al. 2005; Egeghy et al. 2003).
The duration of exposure was approximately
4 hr. The concentration of naphthalene in the
personal breathing-zone air (referred to as “air
concentration” in this article) was measured
using passive monitors (Egeghy et al. 2003).
End-exhaled breath samples were collected pre-
and postexposure (Egeghy et al. 2003). The
end-exhaled breath measurements are indica-
tive of alveolar air (Egeghy et al. 2000). Both
air and breath samples were analyzed by GC
with photoionization detection. Tape strips
were used to quantify dermal exposure to
naphthalene at specific body regions; results
were extrapolated to the total surface area of
skin to estimate whole-body dermal exposure
to naphthalene. We collected dermal samples
postexposure using adhesive tape strips with
the dimension of 2.5 cm × 4.0 cm (surface area
10 cm2) from exposed body regions including
the forehead, neck, shoulders, arms, hands,
legs, knees, feet, and buttocks (Chao et al.
2005). Tape-strip samples were extracted with
acetone and analyzed by GC-MS.
The median air concentrations of naph-
thalene in air samples were 1.9 μg/m3 (range,
< 1.0–16.9 μg/m3), 29.8 μg/m3 (range,
< 1.0–932 μg/m3), and 867 μg/m3 (range,
12.8–3,910 μg/m3) for the low-, medium-,
and high-exposure groups, respectively
(Egeghy et al. 2003). The median preexposure
breath levels of naphthalene were < 0.5 μg/m3
(range, < 0.5–36.3 μg/m3), < 0.5 μg/m3
(range, < 0.5–16.1 μg/m3), and < 0.5 μg/m3
(range, < 0.5–6.1 μg/m3) for the low-,
medium-, and high-exposure groups, respec-
tively. The median postexposure breath levels
were 0.73 μg/m3 (range, < 0.5–6.9 μg/m3),
0.93 μg/m3 (range, < 0.5–13.0 μg/m3), and
1.83 μg/m3 (range, < 0.5–15.8 μg/m3) for the
low-, medium-, and high-exposure groups,
respectively. The corresponding median con-
centrations of dermal samples were 344 ng/m2
(range, 159–54,200 ng/m2), 483 ng/m2
(range, 150–13,200 ng/m2), and 4188 ng/m2
(range, 100–4,880,000 ng/m2) in the low-,
medium-, and high-exposure groups, respec-
tively (Chao et al. 2005).
Description of the PBTK model. A
dermatotoxicokinetic (DTK) model, which
was previously developed for describing the
disposition of aromatic and aliphatic compo-
nents of JP-8 after controlled dermal exposure
(Kim et al. 2006b), formed the basis of the
PBTK model (Figure 1). The DTK model
consisted of five compartments representing
the surface, stratum corneum, viable epider-
mis, blood, and storage tissues. The parame-
ters for the DTK model were estimated by
ﬁtting the model to the data. The major dif-
ference between the DTK and the PBTK
model structures is that the storage compart-
ment was split into fat and all other tissues.
The rationale for defining the storage com-
partment in this fashion was based on the high
fat:blood partition coefﬁcient (Pf:b) of naph-
thalene (160), which is more than 5 times the
partition coefficient of the other tissues
(Fiserova-Bergerova 1983). Further additions
to the PBTK model included pulmonary
uptake and clearance. The skin compartments
were composed of the skin directly under the
exposed area. All tissues were perfusion limited
and well mixed. Absorbed naphthalene was
distributed to other tissue compartments at a
rate equal to the rate of blood ﬂow to that tis-
sue. Naphthalene was stored in the fat and
other tissue compartments based on the physi-
ologic parameters of that compartment (i.e.,
tissue:blood partition coefficient, tissue vol-
ume, and blood perfusion rate). 
Most physiologically based compartmental
models separate the arterial blood from the
central venous blood, whereas data-based
compartmental models treat the blood as one
compartment. Also in data-based compart-
mental models, the peripheral compartments
represent organs or tissues that, being poorly
perfused with blood, are in slower equilibrium
distribution with blood. Blood samples were
collected from the antecubital vein in the study
by Kim et al. (2006a). The antecubital vein
drains blood from the hand and the superﬁcial
layers of the forearm. The concentration of
PBTK model of human exposure to naphthalene
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Figure 1. Schematic of the physiologically based
toxicokinetic (PBTK) models for the study of naph-
thalene toxicokinetics. Pulmonary uptake of naph-
thalene in the personal breathing-zone and
pulmonary clearance from the blood compartment
are added to a previously published dermatotoxi-
cokinetic model (Kim et al. 2006b). Abbreviations in
the PBTK model: Kuptake, input rate constant for
dermal exposure; Kpv, permeability coefficient for
the viable epidermis; Aexp, exposed surface area;
Psc:ve, stratum corneum:viable epidermis partition
coefﬁcient; QE, blood ﬂow rate to skin; Pve:b, viable
epidermis:blood partition coefficient; QP, pul-
monary ventilation rate; Pb:a, blood:air partition
coefﬁcient; QF, blood ﬂow rate to fat; Pf:b, fat:blood
partition coefficient; QO, blood flow rate to other
tissue; Po:b, other tissue:blood partition coefﬁcient;
EL, extraction ratio.
Dermal
exposure
Stratum
corneum
Viable
epidermis
Blood
Fat
Other
Kuptake
Kpv × Aexp/Psc:ve
QE/Pve:b QE
QP Inhalation
exposure
QP/Pb:a
QL × EL
QF
QO
QF/Pf:b
QO/Po:bsolute in the antecubital vein is different
from the concentrations of solute in the arte-
rial and central venous blood (Levitt 2004).
However, the blood in the antecubital vein is
in rapid equilibrium with arterial and central
venous blood relative to the fat and other tis-
sue compartments. Therefore, we treated the
arterial and central vein as a single compart-
ment, and approximated the concentration
of naphthalene in the central (i.e., blood)
compartment using measurements made
from the antecubital vein.
Two routes of exposure were modeled:
dermal and inhalation. Pulmonary uptake is
equal to the pulmonary ventilation rate (QP)
times the concentration of naphthalene in the
personal breathing-zone (CPBZ):
Pulmonary uptake = QP × CPBZ. [1]
In Equation 1, rapid equilibration of naph-
thalene occurs across the alveolar lining, and
neither storage nor metabolism in the lungs
appreciably affects the uptake of naphthalene
into the systemic circulation. Because arterial,
lung, and venous blood are treated as a com-
bined blood compartment, the rate of absorp-
tion is equal to pulmonary uptake. Dermal
absorption and penetration is modeled as a
one-directional diffusive process according to
Fick’s ﬁrst law of diffusion. As such, the diffu-
sion of naphthalene across the stratum
corneum (SC) and the viable epidermis (VE)
are quantiﬁed using permeability coefﬁcients,
the area of exposure, and the thickness of the
membrane (McCarley and Bunge 2001;
McDougal and Boeniger 2002). The rate of
efﬂux from the SC to the VE is dependent on
the solubility of naphthalene in the SC rela-
tive to the VE. Therefore, the rate of efﬂux of
naphthalene from the SC to the VE is equal
to Kpv × Aexp × CD/Psc:ve, where Kpv is the
permeability coefﬁcient across the VE, CD is
the concentration in the SC, Aexp is the
exposed surface area, and Psc:ve is the SC:VE
partition coefﬁcient. The mass balance differ-
ential equation (MBDE) for the SC is
[2]
where Kuptake is the input rate constant and
DERMDOSE is the dose to the skin. The rate
of input from blood to VE is the cutaneous
blood ﬂow rate (QE) times the concentration
of naphthalene in blood (CB), and the rate of
efﬂux from the VE to blood is controlled by
QE and the solubility of naphthalene in the
blood (Pve:b). The MBDE for the amount of
naphthalene in the VE is
[3]
where AE is the amount and CE is the
concentration of naphthalene in the VE.
Elimination of naphthalene proceeds by
two significant mechanisms: exhalation and
metabolism. The concentration of naphthalene
in end-exhaled air is equal to the blood con-
centration divided by the blood:air partition
coefficient (Pb:a). Pulmonary clearance of
naphthalene is QP divided by Pb:a. Metabolism
of naphthalene occurs in the liver by a single
metabolic pathway following ﬁrst-order kinet-
ics. The initial step in naphthalene metabolism
is the formation of naphthalene-1,2-oxide by
cytochrome P450 monooxygenases [Agency
for Toxic Substances and Disease Registry
(ATSDR) 1995]. Liver clearance (ClL) is
, [4]
where Vmax (millligrams per minute) is the
maximum rate of metabolism, Km (milligrams
per liter) is the Michaelis-Menten constant,
and QL the blood ﬂow rate to the liver (liters
per minute). The ratio of liver clearance to
liver blood flow is the extraction ratio (E L)
where EL is
. [5]
Determination of the blood:air partition
coefﬁcient. Initial sensitivity analysis revealed
that the concentration of naphthalene in end-
exhaled air was highly sensitive to Pb:a.
Therefore, we measured Pb:a by equilibrating
human blood with a known concentration of
naphthalene (Gargas et al. 1989). Samples
were analyzed with a Combi Pal autosampler
configured for headspace analysis (CTC
Analytics, Zwingen, Switzerland). A series of
20-mL crimp seal vials (MicroLiter Analysis
Supplies, Suwanee, GA, USA) containing
blood (test), air (reference), and a known
amount of naphthalene (gas) were used in the
experiment. The test and reference vials
underwent the same process. First, the vial was
heated to a temperature of 37°C, and a vent
tool (LEAP Technologies, Carrboro, NC,
USA) was used to equilibrate the pressure
between the test/reference vials and the room.
Next, a 2.5-mL gas-tight syringe was used to
draw from the vial 1 mL of air, which was
injected into the room air. Then, 1 mL of gas
from the gas vial was transferred to the
test/reference vial. The test/reference vial was
kept at 37°C and agitated for 1 hr; we deter-
mined, by adjusting the incubation period,
that 1 hr was the optimal time for achieving
equilibrium. After incubation, a 1-mL sample
was extracted from the test/reference vial and
injected into the GC-MS for analysis. All
analyses were conducted in triplicate. A six-
point standard curve (R 2 = 0.999) was used
for quantitation of the naphthalene concentra-
tion in the test and reference vials. Partition
coefﬁcients were determined using Equation 6
(Gargas et al. 1989).
, [6]
where Cref is the naphthalene concentration
in the reference vial, Vvial is the volume of the
reference vial (20 mL), Cblood is the naphtha-
lene concentration in the headspace of the test
vial, and Vblood is the volume of blood
(2 mL). Using Equation 6, we calculated a
Pb:a value of 10.3.
Model optimization. All physiologic para-
meters (cardiac output, ventilation rate, blood
ﬂow rate to the tissues, and tissue volumes) for
humans were obtained from the literature
(Brown et al. 1997). Other tissue partition
coefﬁcients were predicted from the octanol–
water partition coefficients and regression
models for different tissues (Abraham et al.
1985; Fiserova-Bergerova et al. 1984; Hansch
et al. 1995; Willems et al. 2001). The maxi-
mum rates of naphthalene metabolism (Vmax)
and Michaelis-Menten constant (Km) have
been estimated for rats and mice (Willems
et al. 2001). In our study, the rate of metabo-
lism was assumed to follow ﬁrst-order kinetics,
given the relatively low naphthalene concentra-
tions measured in post-exposure breath sam-
ples (Egeghy et al. 2003). Initial sensitivity
analysis revealed that the concentration of
naphthalene in end-exhaled breath was not
sensitive to Vmax/Km. Therefore, the parame-
ters Kuptake, Kpv, Pf:b, and Po:b (other
tissue:blood partition coefficient) were
adjusted to ﬁt the blood time course data for
each volunteer in the laboratory study. Initial
values of all parameters were obtained from
the literature (Guy and Potts 1992; McCarley
and Bunge 2001; Qiao et al. 2000; Willems
et al. 2001; Williams and Riviere 1995). The
Nelder-Mead algorithm, with tolerance set at
1 × 10–5, was used to optimize the parameters
(Xcellon 2004).
Comparison of dermal and inhalation
routes of exposure. The Air Force data set was
used to compare the relative contribution of
dermal exposure with the end-exhaled breath
concentration of naphthalene. The data set
included personnel from the U.S. Air Force
who had both dermal and inhalation expo-
sures to JP-8 (Chao et al. 2005; Egeghy et al.
2003). From the Air Force personnel, end-
exhaled breath samples were collected imme-
diately at the end of the work shift and, later,
at a central testing site (CTS). Three Air
Force personnel were selected who repre-
sented the 10th, 50th, and 90th percentiles
based on their end-exhaled breath measure-
ments. The group had regular contact with jet
fuel, and consisted of fuel-cell maintenance
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work. Thus, the concentration of naphthalene
in the air was much higher in the immediate
work environment for these individuals com-
pared with personnel who had no direct con-
tact with JP-8 and, therefore, represented
background exposures to naphthalene. The
air concentration of naphthalene was reported
for the duration of the sampling period,
which included travel time to the CTS
(~ 30 min). Thus, the air concentration at the
work site was estimated as
[7]
where INHAL1est is the estimated concentra-
tion of naphthalene in the breathing zone
during the work shift of Δtwork hr, CPBZ is the
air concentration measured during the full
sampling period of Δttotal hr, INHAL2est is the
estimated background air concentration of
naphthalene (i.e., air measurements from the
U.S. Air Force personnel who had no direct
contact with JP-8), and Δttravel is the time
required to travel from the workplace to the
CTS. The concentrations of naphthalene in
the air and dermal samples and the duration
of exposure were used as input terms for the
PBTK model. Predicted end-exhaled breath
concentrations were compared with measured
levels of naphthalene in end-exhaled breath.
Sensitivity analysis. Sensitivity analyses
were performed to evaluate the relative
importance of model parameters on the con-
centration of naphthalene in end-exhaled
breath. Normalized sensitivity coefficients
(NSC) were calculated using Equation 8
(Evans and Andersen 2000): 
, [8]
where m is the response variable (i.e., concen-
tration of naphthalene in end-exhaled breath),
Δm is the change in the response variable, p is
the value of the parameter of interest (e.g.,
blood:air partition coefﬁcient), and Δp is the
change in the parameter value. Each parame-
ter was changed 1% (i.e., Δp ÷ p = 0.01).
Results
Dermal exposure toxicokinetics. The PBTK
model was optimized for dermal exposure
using data from 10 individuals who were
exposed to JP-8 on the skin under laboratory
conditions. The average height and weight of
the subjects to whom JP-8 was administered
on the skin was 174 cm and 61 kg, respec-
tively (BMI = 21 kg/m2). Time-course plots
showed considerable variability among the
study volunteers (Figure 2). The mean ± SD
of the peak concentration of naphthalene in
blood was 0.18 ± 0.22 ng/mL and occurred at
62 ± 16 min. The time course for subject
no. 1 was very different from that of the other
volunteers. The peak concentration for this
volunteer was 0.80 ng/mL and occurred at
37 min. Model predictions of the blood con-
centration of naphthalene are also shown for
each volunteer using optimized parameter val-
ues in Figure 2. The skin parameters (Kuptake
and Kpv) and the partition coefficients Pf:b
and Po:b were adjusted to ﬁt the blood time-
course data for dermal exposures only; the
optimal values are reported in Table 1. The
rate of input from dermal exposure is equiva-
lent to the product of the permeability coefﬁ-
cient for the SC (Kps), the exposed surface
area (Aexp), and the concentration of the
naphthalene in JP-8 (CJP-8) (McCarley and
Bunge 2001; McDougal and Boeniger 2002): 
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Figure 2. Plots comparing the PBTK model simulations to experimentally measured naphthalene concen-
trations in blood from 10 study volunteers (A–J) who were dermally exposed to JP-8 on the volar forearm.
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Volunteer 9 Volunteer 10rate of input = Kuptake × DERMDOSE
= Kps × Aexp × CJP-8 [9]
Equation 9 can be rearranged to solve for Kps
as follows:
. [10]
The optimized value of Kuptake is 0.031 ±
0.056 hr–1 (mean ± SD), and for Kps it is 6.8 ×
10–5 ± 5.8 × 10–5 cm/hr (mean ± SD)
(Table 2). The sensitive parameters in the der-
mal only model were DERMDOSE (NSC =
1.0), Aexp (NSC = 1.0), Kuptake (NSC = 1.0),
and Po:b (NSC = –0.3).
Prediction of end-exhaled breath concen-
trations. The optimized PBTK model was used
to predict the end-exhaled breath concentra-
tion of naphthalene for 53 U.S. Air Force per-
sonnel (13 females and 40 males) who did not
have dermal contact with jet fuel and had
naphthalene end-exhaled breath concentrations
> 0.0 μg/m3. The median height and weight of
the personnel were 175 cm (range,
155–193 cm) and 77 kg (range, 52–116 kg),
respectively. In the simulation, the median air
concentration of naphthalene was 2.4 μg/m3
(range, 0.7–481.7 μg/m3) and was held con-
stant for the duration of exposure (median
duration, 237 min). For each U.S. Air Force
subject, the preexposure concentration of
naphthalene in the end-exhaled breath was
subtracted from the postexposure measure-
ments. The predicted concentration of naph-
thalene in end-exhaled breath (0.5 μg/m3) was
the same as the median of the measured values.
In addition, comparisons were made between
measured and predicted concentrations of
naphthalene in end-exhaled breath for each
U.S. Air Force subject, using information on
the subject’s height, weight, air concentration
of naphthalene, and duration of exposure. The
median relative difference between measured
and predicted values was 26% (10th–90th per-
centile range, –71 to 196%).
Model predictions of the end-exhaled
breath concentration of naphthalene were
compared with field measurements among
three Air Force personnel who represented the
10th, 50th, and 90th percentiles based on their
end-exhaled breath measurements. These three
U.S. Air Force personnel spent time in a fuel
tank during their work shift and were exposed
to JP-8 on the skin. The input parameters and
values for each U.S. Air Force personnel are
reported in Table 3. The PBTK model consis-
tently overpredicted the end-exhaled breath
concentrations at the end of work shift for all
three U.S. Air Force personnel (Figure 3). This
could be attributed to the use of supply-air res-
pirators. Therefore, the air concentration of
naphthalene during work (i.e., INHAL1est) was
adjusted (i.e., INHAL1adj) to estimate the
likely inhalation exposure (Figure 3). The
values of INHAL1adj are reported in Table 4.
Comparison of dermal and inhalation expo-
sure routes. Simulations were conducted for
three U.S. Air Force personnel to compare the
contribution of dermal exposure with the end-
exhaled breath concentrations relative to inhala-
tion exposure (Table 4). These three individuals
were fuel-cell maintenance workers. The area
under the end-exhaled breath concentration
time curve (AUCex) was calculated for dermal
exposures using the following equation:
, [11]
where Cex is the concentration of naphthalene
in the end-exhaled breath and t1 is the time at
the end of the exposure. The values of AUCex
for dermal exposures were 1.7, 41.7, and
521 μg × min/m3 for the 10th, 50th, and 90th
percentiles, respectively. Dermal exposures
were set to zero and the naphthalene air con-
centration was adjusted to obtain the same
value of AUCex. The predicted air concentra-
tions (INHAL1pred) were 0.1, 0.7, and 11.7
μg/m3, respectively. These values are 1, 4, and
11% of the air concentrations of naphthalene
for the individuals whose breath meas-
urements represented the 10th, 50th, and
90th percentiles, respectively.
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Table 1. Naphthalene PBTK model parameters.
Parameter Symbol Unit Value Notes and references
Body weight BW kg 61 Kim et al. (2006a)
Height HT cm 174 Kim et al. (2006a)
Body mass index BMI kg/m2 20 BMI = BW/HT2
Organ volumes
Blooda Vb L 4.5 BW = (72.447/1000) × BW1.007
Stratum corneum Vsc L2   × 10–5 VD = Aexp × Td
Viable epidermisb Vve L 1.9 × 10–3 VE = VEC × BW–VD
Fatc Vf L 5.5 VF = BW × (ln BMI–126.2)/100
Other tissue Vo L 51.0 VO = BW–(VB + VD + VE + VF)
Pulmonary ventilation rate QP L/hr/BW0.75 15 Brown et al. (1997)
Cardiac output QC L/hr/BW0.75 15 Brown et al. (1997)
Regional blood ﬂow
To skind QE L/hr 1.7 × 10–2 QE = QEC × (Aexp/SURFA)
To fat QF L/hr 16.4 QF = QFC × QC
To other tissues QO L/hr 311.0 QO = QC–(QE + QF)
Metabolic clearance parameters
Ratio of Vmax:Km Vmax/Km L/hr 698 Willems et al. (2001)
Blood ﬂow to liver QL L/hr 75.3 QL = QLC × QC
Partition coefﬁcients
Blood:air Pb:a — 10.3 Measurede
Stratum corneum:viable epidermis Psc:ve — 1.8 McCarley and Bunge (2001)
VE:blood Pve:b — 2.8 McCarley and Bunge (2001)
Fat:blood Pf:b — 25.6 Estimatedf
Other tissue:blood Po:b — 5.2 Estimatedf
Skin permeation parameters
Area of exposure Aexp cm2 20 Dimensions of the tape strip
Thickness of the stratum corneum Td µm 10 McCarley and Bunge (2001)
Total body surface areag SURFA cm2 19,238 (BW 0.45) × (HT 0.725) × 71.84
Permeability coefﬁcient for stratum corneum Kps cm/hr 6.8 × 10–5 Estimatedf
Permeability coefﬁcient for viable epidermis Kpv cm/hr 3.0 × 10–3 Estimatedf
aFrom Davies and Morris 1993. bThe volume of the viable epidermis is calculated as the volume of the exposed skin minus
the volume of the stratum corneum under the exposed area. The fraction of body weight in skin (VEC) is from Brown et al.
(1997). cThe fraction of body weight in fat = ln BMI–126.2 (Mills 2005). dThe fractions of cardiac output to skin (QEC) and to
liver (QLC) were obtained from Brown et al. (1997). eThe blood:air partition coefﬁcient was measured using the vial equili-
bration technique (Gargas et al. 1989). fModel parameters were estimated by ﬁtting the model to the data (Figure 2). gTotal
body surface area (Haycock et al. 1978).
Table 2. Optimized values of the skin parameters Kuptake, Kpv, Pf:b, and Po:b. Kps were calculated using
Equation 10. The parameters were optimized for each of the 10 study volunteers.
Volunteer Kuptake × 10–3 (hr–1) Kps × 10–5 (cm/hr) Kpv × 10–3 (cm/hr) Pf:b Po:b
1 190.7 18.8 7.6 4.4 0.6
2 4.4 1.1 1.5 0.1 0.6
3 13.6 8.0 0.6 1.6 8.9
4 21.3 3.2 3.1 15.2 2.4
5 16.9 11.8 2.4 15.4 12.2
6 22.8 11.7 1.7 3.1 8.3
7 12.2 6.8 2.1 22.4 2.7
8 18.6 4.1 5.4 11.1 16.1
9 8.3 1.5 2.2 7.3 0.3
10 3.7 1.3 3.5 175.7 0.1
Mean ± SD 31.3 ± 56.4 6.8 ± 5.8 3.0 ± 2.1 25.6 ± 53.2 5.2 ± 5.8PBTK model of human exposure to naphthalene
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Sensitivity analysis. Normalized sensitiv-
ity coefficients (mean) were calculated sepa-
rately for exposure and physiologic
parameters. The sensitivity analysis was con-
ducted for a typical mixed exposure scenario,
that is, the subject representing the 50th per-
centile in terms of end-exhaled breath meas-
urements. Each parameter was changed 1%
from its optimal value (Table 1) in the for-
ward direction (Equation 8). The response
variable in both sets of calculations was the
concentration of naphthalene in the end-
exhaled breath. For exposure variables, the
end-exhaled breath concentration was most
sensitive to the estimated air concentration of
naphthalene during work (NSC = 1.0). End-
exhaled breath concentrations were not sensi-
tive to the variables DERMDOSE and Aexp, as
the dermal route accounts for only a small
percentage of total exposure in these individu-
als. In the multidose route PBTK model, the
end-exhaled breath concentration of naphtha-
lene was most sensitive to cardiac output
(NSC = –0.7), ventilation rate (NSC = 0.9),
and the blood:air partition coefﬁcient (NSC =
–0.9) (Figure 4). The NSCs for other parame-
ters were < |0.2|.
Discussion
A PBTK model was developed to predict end-
exhaled breath concentrations of naphthalene
from dermal and inhalation exposure to JP-8.
Our model consisted of ﬁve compartments rep-
resenting the stratum corneum, viable epider-
mis, blood, fat, and other tissues, and contains
fewer parameters than previously published
physiologically based compartmental models of
naphthalene (Quick and Shuler 1999; Willems
et al. 2001). The fat was considered separate
from the other tissues because the time constant
for fat (8.6 hr) was larger than the time con-
stant for other tissues (0.9 hr). However, the
other tissue compartment was included in the
model because the skin compartment consisted
of the skin directly under the exposed area. The
remaining skin was included in the other tissue
compartment. 
Adjustments were made to the fat:blood
and other tissue:blood partition coefﬁcients for
the PBTK model predictions to ﬁt the experi-
mental and occupational exposure data. For
many chemicals, the partition coefﬁcients are
not known. In such cases, quantitative struc-
ture–activity relationship (QSAR) models may
be used to predict the necessary partition coef-
ﬁcients; however, the predictions are limited to
chemicals with physicochemical properties that
lie within the calibration data set (Beliveau
et al. 2003). In our study we calibrated the val-
ues of Pf:b and Po:b, which were predicted by
Willems et al. (2001) using QSAR models,
against human exposure data. We estimated a
Pf:b value of 25.6 for naphthalene, which is
more plausible than 160 given that the Pf:b for
benzene is 55 and 25 for decane. Using the vial
equilibration technique of Gargas et al. (1989),
we also measured a Pb:a value of 10.3 for naph-
thalene, which is more consistent with the Pb:a
for other compounds than is the value of 571
reported by Willems et al. (2001). For exam-
ple, the human Pb:a for benzene, cyclohexane,
JP-10, and p-xylene were 8.19, 1.41, 52.5, and
44.7, respectively (Gargas et al. 1989). 
The PBTK model was used to calculate the
permeability coefﬁcient (Kp) for naphthalene
in humans in vivo. Previously, the Kp had been
calculated using Fick’s law of diffusion. A
Kp value of 5.1 × 10–4 cm/hr was estimated for
rat skin in vitro (McDougal et al. 2000). This
in vitro Kp value was compared with a Kp value
that was estimated by calculating the ﬂux value
for aromatic and aliphatic components of JP-8
in humans from the slope of the linear portion
of the cumulative mass of chemical in blood
per square centimeter versus time curve (Kim
et al. 2006a). We calculated an apparent Kp of
5.3 × 10–5 cm/hr, which is approximately an
order of magnitude lower than that for the rat
Kp. This Kp calculation was revised using a
DTK model and Equation 9. A larger Kp value
was estimated (1.8 × 10–3 cm/hr), which was
more similar to the Kp estimated in vitro by
McDougal et al. (2000). The limitation of
using a data-based compartmental model is
that the parameter values are not constrained
by the actual anatomy and physiology of the
human body and the biochemistry of naphtha-
lene in vivo. We incorporated such constraints
into our PBTK model and revised our calcula-
tion of Kp for naphthalene. We estimated a Kps
value of 6.8 × 10–5 cm/hr and a Kpv value of
3.0 × 10–3 cm/hr. The value of Keff, which is
the overall permeability coefﬁcient for chemi-
cals crossing the skin (McCarley and Bunge
2001), is 6.6 × 10–5 cm/hr.
Keff is approximately 7-fold smaller than
the Kp reported by McDougal et al. (2000). A
7-fold difference was not unexpected because
rat skin used in the McDougal et al. (2000)
study is generally considered more permeable
than human skin. Molecular diffusion is the
dominant mechanism that governs the per-
meation of naphthalene across the skin. For
diffusion, the flux (and Kp) is inversely pro-
portional to the thickness of the diffusion dis-
tance, as stated by Fick’s ﬁrst law of diffusion.
Therefore, doubling the thickness of the skin
will result in halving the Kp. McDougal et al.
(2000) estimated Kp across rat skin of thick-
ness 560 μm. The human skin thickness
ranges from 500 μm to 4,000 μm; therefore,
the human Kp value is expected to be between
6.4 × 10–5 cm/hr and 5.7 × 10–4 cm/hr. Our
estimate of the effective permeability coeffi-
cient for naphthalene lies within this range of
expected values. 
Figure 3. Model simulations and end-exhaled breath concentrations for the U.S. Air Force personnel who were exposed to JP-8 via inhalation and dermal routes.
Breath samples were collected immediately at the end of the work shift and at a central testing site. Shown are the measured and predicted values for three U.S.
Air Force personnel who represented the 10th (A), 50th (B), and 90th (C) percentiles of measured end-exhaled breath concentrations. Simulations are also shown
after adjusting the air concentration of naphthalene during work to better estimate the true inhalation exposure [adjusted (Adj) model].
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Table 3. Input parameters and values for prediction of end-exhaled breath concentrations of naphthalene
in the U.S. Air Force personnel who represented the 10th, 50th, and 90th percentiles based on end-exhaled
breath measurements.
Percentile
Variable 10th 50th 90th
Height (cm) 175 188 168
Body weight (kg) 81 109 73
INHAL1est (µg/m3) 499 322 3,640
INHAL2est (µg/m3) 2.0 2.0 2.0
DERMDOSE (µg/cm2) 3.9 × 10–5 5.5 × 10–4 9.2 × 10–3
Duration of exposure (min) 224 322 260The optimized PBTK model was used to
predict end-exhaled breath measurements col-
lected in the workplace for the U.S. Air Force
personnel exposed to JP-8 by the inhalation
route. The predicted concentration at the end
of their work shift was the same as the meas-
ured values. Further comparisons of predicted
versus measured values revealed considerable
interindividual variability. Sources of hetero-
geneity in a population may include physical
condition, level of activity, disease state, age,
hormonal status, and interactions with other
chemicals and drugs (Clewell and Andersen
1996). Further, we observed considerable
variation in the values of Kps and Kpv, but the
small sample size (10 subjects) limited the
analysis of variability in our study. Further
study of the heterogeneity of parameter values
and the impact on the toxicokinetic proﬁle of
naphthalene in humans is needed.
We also used the optimized PBTK model
to examine dermal and inhalation exposure to
JP-8. Three U.S. Air Force personnel were
selected who represented the 10th, 50th, and
90th percentiles based on their end-exhaled
breath concentrations. The predicted concen-
trations of naphthalene were well above what
was expected in end-exhaled breath. For
example, for the personnel representing the
50th percentile, INHAL1est overpredicted the
end-exhaled breath concentration of naphtha-
lene by 1,540% (i.e., 75.8 μg/m3 vs. 4.6 μg/
m3). The reason for overpredicting breath
concentrations was that these workers wore
personal protective equipment that included
forced supply-air respirators while working in
fuel tanks. Thus, the air concentration that
was measured using the passive monitors was
not the actual air concentration that the Air
Force personnel were exposed to while work-
ing inside the fuel tanks. 
The PBTK model was exercised to obtain a
better estimate of the air concentration that
corresponded to the breath measurements. The
adjusted air concentration was used in our cal-
culation of the relative contribution of dermal
exposure to the end-exhaled breath concentra-
tion of naphthalene. We observed that the
median contribution of dermal exposure to the
end-exhaled breath concentration of naphtha-
lene was relatively small (4%). However, in the
U.S. Air Force personnel who represented the
90th percentile, the relative contribution of der-
mal exposure to the end-exhaled breath con-
centration was 11%. The U.S. Air Force
personnel examined in this study comprised
fuel-cell maintenance workers. Thus, the use of
dermal protective equipment can further
decrease the end-exhaled breath concentration
of naphthalene in the fuel-cell maintenance
workers.
This PBTK model has reduced the uncer-
tainty in modeling JP-8 exposures because
fewer parameters were required to predict the
time-course of naphthalene. However, our
model has identified some data gaps. First,
inhalation exposures should be measured over
shorter time intervals. Sensitivity analysis
demonstrated that end-exhaled breath levels of
naphthalene were most sensitive to the air
concentration of naphthalene during work. In
our study, we used time-weighted average con-
centrations (over approximately 4 hr) that did
not capture exposures to high levels of naph-
thalene from local sources. Therefore, shorter
time-resolved data may be used to better
explain the transient nature of inhalation
exposures to JP-8. Second, occupational and
environmental exposure studies of other com-
ponents of JP-8 are needed to gain a more
complete picture of JP-8 exposures. Currently,
occupational exposure studies have focused on
single chemical components of JP-8. The
results of multichemical exposure assessment
studies may be compared with results from
single-chemical studies and add to our under-
standing of the absorption, distribution,
metabolism, and elimination of complex
chemical mixtures.
The modeling approach used in this study
represents a useful technique for assessing the
contribution of dermal and inhalation expo-
sures to the systemic levels of chemicals. One
of the primary applications of this work could
be to improve the understanding of exposure
processes by quantifying the relationship
between external exposure measurements and
biomarkers of internal dose. For example, a
series of air and dermal exposure measure-
ments may be collected from a sample of
individuals from groups stratiﬁed by ﬁxed fac-
tors such as location relative to the source of
exposure. One could, for example, introduce
an intervention (e.g., respirators) and use the
PBTK model to quantify the efficacy of the
intervention for reducing systemic levels of
the toxicant. This approach would be useful
for protecting the health of individuals. For
example, if the concentration of the exposure
biomarker (i.e., blood and/or breath concen-
tration) is driven primarily by the dermal
route in a given group, there would be little
advantage in additional respiratory protec-
tion. This approach may be used in both
occupational and environmental risk assess-
ment applications. However, additional mod-
eling and experimental studies are required
before generalization of this model to conﬁrm
scenarios/dose metrics beyond the limitations
of the current study.
In conclusion, we used the PBTK model to
quantify the contribution of dermal exposures
Kim et al.
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Table 4. Estimated contribution of dermal exposure to the end-exhaled breath concentrations of naphtha-
lene relative to inhalation exposure.a
Percentile Breath (µg/m3) AUCex (µg × min/m3) INHAL1adj (µg/m3) INHAL1pred (µg/m3) Ratio (%)
10th 1.7 1.7 7.4 0.1 1
50th 4.7 41.7 18.8 0.7 4
90th 29.4 521 103 11.7 11
aThis analysis was based on three U.S. Air Force personnel whose end-exhaled breath concentrations represented the
10th, 50th, and 90th percentiles. The ratio of INHAL1pred to INHAL1adj is a measure of the relative percent contribution of
dermal exposure to the end-exhaled breath concentration. 
Figure 4. Normalized sensitivity coefﬁcients for the end-exhaled breath concentrations. Parameters were
adjusted at the 1% level. 
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to the systemic levels of naphthalene. We
estimated a permeability coefficient that was
7-fold lower than estimates for rat skin made
in vitro. Our approach used a combination of
exposure assessment, biological monitoring,
and toxicokinetic modeling tools to integrate
external exposure and biomarker data into a
single description of the toxicokinetic behavior
of naphthalene. The PBTK model incorpo-
rated exposures from both dermal and inhala-
tion routes and required estimation of fewer
parameters than previously published PBTK
models of naphthalene. This PBTK model,
which included two major exposure routes rel-
evant to occupational and environmental
exposure scenarios, may be used for integrat-
ing animal and human observational studies
into an improved understanding of human
health risks for JP-8. A wide range of perme-
ability coefﬁcient values was noted in the indi-
viduals in this research and further study of
the sources of inter- and intraindividual varia-
tion in these processes appears necessary.
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Research
During fetal life, alterations in normal
prostate gland development can produce per-
manent changes that persist throughout
adulthood and may increase the risk of dis-
ease in later life (Ho et al. 2006; Risbridger
et al. 2005). The prostate differentiates from
the cranial region of the urogenital sinus
(UGS) (Marker et al. 2003). In humans, the
ﬁrst epithelial buds are observed in the lateral
region of the UGS during the tenth week of
gestation in a pattern that shows a remark-
able similarity to that of bud development in
mice and rats during the early phase of gland
genesis (Timms et al. 1994). Prostate ductal
budding begins on gestation day (GD) 17 in
mice (2 days before birth) (Timms et al.
1994). Prostate development is dependent
on 5α-dihydrotestosterone (DHT) produc-
tion from testosterone within the UGS
mesenchyme (Marker et al. 2003). Androgen
receptor expression in prostatic mesenchyme
is required for directing growth and branch-
ing morphogenesis of epithelial buds, pre-
sumably by induction of paracrine factors
secreted by mesenchyme (Cunha and
Donjacour 1987; Kokontis and Liao 1999).
During development, prostatic epithelial
cells exhibit little androgen binding, and
androgen receptor protein expression in
epithelium is not required for differentiation
(Cunha and Donjacour 1987; Prins and
Birch 1995; Timms et al. 1999). Therefore,
fetal mouse UGS mesenchyme cells provide
an informative model of endocrine control of
prostate development.
There is now considerable evidence that
estrogens modulate the activity of androgens
in regulating prostate development. The UGS
mesenchyme in mice and rats responds to
estrogens via estrogen receptor 1 (α), whereas
in the human prostate estrogen receptor 2 (β)
may mediate most responses to estrogens dur-
ing development (Adams et al. 2002; Prins
et al. 1998). Prostatic growth and androgen
receptor ligand-binding activity are perma-
nently decreased in response to high, pharma-
cologic doses of both natural and xenobiotic
estrogens during development (Prins and
Birch 1995; Rajfer and Coffey 1978;
vom Saal et al. 1997). In contrast, increases in
prenatal estrogen levels within the physiologic
range (the normal range for endogenous
estradiol) stimulate prostate development,
leading to permanently increased prostate size
and androgen receptor ligand-binding activity
(Gupta 2000; Timms et al. 1999; vom Saal
et al. 1997). 
Estrogenic endocrine disruptors have the
potential to alter prostate development in a
manner similar to that of endogenous estra-
diol. In this study, we chose to examine
bisphenol A (BPA), the monomer used to
make polycarbonate plastic and as an addi-
tive in many other plastic products. BPA is
produced in excess of 6 billion pounds per
year, and the potential for human exposure is
great due to leaching from plastic and plastic-
lined metal food and beverage containers, as
well as from dental sealants (Takao et al.
2002; Welshons et al. 2006).
We have proposed that one mechanism
by which fetal estrogen exposure stimulates
prostate development is by increasing pros-
tatic androgen receptor gene [Ar; GenBank
accession no. X53779 (Benson et al. 2007)]
expression, thereby increasing the androgen
responsiveness of the developing prostate,
leading to enhanced gland genesis and growth
(Richter et al. 2005; vom Saal et al. 1997). In
the present study we sought to determine
whether the endogenous hormone 17β-estra-
diol (E2), within its physiologic range, and the
manmade estrogenic endocrine disruptor
BPA, within the range measured in human
serum (Schönfelder et al. 2002), directly inﬂu-
ence Ar and estrogen receptor 1 (α) (Esr1;
GenBank accession no. NM_007956.2) gene
expression at the transcriptional level in fetal
mouse UGS mesenchyme.
Materials and Methods
Animals, housing, mating, and organ collec-
tion. CD-1 mice were purchased from
Charles River Laboratories (Wilmington,
MA) and bred at the University of Missouri
in a facility accredited by the Association for
Assessment and Accreditation of Laboratory
Animal Care. Animals were housed on corn-
cob bedding in standard polypropylene cages.
They received water puriﬁed by ion exchange
and carbon filtration from glass bottles.
Pregnant and lactating females were fed
Purina 5008 chow (Purina Mills, St. Louis,
MO). After being weaned, animals were fed
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Estradiol and Bisphenol A Stimulate Androgen Receptor and Estrogen
Receptor Gene Expression in Fetal Mouse Prostate Mesenchyme Cells
Catherine A. Richter,1 Julia A. Taylor,1 Rachel L. Ruhlen,1 Wade V. Welshons,2 and Frederick S. vom Saal1
1Division of Biological Sciences, and 2Veterinary Biomedical Sciences, University of Missouri-Columbia, Columbia, Missouri, USA
BACKGROUND: Hormonal alterations during development have lifelong effects on the prostate gland.
Endogenous estrogens, including 17β-estradiol (E2), and synthetic estrogenic endocrine disruptors,
such as bisphenol A (BPA), have similar effects on prostate development. Increasing exposure to
estrogens within the low-dose, physiologic range results in permanent increases in the size and
androgen responsiveness of the prostate, whereas exposure within the high-dose, pharmacologic
range has the opposite effects.
OBJECTIVES: We tested the hypothesis that the low-dose effects of estrogens on the developing
prostate are associated with increased expression of androgen receptor (Ar) and estrogen receptor 1 (α)
(Esr1) genes in mesenchyme cells.
METHODS: Ar and Esr1 mRNA levels were quantiﬁed in primary cultures of fetal mouse prostate
mesenchyme cells treated with E2 and BPA. 
DISCUSSION: Ar and Esr1 mRNA expression increased in response to E2, with thresholds of 0.001
and 0.037 nM, respectively; and in response to BPA, with a threshold of 1 nM for both mRNAs.
We did not observe the expected inhibition of Ar mRNA expression by pharmacologic levels of E2
relative to unexposed cells. 
CONCLUSIONS: The observed induction of gene expression occurred at concentrations within the
range of free E2 previously shown to permanently increase prostate size, thus supporting the
involvement of direct effects of estrogens on gene expression in prostate mesenchyme. The effects
of BPA occurred within the range of concentrations currently measured in human serum, demon-
strating the vulnerability of developing tissues to xenoestrogens.
KEY WORDS: 17β-estradiol, androgen receptor gene, bisphenol A, dose–response relationship, estrogen
receptor 1 (α) gene, prostate, sexual differentiation. Environ Health Perspect 115:902–908 (2007).
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were maintained at 25 ± 2°C under a
12 hr:12 hr light:dark cycle. Animals were
treated humanely and with regard for allevia-
tion of suffering. Animal procedures were
approved by the University of Missouri
Animal Care and Use Committee and con-
formed to the NIH Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory
Animal Resources 1996). 
Tissue collection, primary cell culture, and
dosing. Timed-pregnant females were killed on
GD17 (mating = GD0) by CO2 asphyxiation,
and fetuses were removed from the uterine
horns. The bladder and UGS were removed
from male fetuses as previously described
(Timms et al. 1999; vom Saal et al. 1997). The
prostatic region of the UGS was removed from
the bladder at the bladder neck, and mesenchy-
mal cells were isolated as described by Gupta
(1999). Brieﬂy, UGS tissue was disrupted by
digestion with 3 mg collagenase type I/mL
(Sigma Chemical Co., St. Louis, MO) for
30–50 min at 37°C in a shaking water bath
followed by manual pipetting. Clumps of
epithelium were allowed to settle out, and sus-
pended mesenchymal cells were collected and
cultured in complete medium [RPMI-1640
without phenol red (Gibco, Grand Island, NY)
supplemented with 2 mM L-glutamine, 100 U
penicillin G sodium/mL, 100 mg streptomycin
sulfate/mL, and 0.25 mg fungizone/mL] with
10% (vol/vol) fetal bovine serum (FBS; U.S.
Bio-Technologies, Parkerford, PA). Cells were
grown to 95% conﬂuence and then passaged
by digestion with 0.05% trypsin in 0.53 mM
EDTA (Gibco) for 5 min at room tempera-
ture. Cell viability was assayed with alamarBlue
(BioSource International, Camarillo, CA)
according to the manufacturer’s instructions.
We characterized the cell-type composi-
tion of the UGS cell primary cultures by
immunofluorescent staining of cytokeratins
with mouse anti-pan-cytokeratin clone
PCK-26 ﬂuorescein isothiocyanate conjugate
(Sigma), and co-staining of the mesenchymal
cell marker vimentin with goat anti-vimentin
(Sigma) and rabbit anti-goat Cy3 conjugate
(Sigma) (Prins et al. 1991).
During experimental treatments with E2,
BPA, tamoxifen, and raloxifene, FBS was
charcoal-stripped to remove all hormones,
and cells were maintained in a constant back-
ground of 690 pM DHT (200 pg/mL). Cells
were treated with DHT rather than testos-
terone to control for potential treatment
effects on the intracellular concentration of
this high-affinity ligand for the androgen
receptor, which is formed from testosterone
in UGS mesenchyme cells in vivo, and also to
avoid the intracellular metabolism of testos-
terone to E2 by aromatase; DHT is not a sub-
strate for aromatase (Kokontis and Liao
1999). First passage cells were seeded onto
24-well plates at 7 × 104 cells/well in estro-
gen-free complete medium with 5% (vol/vol)
charcoal-stripped FBS, 5% (vol/vol) charcoal-
stripped horse serum (Sigma), 690 pM DHT
(Steraloids, Wilton, NH), and ITS supple-
ment (insulin-transferrin-selenium; Cambrex,
Walkersville, MD) for ﬁnal concentrations of
10 μg insulin/mL, 10 μg transferrin/mL, and
10 ng selenium/mL. Cells were maintained in
this estrogen-free medium for 3 days, with
one medium change, before the start of treat-
ments. E2, BPA, and tamoxifen were obtained
from Sigma. Raloxifene (LY 156,758) was
obtained from Eli Lilly (Indianapolis, IN).
During treatments with E2 and BPA, cells
were grown for 4 days, and the medium was
changed every day, except where noted. The
concentration of E2 in culture medium dur-
ing treatments was measured by radio-
immunoassay as previously described by vom
Saal et al. (1990).
Real time RT-PCR measurement of gene
expression. Total RNA was isolated with the
RNAqueous kit (Ambion, Austin, TX) accord-
ing to the manufacturer’s instructions. Total
RNA was quantiﬁed by absorbance at 260 nm.
Expression of speciﬁc mRNAs were measured
by one-step real-time reverse transcription-
polymerase chain reaction (RT-PCR) as
described by Bustin (2000), with the TaqMan
EZ RT-PCR kit (PE Applied Biosystems,
Foster City, CA) on the ABI PRISM 7700
Sequence Detection System (PE Applied
Biosystems). The concentrations of Mn2+,
probe, and primers were optimized for each
primer/probe set. Primer/probe sets for Ar,
vimentin (Vim; GenBank accession no.
NM_011701.3), and acidic ribosomal phos-
phoprotein P0 (Arbp; GenBank accession no.
NM_007475.2) were designed using Primer
Express software (PE Applied Biosystems)
and are shown in Table 1. Primers were
designed to span exon boundaries in order to
prevent amplification of genomic DNA.
Primers were synthesized by Invitrogen
(Carlsbad, CA), and probes were synthesized
by PE Applied Biosystems. The primer/probe
set for Esr1 was TaqMan Gene Expression
Assay ID Mm00433149_m1 (PE Applied
Biosystems), which spans Esr1 exons 3–4. 
The relative concentrations of specific
mRNAs in each sample were normalized to
total RNA per well, as described by Bustin
(2000) and Latil et al. (2001). Normalization
to total RNA allowed for comparisons between
independent experiments. In parallel experi-
ments, total DNA per well was measured by
fluorescence of Hoechst 33258 (Sigma), as
described by Labarca and Paigen (1980). From
these data, the average RNA/DNA ratio was
calculated for each treatment; we used these
values to convert the mRNA/total RNA meas-
urements to mRNA/DNA to assess the effect
of E2 and BPA on gene expression per cell.
Statistical analyses. Treatments were repli-
cated in three wells per experiment and at least
two, and in most cases more (up to 10), repli-
cate experiments. Outliers were detected with
Grubbs’ test (Grubbs 1969) and removed.
Treatment effects were evaluated on untrans-
formed data for RNA, and on reciprocals for
DNA and gene expression, with the analysis of
variance (ANOVA) general linear model pro-
cedure using SAS software (SAS Institute Inc.,
Cary, NC). We made planned comparisons of
means for each treatment relative to controls
using the least-squares means test only if the
overall ANOVA showed signiﬁcant treatment
effects. To avoid inflation of error rates, we
did not use multiple comparisons among all
treatments. The criterion for statistical signiﬁ-
cance was p < 0.05.
Results
Characterization of UGS cells and nominal E2
concentration in primary culture. Consistent
with previous reports (Gupta 1999), immuno-
ﬂuorescent staining for the mesenchymal cell
marker vimentin revealed no epithelial cells
in first passage cells treated for 5 days with
0.1 nM E2 or with no E2 (data not shown).
The UGS primary cell cultures that we exam-
ined were thus homogenous populations of
mesenchyme cells that retained mesenchymal
differentiation markers throughout the incu-
bation period.
After the initial administration of E2 in
culture medium, the E2 concentration slowly
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Table 1. Sequences of primers and probes for real time RT-PCR assays.
Gene Sequence (5´→ 3´) 5´ position in CDS Exon boundary
Ar
Forward TGTCAAAAGTGAAATGGGACC 1494
Reverse TGGTACTGTCCAAACGCATGT 1567 1–2 at 1553
Probe TGGATGGAGAACTACTCCGGACCTTATGGG 1516
Arbp 
Forward GAGATTCGGGATATGCTGTTGG 289 2–3 at 302
Reverse GGCGATGGCACCAGCC 351
Probe CAATAAGGTGCCAGCTGCTGCTCG 312
Vim
Forward GCACCCTGCAGTCATTCAGA 602
Reverse CCACTTTCCGTTCAAGGTCAA 673 3–4 at 660
Probe AGGATGTTGACAATGCTTCTCTGGCACG 623
CDS, coding sequence. decreased, presumably by metabolism, seques-
tration in cells, and/or binding to the tissue
culture dish. In more detail, E2 was adminis-
tered at a concentration of 1 nM, in the mid-
dle of the dose range in our experiment. The
concentration of E2 in medium decreased by
2 hr to approximately 90% and by 18 hr to
approximately 60% of the administered dose,
and then remained stable through the remain-
ing time period examined (up to 48 hr). 
In the experiments we conducted, test
chemicals were added to medium every 24 hr.
Thus, at the midpoint of the dose–response
curve tested, the actual E2 concentration in the
culture medium was approximately 60% of the
initial concentration at the time we collected
the cells for analysis of mRNA. Measurement
of DNA and RNA content and induction of
gene expression confirmed that bioactive
amounts of E2 were thus present at nominal
concentrations < 0.001 nM (Figures 1 and 2).
E2 induces growth of UGS mesenchyme
cells. E2 treatment induced a small increase in
cell growth and proliferation as indicated by
DNA and RNA content at doses of 0.01–
10,000 nM (Figure 1A, 1B). At 100,000 nM
E2, inhibition of cell growth and proliferation
was observed (Figure 1A, 1B). Cell viability
was not affected at any E2 dose tested (data not
shown). Subsequent experiments used a dose
range of 0.0001–10,000 nM in order to avoid
the cell growth–inhibiting effects of very high
doses of E2. Relative total RNA was induced to
a greater degree than DNA (Figure 1A, 1B).
The housekeeping genes Vim, a component of
the cytoskeleton in mesenchyme cells, and
Arbp, a component of the ribosome, were
examined to determine whether either could be
used as a reference gene. However, both of
these genes increased expression in response to
E2, consistent with a general induction of cell
growth (Figure 1C, 1D). Vimentin and acidic
ribosomal phosphoprotein P0 exhibited differ-
ently shaped dose–response curves, suggesting
differences in their mechanisms of transcrip-
tional regulation by E2. Because neither house-
keeping gene was an appropriate control gene,
expression of speciﬁc mRNAs was normalized
to DNA.
E2 induces the steroid receptor mRNAs Ar
and Esr1. Ar mRNA expression was induced
by E2 up to just over 2-fold above control lev-
els (Figure 2A). The observed threshold of
induction, 0.001 nM, is slightly higher than
the measured free serum E2 concentration of
0.00077 nM or 0.21 pg/mL in male mouse
fetuses on GD18 (vom Saal et al. 1997). The
increase in Ar mRNA with E2 dose was
monotonic up to 100 nM E2. At doses of
≥ 1,000 nM E2, Ar mRNA levels declined
relative to the maximum observed induction
at 100 nM E2. Inhibition of cell growth was
only evident at 100,000 nM E2. 
The induction of Ar mRNA by a physio-
logically relevant level of E2, 0.037 nM
(10 pg/mL), was significantly inhibited by
antiestrogen treatment (Figure 3A). The anti-
estrogen raloxifene (100 nM) had similar
effects to 100 nM tamoxifen (raloxifene data
not shown). The inhibition of the Ar response
to E2 by tamoxifen was overcome by addition
of a pharmacologic dose of 100 nM E2,
demonstrating that the inhibition by
tamoxifen observed at 0.037 nM E2 is not due
Richter et al.
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Figure 1. Indicators of cell growth increase with E2 dose. (A) DNA content slightly increased with E2 in a
dose-independent manner up to 10,000 nM and decreased significantly at 100,000 nM E2. (B) Total RNA
content increased with E2 in a dose-dependent manner up to 10,000 nM and decreased significantly at
100,000 nM E2. (C and D) Gene expression of the cytoskeleton protein vimentin (C) and the ribosomal com-
ponent acidic ribosomal phosphoprotein P0 (D) increased with E2 treatment. Units are fold induction rela-
tive to the control. Error bars represent 1 SE. The number of replicates measured for each treatment is
shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05).
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Figure 2. Biphasic Ar and Esr1 gene expression responses induced by E2. (A) Ar mRNA expression increases
with increasing dose of E2 up to a dose of 100 nM. A dose of 0.001 nM (0.27 pg/mL) is within the physiologic
range of free E2in mouse fetuses, and a signiﬁcant response to this dose is consistent with prior in vivo ﬁndings
(vom Saal et al. 1997). (B) Esr1 mRNA expression increases with increasing dose of E2 up to a dose of 100 nM.
Error bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05).
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(Figure 3A). 
Esr1 mRNA expression was induced by
E2 by approximately 3-fold over the control,
with a threshold at 0.037 nM (Figure 3B)
and a peak at 10–100 nM E2 (Figure 2B).
The induction of Esr1 mRNA by 0.037 nM
E2 was not significantly inhibited by anti-
estrogen treatment (Figure 3B).
BPA acts as an estrogen agonist in UGS
mesenchyme cells. The effects of BPA on cell
growth as indicated by DNA and RNA con-
tent (Figure 4) were much less pronounced
than the effects of E2 (Figure 1). The dose–
response curve for RNA was biphasic, with
significant reductions in RNA content, but
not DNA, at very low concentrations of BPA
(Figure 4). Ar and Esr1 mRNA expression
were induced by BPA treatment (Figure 5).
The dose–response curves for BPA were
shifted to the right by approximately
1,000-fold for Ar and approximately 30-fold
for Esr1, relative to E2 (based on the signiﬁ-
cant stimulation of Esr1 in response to
0.037 nM E2; Figure 3B). As indicated in
Figure 5A and 5B, a significant increase in
both Ar and Esr1 transcription occurred at
BPA concentrations within the range typically
reported in human blood and tissues, includ-
ing fetal blood (Schönfelder et al. 2002;
Welshons et al. 2006). The induction of both
Ar and Esr1 mRNAs by a physiologically rele-
vant low dose of BPA (10 nM) was inhibited
by a 100-nM dose of tamoxifen. For both
genes, the inhibition by tamoxifen was over-
come by a high dose of BPA (1,000 nM)
(Figure 6). 
Discussion
The aims of the present study were to investi-
gate whether there were direct effects on Ar
and Esr1 gene activity that could be related to
the previously observed stimulatory effect on
prostate development caused by prenatal
exposure to serum concentrations of bioactive
E2 in fetal mice and the concentration of
bioactive BPA currently measured in human
fetal serum. We found that both the natural
estrogen E2 and the synthetic estrogenic
endocrine disruptor BPA stimulated increases
in prostate Ar and Esr1 mRNAs. The stimu-
lation occurred at physiologically relevant
part-per-trillion doses of E2, and at parts-per-
billion doses of BPA, which are within the
range found in human fetal blood (reviewed
by Welshons et al. 2006).
Exposure of male mouse and rat fetuses to
slightly elevated estrogen levels results in per-
manent prostate enlargement and elevated
androgen receptor levels in adulthood
(Timms et al. 1999; vom Saal et al. 1997).
Some confusion concerning effects of estro-
gen on the prostate has been created by stud-
ies in which only very high, pharmacologic
(supraphysiologic) doses of estrogen were
tested. Effects of pharmacologic doses of
estrogenic chemicals on prostate development
are not predictive of effects at physiologic
doses. The dramatic effects of physiologic
doses of estrogens have been revealed in stud-
ies in which pregnant mice were administered
low doses of E2, the drugs diethylstilbestrol
(DES) and ethinylestradiol, BPA, or the
estrogenic insecticide methoxychlor, resulting
in a permanent increase in prostate size in
male offspring (Gupta 2000; Nagel et al.
1997; Thayer et al. 2001; vom Saal et al.
1997; Welshons et al. 1999). As the dose of
E2 or DES was increased into the pharmaco-
logic range, the stimulating effect observed at
low doses disappeared and inhibition of
prostate development occurred (Gupta 2000;
Timms et al. 2005; vom Saal et al. 1997).
Thus, the inhibitory effects of pharmacologic
doses of estrogens on the developing prostate
are opposite to effects of physiologic doses of
the same estrogenic chemicals. 
Available data on short-term effects of
developmental estrogen exposures are consis-
tent with the long-term effects observed in
adulthood. For example, a high, pharmaco-
logic dose of estradiol benzoate given to
neonatal rats induced down-regulation of
androgen receptor protein expression as early
as postnatal day (PND) 6 (Prins and Birch
1995). In contrast, low, physiologically rele-
vant doses of estrogenic chemicals (DES and
BPA) fed to pregnant mice induced up-regula-
tion of prostatic androgen receptor ligand
binding activity in male offspring as early as
PND3; this observation was replicated in
organ culture of fetal mouse prostate treated
with 0.1 pg/mL DES or 50 pg/mL BPA
(Gupta 2000). The increase in prostate size in
E2 and BPA induce Ar and Esr1 in fetal prostate
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Figure 3. Antiestrogen treatment inhibits E2-induced expression of Ar but does not signiﬁcantly inhibit E2-
induced expression of Esr1. (A) The antiestrogen tamoxifen (Tam) blocks induction of Ar mRNA by a
physiologic dose of E2, and the inhibition by Tam is overcome by a pharmacologic dose of E2. (B) Tam does
not signiﬁcantly inhibit induction of Esr1 mRNA by a physiologic dose of E2, or by a pharmacologic dose of
E2. Error bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05). **Signiﬁcant differences between the same E2 treatment with
and without Tam (p < 0.05).
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organ culture is below the threshold observed
for stimulation of either Ar or Esr1 gene
expression observed in the present study.
Our ﬁndings support the hypothesis that
prenatal exposure to elevated estrogen levels
permanently increases prostate size and
androgen responsiveness at least in part by
inducing Ar mRNA expression. Importantly,
the effects on Ar mRNA expression occurred
with a threshold at 0.001 nM E2 (0.28 pg/mL),
consistent with concentrations previously
shown to alter prostate development in vivo.
Speciﬁcally, the total serum E2 concentration
in male mouse fetuses on GD18 is approxi-
mately 0.35 nM (94 pg/mL), and the free
(unconjugated and unbound to plasma
proteins) serum concentration of E2 is
0.00077 nM (0.21 pg/mL), or 0.2% of total
serum E2 (vom Saal et al. 1997), similar to
findings in rats (Montano et al. 1995). An
increase in free serum E2 in male mouse
fetuses (due to maternal administration of
E2 via Silastic capsule) to 0.0012 nM
(0.31 pg/mL) signiﬁcantly increased prostate
size and the number of prostatic androgen
receptors in adulthood (vom Saal et al. 1997).
Our results show that at these same physio-
logic doses, E2 acts directly on fetal UGS
mesenchyme cells to increase Ar mRNA
expression. This response was inhibited by
the antiestrogens raloxifene (data not shown)
and tamoxifen (Figure 3), suggesting that
the induction of Ar mRNA by E2 is mediated
through the classical genomic estrogen
receptor pathway.
The differences in the shapes of the dose–
response curves for Ar and Esr1 suggest that
the receptors are regulated by distinct mecha-
nisms. Distinct dose–response relationships
were also noted for vimentin, acidic riboso-
mal protein P0, total RNA content, and
DNA content. These findings are consistent
with data from microarray studies demon-
strating considerable diversity in dose–
response relationships of different estrogen-
responsive genes; in particular, as one moves
across the dose–response curve, entirely differ-
ent sets of genes are activated or inhibited
(Coser et al. 2003; Shioda et al. 2006).
Induction of Ar and Esr1 also displayed dif-
ferent responses to inhibition by anti-
estrogens, in that Esr1 induction was not
significantly inhibited by antiestrogen co-
treatment (Figure 3). The threshold for effects
on Esr1 expression was between 0.01 nM
(2.3 ng/mL) and 0.037 nM (8.4 ng/mL) E2
(Figures 2B and 3B). This is above the nor-
mal range of free E2 in serum in male mouse
fetuses. However, serum estradiol may under-
estimate estrogen levels in prostate tissue
because cells in the developing prostate
express aromatase, which metabolizes testos-
terone to E2 (Ellem and Risbridger 2006;
Risbridger et al. 2003), and because estrogen
receptor agonists, including xenoestrogens,
exhibit additive effects in combination
(Rajapakse et al. 2002). The induction of
Esr1 expression by E2 suggests that estrogen
exposure may create a positive feedback loop
in the UGS, such that exposure to estrogens
increases sensitivity to future or continuing
exposure. 
Although the observed effects of physio-
logic concentrations of E2 on Ar mRNA
expression are consistent with established in
vivo effects, our pharmacologic dose range
(e.g., 100 nM) in vitro observations are not
consistent with established in vivo effects
(Gupta 2000; Prins and Birch 1995; vom Saal
et al. 1997), which predicted a decline in Ar
mRNA expression relative to control levels at
this high dose of E2 (Figure 2A). The in vivo
regulation of androgen receptors by pharma-
cologic doses of estrogens may thus involve
systemic and posttranscriptional effects that
are not observable in terms of Ar mRNA levels
in isolated mesenchyme cells. The involve-
ment of posttranscriptional mechanisms is
supported by the observation that develop-
mental exposure to pharmacologic doses of
estrogens permanently up-regulates androgen
receptor degradation by the proteasome
(Woodham et al. 2003).
The behavior of BPA in this system is
consistent with the established activity of BPA
as an estrogen receptor agonist (reviewed by
vom Saal and Hughes 2005; vom Saal and
Welshons 2006; Welshons et al. 2006), which
was first reported in 1936 (Dodds and
Lawson). The weak effects of BPA on cell
growth, measured as DNA and RNA content,
Richter et al.
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Figure 5. Gene expression of Ar and Esr1 are induced by the synthetic estrogen BPA. (A) Ar mRNA expres-
sion increases with increasing dose of BPA. (B) Biphasic Esr1 mRNA expression response increases with
increasing dose of BPA up to a dose of 10,000 nM (10 µM or 2.28 µg/mL). Shaded areas represent the typi-
cal range of concentrations of unconjugated BPA measured in human serum (Welshons et al. 2006). Error
bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar.
*Values signiﬁcantly different from the control (p < 0.05).
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15 15 11 11 86 6 6 99 89are consistent with previous reports that the
relative potency of BPA is greater in stimulat-
ing estrogen receptor–dependent gene tran-
scription than in stimulating growth of
uterine tissue (Nagel et al. 2001). There are
several interesting differences between the
dose–response curves of Ar and Esr1 in
response to BPA compared with E2. Based on
the thresholds of induction of gene expres-
sion, BPA is approximately 1,000-fold less
potent than E2 for induction of Ar, but only
about 30-fold less potent than E2 for induc-
tion of Esr1 (based on a threshold of Esr1
induction of 0.037 nM E2; Figure 3B). In
addition, the shape of the dose–response
curve for Esr1 differs between E2 and BPA;
induction of Esr1 by BPA was inhibited by
tamoxifen, whereas induction of Esr1 by E2
was not signiﬁcantly inhibited by tamoxifen.
These differences between E2 and BPA,
which are seen in the Esr1 dose–response
curves but not the Ar dose–response curves,
underline the probability that distinct mecha-
nisms are at work in the induction of Ar and
Esr1 by estrogens. 
Of great importance, the doses of BPA
required for induction of both Ar and Esr1
are within the range of typical levels of BPA
measured in human serum, which range
from approximately 1 to 10 nM (Figure 5)
(Schönfelder et al. 2002; Welshons et al.
2006). Because our experiments measured the
response to BPA in the absence of other estro-
gens, they are likely to underestimate the
induction of Ar and Esr1 expression in
response to the additive mixture of endoge-
nous estrogens, BPA, and other xenoestrogens
to which humans are continuously exposed in
our modern world (Colborn et al. 1993). The
consequences of developmental induction of
Ar and Esr1 for the adult phenotype of the
prostate have not been directly examined, but
exposure during fetal life to very low doses of
BPA (2–50 μg/kg/day) permanently increases
prostate size in mice (Gupta 2000; Nagel et al.
1997). Neonatal exposure to a 10 μg/kg/day
dose of BPA results in precancerous lesions
(prostate interepithelial neoplasia) in adult
male rats, associated with epigenetic changes
(Ho et al. 2006). The report of Ho et al.
(2006) is consistent with the finding that
estrogenic chemicals stimulate an abnormal
rate of proliferation in basal epithelial cells in
the primary ducts of the mouse fetal prostate
(Timms et al. 2005). Basal cells are progenitor
cells proposed to be involved in prostate can-
cer (Kirschenbaum et al. 2006). We are cur-
rently examining whether the permanent
increase in prostate AR receptor protein in
mice exposed during fetal life to low doses of
estrogenic chemicals is caused by a permanent
increase in expression of the Ar gene, and
whether this is associated with a change in
DNA methylation at the Ar gene.
Conclusions
Ar mRNA in mesenchyme cells isolated from
fetal mouse prostate is up-regulated by E2
within its physiologic range, and by BPA
within the range detected in human fetal
serum. Induction of Ar mRNA by E2 or BPA
was inhibited by antiestrogen co-treatment.
Therefore, the low-dose effects of estrogens
on prostatic Ar regulation are estrogen recep-
tor–dependent, act at the transcriptional level,
are mediated through local effects on UGS
mesenchyme cells, and can be modeled in a
primary cell culture system. In contrast,
down-regulation of androgen receptor protein
in response to high doses of estrogens in vivo
likely includes systemic and post-transcrip-
tional mechanisms. Esr1 mRNA is also up-
regulated by E2 and BPA in a dose-dependent
manner, suggesting the possibility of positive
feedback in estrogen effects on the prostate.
The induction of Esr1 by E2 is not signifi-
cantly inhibited by antiestrogen treatment,
suggesting the involvement of non-estrogen
receptor–mediated mechanisms.
Taken together, these results are consis-
tent with the hypothesis that prenatal expo-
sure to elevated estrogen or xenoestrogen
levels within the physiologic range results in
an increase in androgen receptor and estrogen
receptor 1 (α) number in the developing
prostate mesenchyme, which increases andro-
gen and estrogen responsiveness and growth.
The estrogen receptor–dependent induction
of Ar by BPA conﬁrms that this mechanism is
not unique to E2 and underscores the vulner-
ability of the developing reproductive system
to the additive effects of exogenous estrogenic
endocrine disruptors. 
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144:4841–4850.The developmental neurotoxicity of organo-
phosphate pesticides represents a biological
conundrum that has important ramiﬁcations
for human exposures (for review see Colborn
2006; Costa 2006; Landrigan 2001; Mileson
et al. 1998; Slotkin 2005; Weiss et al. 2004).
All of the organophosphates produce systemic
toxicity by inhibiting acetylcholinesterase,
resulting in overt symptoms of cholinergic
hyperstimulation; these effects have therefore
been assumed to be the common mechanism
underlying adverse developmental conse-
quences (Mileson et al. 1998). However, the
fetus and neonate recover from cholinesterase
inhibition much more quickly than adults
(Chakraborti et al. 1993; Lassiter et al. 1998),
yet display greater overall toxicity and damage
to the central nervous system (for review see
Pope 1999; Slotkin 2004, 2005). Indeed,
evidence accumulating over the past decade
implicates a host of other mechanisms in
the developmental neurotoxicity of the
organophosphates that depend instead upon
the direct targeting of events specific to the
developing brain (for review see Barone et al.
2000; Pope 1999; Rice and Barone 2000;
Slotkin 2004). Importantly, many of these
processes are vulnerable to organophosphates
at doses below those necessary to elicit signs of
systemic toxicity and even below the threshold
for significant inhibition of cholinesterase
(Pope 1999; Slotkin 2004, 2005).
Although a wide variety of intermediate
events in brain development connect the ini-
tial effects of organophosphates on neural cell
differentiation to the eventual synaptic and
behavioral defects (Pope 1999; Slotkin 2004,
2005), little information is currently available
about speciﬁc cellular mechanisms that render
the developing brain so vulnerable to these
agents. Indeed, many events in differentiation
and assembly of neural circuits are affected,
including the processes of neuronal and glial
cell replication and differentiation, speciﬁca-
tion of neurotransmitter phenotypes, axono-
genesis and synaptogenesis, and synaptic
function (Barone et al. 2000; Casida and
Quistad 2004; Gupta 2004; Jameson et al.
2006; Pope 1999; Slotkin 1999, 2004). In
turn, the diversity of these targets suggests that
the organophosphates disrupt some very basic
processes in neural cell differentiation. For
that reason, a number of investigations have
turned to the neurotrophic factors known to
play critical roles in neural development and
damage/repair processes. 
In adults, fully symptomatic organo-
phosphate poisoning produces peripheral
neuropathies and then a reactive increase in
formation of neurotrophic factors mediating
repair and neuritic outgrowth (Pope et al.
1995). Although we are dealing with events in
the central nervous system rather than with
peripheral neuropathies, it is not unreasonable
to hypothesize that these factors are equally or
even more important at the subtoxic exposures
that damage the developing brain. Two sets of
neurotrophic factors have been explored to
date. First, acetylcholinesterase itself is thought
to play a nonenzymatic role in neural develop-
ment (Brimijoin and Koenigsberger 1999),
and we recently demonstrated induction of the
neurotoxic splice variant of acetylcholinesterase
at organophosphate exposures below the
threshold for detectable inhibition of enzy-
matic activity in neonatal rat brain after
apparently subtoxic exposures to chlorpyrifos
or diazinon (Jameson et al. 2007). In addi-
tion, two recent studies (Betancourt and Carr
2004; Betancourt et al. 2006) focused on
nerve growth factor and brain-derived neuro-
trophic factor after exposure of newborn rats
to chlorpyrifos or chlorpyrifos oxon, the active
metabolite that inhibits cholinesterase.
Although these researchers used exposures that
were above the threshold for cholinesterase
inhibition and somatic growth impairment,
they found no significant decrease in either
protein (Betancourt and Carr 2004) and only
a small decrease (10–20%) in the mRNA
encoding nerve growth factor (Betancourt
et al. 2006).
Thus, if organophosphate effects on
neurotrophic factors play an important role in
the developmental neurotoxicity of these
agents, then other factors are likely to be more
highly affected. In the present study, we
turned our attention to the large number of
fibroblast growth factors (FGFs) and their
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Exposure to Organophosphates Reduces the Expression of Neurotrophic
Factors in Neonatal Rat Brain Regions: Similarities and Differences in the
Effects of Chlorpyrifos and Diazinon on the Fibroblast Growth Factor
Superfamily
Theodore A. Slotkin,1 Frederic J. Seidler,1 and Fabio Fumagalli 2
1Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA; 2Center of
Neuropharmacology, Department of Pharmacological Sciences, University of Milan, Milan, Italy
BACKGROUND: The ﬁbroblast growth factor (FGF) superfamily of neurotrophic factors plays critical
roles in neural cell development, brain assembly, and recovery from neuronal injury. 
OBJECTIVES: We administered two organophosphate pesticides, chlorpyrifos and diazinon, to
neonatal rats on postnatal days 1–4, using doses below the threshold for systemic toxicity or growth
impairment, and spanning the threshold for barely detectable cholinesterase inhibition:
1 mg/kg/day chlorpyrifos and 1 or 2 mg/kg/day diazinon. 
METHODS: Using microarrays, we then examined the regional expression of mRNAs encoding the
FGFs and their receptors (FGFRs) in the forebrain and brain stem. 
RESULTS: Chlorpyrifos and diazinon both markedly suppressed fgf20 expression in the forebrain
and fgf2 in the brain stem, while elevating brain stem fgfr4 and evoking a small deﬁcit in brain stem
fgf22. However, they differed in that the effects on fgf2 and fgfr4 were signiﬁcantly larger for diazi-
non, and the two agents also showed dissimilar, smaller effects on fgf11, fgf14, and fgfr1. 
CONCLUSIONS: The fact that there are similarities but also notable disparities in the responses to
chlorpyrifos and diazinon, and that robust effects were seen even at doses that do not inhibit
cholinesterase, supports the idea that organophosphates differ in their propensity to elicit develop-
mental neurotoxicity, unrelated to their anticholinesterase activity. Effects on neurotrophic factors
provide a mechanistic link between organophosphate injury to developing neurons and the even-
tual, adverse neurodevelopmental outcomes.
KEY WORDS: brain development, chlorpyrifos, diazinon, ﬁbroblast growth factor, ﬁbroblast growth
factor receptors, microarrays, neurotoxicity, organophosphate insecticides. Environ Health Perspect
115:909–916 (2007). doi:10.1289/ehp.9901 available via http://dx.doi.org/ [Online 27 February 2007]receptors (FGFRs). The FGF superfamily
plays a widespread and vital role in brain
development and in the repair from neural
injury (Dono 2003). Across the various stages
of development, the FGFs promote and main-
tain neuronal cell replication and are required
for differentiation into the terminal transmit-
ter phenotype (Gage et al. 1995; Johe et al.
1996). The different FGFs play speciﬁc roles
in neuronal cell differentiation, neurite out-
growth, and the recovery from damage in
regions such as the striatum and hippocampus
(Hart et al. 2000; Limke et al. 2003; Murase
and McKay 2006; Ohmachi et al. 2000; Ray
et al. 1993; Takagi et al. 2005). The same
regions are known targets for the adverse neuro-
developmental effects of organophosphates
(Barone et al. 2000; Slotkin 1999, 2004,
2005), which disrupt the very same cellular
events for which the FGFs provide trophic sig-
nals (Axelrad et al. 2003; Das and Barone
1999; Howard et al. 2005; Song et al. 1998).
Accordingly, we used a microarray approach to
examine the family of FGFs and their recep-
tors, comparing the effects of two different
organophosphates, chlorpyrifos and diazinon,
to emphasize points of similarity and differ-
ence: if the developmental neurotoxicity of the
organophosphates involves neurotrophic
mechanisms unrelated to the inhibition of
cholinesterase, then there may be significant
disparities in their impact on neurotrophic fac-
tors. We concentrated on doses that evoke
barely detectable inhibition, too low to elicit
any signs of cholinergic hyperstimulation
(Slotkin et al. 2006b; Song et al. 1997); our
assessments were conducted in two brain
regions, the brain stem and forebrain, that dif-
fer both in anatomical attributes as well as in
maturational timetables (Rodier 1988).
Materials and Methods
Animal treatments. All experiments were car-
ried out in accordance with federal and state
guidelines and with prior approval of the
Duke University Institutional Animal Care
and Use Committee; all animals were treated
humanely and with due care for alleviation of
distress. Timed-pregnant Sprague-Dawley
rats (Charles River, Raleigh, NC, USA) were
housed in breeding cages, with a 12-hr
light/dark cycle and free access to food and
water. On the day of birth, all pups were ran-
domized and redistributed to the dams with a
litter size of 9–10 to maintain a standard
nutritional status. 
Chlorpyrifos and diazinon (both from
Chem Service, West Chester, PA, USA) were
dissolved in dimethylsulfoxide to provide con-
sistent absorption (Whitney et al. 1995), and
were injected subcutaneously in a volume of
1 mL/kg body weight once daily on postnatal
days (PNDs) 1–4; control animals received
equivalent injections of dimethylsulfoxide
vehicle. For both agents, we used doses below
the threshold for growth retardation and sys-
temic toxicity (Campbell et al. 1997; Slotkin
et al. 2006a; Whitney et al. 1995): 1 mg/kg
for chlorpyrifos and either 1 or 2 mg/kg for
diazinon. This chlorpyrifos treatment and the
higher dose of diazinon produce neurotoxicity
in developing rat brain while eliciting < 20%
cholinesterase inhibition, whereas the lower
dose of diazinon does not produce any
detectable inhibition (Slotkin 1999, 2004;
Slotkin et al. 2006b; Song et al. 1997;
Whitney et al. 1995), or any of the symptoms
of cholinergic hyperstimulation known to be
characteristic of anticholinesterase activity
(Clegg and van Gemert 1999). These treat-
ments thus resemble the nonsymptomatic
exposures reported in pregnant women
(De Peyster et al. 1993) and are within the
range of expected fetal and childhood expo-
sures after routine home application or in
agricultural communities (Gurunathan et al.
1998; Ostrea et al. 2002). 
On PND5 (24 hr after the last dose), one
male pup was selected from each of ﬁve litters
in each treatment group. Animals were decap-
itated, the cerebellum was removed, and the
brain stem and forebrain were separated by a
cut made rostral to the thalamus. Tissues were
weighed and flash-frozen in liquid nitrogen
and maintained at –45°C until analyzed. Our
study design involved the analysis of 40 sepa-
rate tissues: one animal from each of ﬁve lit-
ters for each of the four treatment groups,
with two tissues (brain stem, forebrain) from
each animal.
Microarray determinations. Tissues were
thawed and total RNA was isolated using the
Aurum total RNA Fatty and Fibrous Tissue
Kit (Bio-Rad Laboratories, Hercules, CA,
USA). RNA quality was verified using the
RNA 6000 LabChip Kit and the Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA). An aliquot of each sample used in
the study was withdrawn and combined to
make a reference RNA preparation to be
included on each array. RNA amplification
was carried out using a commercial kit (Low
RNA Input Fluorescent Linear Ampliﬁcation
Kit; Agilent). 
Each RNA sample was annealed with a
primer containing a polydT and a T7 poly-
merase promoter. Reverse transcriptase pro-
duced a first and second strand cDNA. T7
RNA polymerase then created cRNA from
the double stranded cDNA by incorporating
cyanine-3– (for the reference RNA) or cya-
nine-5– (for the sample RNA) labeled cyti-
dine 5-triphosphate; the quality of the labeled
cRNA was again verified and the absolute
concentration was measured spectrophoto-
metrically. For each pair of reference cRNA
and experimental cRNA hybridized to an
array, equal amounts of cRNA (0.75 μg) were
hybridized using a commercial kit (In situ
Hybridization Kit-Plus; Agilent). Hybridiza-
tion was performed at 60°C for 17 hr with
Agilent Whole Rat Genome Arrays (G4131A).
The arrays were washed with Agilent’s SSPE
Wash Protocol using a solution of 6× SSPE,
0.005% N-lauroylsarcosine, a solution of
0.06× SSPE, 0.005% N-lauroylsarcosine, and
Agilent’s Stabilization and Drying Solution.
The arrays were scanned on an Agilent
G2565BA Microarray Scanner, and data from
the scans were compiled with Agilent Feature
Extraction Software 8.1. The steps from RNA
ampliﬁcation through extraction of the scanner
output data were performed by a private con-
tractor (Cogenics, Research Triangle Park,
NC, USA).
Array normalizations and error detection
were carried out using Silicon Genetics’
GeneSpring GX Version 7.2 (Agilent), via the
Enhanced Agilent Feature Extraction Import
Preprocessor. First, values of poor quality
intensity and low dependability were removed
using a “filter on flags” feature, where stan-
dardized software algorithms determined
which spots were “present,” “marginal,” or
“absent”; spots were considered “present” only
where the output was uniform, not saturated
and significant above background, whereas
spots that satisﬁed the main requirements but
were outliers relative to the typical values for
the other genes were considered “marginal.”
Filters were set to retain only the values that
were found to be present or marginal for fur-
ther analysis; however, of the genes that passed
the ﬁlter, none was marginal.
Data were normalized in three steps using
the algorithms supplied with the Feature
Extraction software. The ﬁrst step divides the
signal in the Cy5 channel (sample RNA) by
that in the Cy3 channel (reference RNA), to
give the measured ratio for each gene in the
array. The second normalization adjusts the
total signal of each chip to a standard value
(“normalize to 50th percentile”) determined by
the median of all the reliable values on the
chip; this renders the output of each chip com-
parable with that of every other chip in the
study. The third normalization step is applied
to each gene across all the arrays in the study
(“normalize to median”): The median of all the
values obtained for a given gene is calculated
and used as the normalization standard for that
gene, so that, regardless of absolute differences
in the expression of the various genes, they are
placed on the same scale for comparison.
After normalization, one final quality-
control ﬁlter was applied in which genes show-
ing excessive biologic variability were discarded;
the criterion for retention was that more than
half of the eight treatment × region groupings
had to have coefﬁcients of variation < 30%.
For some of the genes, the arrays con-
tained multiple probes and/or replicates of the
Slotkin et al.
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and these were used to verify the reliability of
values and the validity of the measures on the
chip. In these cases, to avoid artiﬁcially inﬂat-
ing the number of positive ﬁndings, we limited
each gene to a single set of values, selecting
those obtained for the probe showing the
smallest intragroup (treatment, region) vari-
ance; the other values for that gene were used
only to corroborate direction and magnitude
of change. Through these procedures we iden-
tiﬁed ﬁve defective arrays with sequential pro-
duction numbers, for which one corner of the
array showed a nonuniform overall difference
in brightness that affected the readings in that
region of the chip. The affected samples were
reevaluated on replacement arrays that did not
repeat the problem. Our experimental design
ensured that the replacement readings were
distributed among all the treatment groups
because our sample sequence was control,
chlorpyrifos, diazinon 1 mg/kg, diazinon
2 mg/kg; thus we did not run the risk of gen-
erating a spurious apparent treatment effect
from differences among arrays. The defective
arrays did allow us to perform an additional
quality-control evaluation because most of the
spots on the defective arrays were in the por-
tion that did not show the defect. Comparing
the values on the replacement arrays to the
valid portions of the defective arrays produced
a close correspondence of values (correlation
coefﬁcient = 0.98).
Statistical procedures. Because of the
requirement to normalize the data across
arrays and within each gene, the absolute val-
ues for a given gene are meaningless; only the
relative differences between regions and treat-
ments can be compared. Accordingly, results
for the regional differences in gene expression
in control rats are presented as means ± SEs of
the normalized ratios for each gene, but the
effects of the treatments are given as the per-
centage change from control to allow for
visual comparison of the relative changes
evoked for each gene, regardless of its control
ratio. However, statistical comparisons were
based on the actual ratios (log-transformed
because the data are in the form of ratios)
rather than the percent change.
Our design involved planned comparisons
of the organophosphate-exposed groups to
the controls and between the two different
organophosphates, so it was important to
consider the false positive rate and to protect
against type 1 errors from repeated testing of
the same database. Accordingly, before look-
ing at effects on individual genes, we per-
formed a global analysis of variance (ANOVA)
incorporating all treatments, both regions,
and all genes in a single comparison. Lower-
order ANOVAs were then carried out as per-
mitted by the interactions of treatment with
region and gene that justiﬁed subdivisions of
the data set. Finally, differences for individual
treatments for a speciﬁed gene in a single brain
region were evaluated with Fisher’s protected
least significant difference test. However,
where there was no treatment × region inter-
action for a given gene; only the main treat-
ment effect was reported without subtesting of
effects in individual regions. For ANOVA
results, effects were considered significant at
p < 0.05 (two-tailed, because we were inter-
ested in both increases and decreases in gene
expression). In addition to these parametric
tests of the direction and magnitude of
changes in gene expression, we evaluated the
incidence of significant differences as com-
pared with the false positive rate using Fisher’s
exact test, applying a one-tailed criterion of
p < 0.05 because only an increase above the
false positive rate would be predicted. Finding
a significant decrease in the incidence of
detected differences relative to the false posi-
tive rate would be biologically implausible and
statistically meaningless.
Results
Of the FGF and FGFR genes present on the
microarray, 19 genes passed the quality control
filters, encoding 15 of the FGFs and all 4
FGFRs (Table 1). In control rats, we did not
observe any overall pattern of regional prefer-
ence for expression of these genes: Of the
19 genes evaluated, only 6 showed signiﬁcant
regional differences, with fgf9, fgf22, and fgfr2
more highly expressed in the brain stem,
whereas fgf14, fgf20, and fgfr1 were higher in
the forebrain. Organophosphate exposures
elicited signiﬁcant, regionally selective changes
in gene expression for the FGFs and FGFRs.
Multivariate ANOVA (all treatments, all
genes, both regions) showed a signiﬁcant treat-
ment × region × gene interaction (p < 0.0001),
enabling separate evaluations for each gene.
Out of the 19 genes, 7 displayed significant
main treatment effects or an interaction of
treatment × region, as compared with an
expected false positive rate of only 1 gene
(p < 0.02).
For the genes encoding FGFs, chlorpyri-
fos exposure produced a significant overall
decrement (main treatment effect, p < 0.05)
and specific reductions in the expression of
fgf2, fgf11, fgf20, and fgf22 (Figure 1). By far,
the largest effect was on fgf20, which showed
a 50% deﬁcit in the forebrain; this region also
displayed a significant deficit in fgf2 and
fgf11. In contrast, the brain stem showed
smaller decreases restricted to fgf2 and fgf22.
The effects of diazinon on the FGF genes
displayed similarities to those of chlorpyrifos,
but also some differences. The lower dose of
diazinon caused a large reduction in forebrain
fgf20 expression as did chlorpyrifos, but diazi-
non failed to decrease forebrain fgf2 or fgf11
signiﬁcantly, and instead evoked a reduction
in fgf14 (Figure 2A). In the brain stem, we
again saw a small decrease in fgf2 and fgf22.
Increasing the dose of diazinon to 2 mg/kg
produced a further divergence from the effects
seen with chlorpyrifos (Figure 2B). Although
we still saw a signiﬁcant reduction in fgf20 in
the forebrain, no other gene was signiﬁcantly
affected for this region. In the brain stem, the
higher dose of diazinon produced an even
larger decrease in fgf2 expression than with
either chlorpyrifos or the lower diazinon
treatment. These regional differences between
diazinon and chlorpyrifos were statistically
significant (p < 0.02 for the interaction of
treatment × region × gene).
Two of the four genes encoding the
FGFRs, fgfr1 and fgfr4, showed statistically sig-
nificant treatment-related changes in expres-
sion, but the magnitude of the effect on fgfr1
was quite small, < 10% (Figure 3). In contrast,
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Table 1. Control values.
Name Gene Genbank accession no. Brainstem Forebrain
Fibroblast growth factor 1 fgf1 NM_012846 0.98 ± 0.05 1.00 ± 0.04
Fibroblast growth factor 2 fgf2 NM_019305 1.17 ± 0.09 1.02 ± 0.03
Fibroblast growth factor 3 fgf3 NM_130817 1.13 ± 0.11 0.87 ± 0.04
Fibroblast growth factor 9 fgf9 NM_012952 1.37 ± 0.08 0.81 ± 0.02*
Fibroblast growth factor 11 fgf11 NM_130816 1.03 ± 0.13 1.18 ± 0.10
Fibroblast growth factor 12 fgf12 NM_130814 1.02 ± 0.07 1.01 ± 0.03
Fibroblast growth factor 13 fgf13 NM_053428 0.97 ± 0.02 1.00 ± 0.02
Fibroblast growth factor 14 fgf14 NM_022223 0.87 ± 0.06 1.20 ± 0.04*
Fibroblast growth factor 15 fgf15 NM_130753 1.04 ± 0.15 1.15 ± 0.20
Fibroblast growth factor 17 fgf17 NM_019198 0.96 ± 0.06 1.00 ± 0.08
Fibroblast growth factor 18 fgf18 NM_019199 0.96 ± 0.04 0.99 ± 0.04
Fibroblast growth factor 20 fgf20 NM_023961 0.92 ± 0.23 1.63 ± 0.22*
Fibroblast growth factor 21 fgf21 NM_130752 0.99 ± 0.08 0.97 ± 0.07
Fibroblast growth factor 22 fgf22 NM_130751 1.11 ± 0.02 0.93 ± 0.04*
Fibroblast growth factor 23 fgf23 NM_130754 1.10 ± 0.10 0.84 ± 0.10
Fibroblast growth factor receptor 1 fgfr1 NM_024146 1.00 ± 0.02 1.08 ± 0.02*
Fibroblast growth factor receptor 2 fgfr2 BF 557.572 1.10 ± 0.04 0.96 ± 0.02*
Fibroblast growth factor receptor 3 fgfr3 NM_053429 0.98 ± 0.02 1.00 ± 0.03
Fibroblast growth factor receptor 4 fgfr4 XM_344570 0.89 ± 0.03 0.98 ± 0.03
GenBank accession numbers from GenBank (2007).
*Signiﬁcant difference between brain stem and forebrain.fgfr4 showed signiﬁcant increases in expression
for all three organophosphate treatment groups,
an effect that was restricted to the brain stem.
Diazinon produced a larger increase than did
chlorpyrifos. Again, the regional differences in
the effects of the two organophosphates were
statistically distinguishable (p < 0.05 for the
interaction of treatment × region × gene).
Earlier work with higher doses of chlorpyri-
fos administered for longer periods of time—
treatments that evoke signiﬁcant and persistent
cholinesterase inhibition and/or growth
impairment—identified small (10–20%)
decreases in the mRNA encoding nerve growth
factor (Betancourt et al. 2006). We also exam-
ined expression of the two corresponding genes
on our arrays, ngfb (GenBank accession no.
XM_227525; GenBank 2007) and ngfg
(Genbank NM_031523) but found only a
small (6%) decrease in ngfb in the forebrain
that did not achieve statistical significance
(data not shown). Similarly, we found no
significant effects on expression of the gene
encoding brain-derived neurotrophic factor
(bdnf; Genbank accession no. NM_012513;
data not shown).
Discussion
Our results show that neonatal exposure to
doses of organophosphates that are below the
threshold for any signs of systemic intoxication
or growth deﬁcits, and just at the threshold for
any detectable inhibition of cholinesterase,
nevertheless causes profound suppression of
several members of the FGF superfamily of
neurotrophic factors. Indeed, the effects for
chlorpyrifos or diazinon in the present study
are far larger than those reported previously for
other neurotrophic factors, even when the ear-
lier work involved chlorpyrifos treatments at
higher doses for longer periods, producing
much greater cholinesterase inhibition or frank
growth impairment (Betancourt and Carr
2004; Jameson et al. 2007). Furthermore, we
found a distinct regional hierarchy correspond-
ing to the maturational and anatomical differ-
ences between the brain stem and the forebrain
(Rodier 1988). The brain stem matures earlier
than the forbrain and contains a high propor-
tion of cell bodies for cholinergic, cate-
cholaminergic, and serotonergic neurons; the
forebrain develops later and contains the termi-
nal projections of these neurotransmitter sys-
tems, all of which are prominent targets for the
developmental neurotoxicity of organophos-
phates (Slotkin 1999, 2004, 2005). In keeping
with this regional specificity, fgf20 was
suppressed by chlorpyrifos or diazinon in the
forebrain, whereas the two organophosphates
differentially targeted fgf2 in the brain stem
(diazinon > chlorpyrifos). There were also
smaller effects on fgf11, fgf14, fgf22, fgfr1, and
fgfr4, each of which also displayed either a
regionally selective effect or a difference
between the two organophosphates. In con-
trast, no such regional differences were
reported for other neurotrophic factors such as
nerve growth factor or acetylcholinesterase
splice variants associated with neural damage/
repair (Betancourt and Carr 2004; Jameson
et al. 2007). Indeed, to obtain any effect on
nerve growth factor gene expression, the dose
and duration of chlorpyrifos exposure have to
be increased to the point where cholinesterase
is persistently inhibited and/or growth is
impaired; even then, there is only a small
(10–20%) decrement (Betancourt et al. 2006).
In the present study, we used lower doses and
shorter durations of exposure that caused
barely detectable cholinesterase inhibition and
no growth impairment, and found no signiﬁ-
cant deﬁcits for either nerve growth factor or
brain-derived neurotrophic factor, indicating
that selective members of the FGF superfamily
Slotkin et al.
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Figure 2. Effects of diazinon exposure on PNDs 1–4 at 1 mg/kg/day (A) or 2 mg/kg/day (B) on expression of
genes encoding the FGFs, shown as the percentage change from control values (Table 1). Multivariate
ANOVA (all genes, both regions) indicates a signiﬁcant interaction of treatment × region × gene (p < 0.003).
Error bars indicate SE.
*Signiﬁcant main treatment effect. #Signiﬁcant difference from corresponding control region after a treatment × region
difference was detected by ANOVA.
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Figure 1. Effects of 1 mg/kg/day chlorpyrifos exposure (PNDs1–4) on expression of genes encoding the
FGFs, shown as the percentage change from control values (Table 1). Multivariate ANOVA (all genes, both
regions) indicates a main effect of treatment (p < 0.05) and interactions of treatment × gene (p < 0.03) and
treatment × region × gene (p < 0.02). Error bars indicate SE.
*Signiﬁcant main treatment effect. #Signiﬁcant difference from corresponding control region after a treatment × region
difference was detected by ANOVA.
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#are indeed far more sensitive to disruption by
the organophosphates.
The regional selectivity suggests that the
effects of neonatal exposure to organo-
phosphates on expression of FGFs reﬂects the
targeting of specific processes in brain
development rather than a global interference
with neurotrophic responses. Below, we will
consider each of the FGFs in turn, emphasiz-
ing their various roles in neural development
and plasticity. However, ﬁrst it is necessary to
consider the important differences between
chlorpyrifos and diazinon. 
In the developing rat brain, treatment
with 1 mg/kg chlorpyrifos produces approxi-
mately a 10–20% inhibition of cholinesterase
(Song et al. 1997), roughly equivalent to that
seen at 2 mg/kg diazinon (Slotkin et al.
2006b); the lower dose of diazinon (1 mg/kg)
produces no signiﬁcant inhibition whatsoever
(Slotkin et al. 2006b). If the effects of these
agents were the result of cholinesterase inhibi-
tion, then the chlorpyrifos treatment should
produce the same pattern of effects as the
higher dose of diazinon, whereas the lower
diazinon dose should have no effect at all. In
fact, though, all three treatments shared the
same major suppression of fgf20 in the fore-
brain. Furthermore, the low dose of diazinon
inhibited brain stem fgf2 and fgf22 expression,
and increased fgfr4, just as did chlorpyrifos. It
is therefore apparent that these effects are
totally unrelated to cholinesterase inhibition,
the mechanism that underlies the systemic
toxicity of the organophosphates, thus rein-
forcing the concept that the developmental
neurotoxicity of these agents represents a sep-
arable set of mechanisms that operate at lower
exposures (Colborn 2006; Slotkin 1999,
2004, 2005; U.S. Environmental Protection
Agency 2006). 
It is also noteworthy that we saw several
important differences in the effects of chlor-
pyrifos as compared with diazinon: chlorpyri-
fos decreased fgf2 and fgf11 in the forebrain,
whereas diazinon did not; in the brain stem,
diazinon reduced fgf2 and induced fgfr4 much
more than did chlorpyrifos, and also had
effects on forebrain fgf14 and fgfr1 that were
not seen with chlorpyrifos. The similarities and
disparities suggest that the two organophos-
phates are likely to produce many parallels in
subsequent neurodevelopmental deficits but
may also differ in important ways. Although
much more information is available for chlor-
pyrifos than for diazinon, several findings
already suggest differential targeting of neural
cell replication, neuritic outgrowth, cytotoxic
events, and cholinergic and monoaminergic
neurotransmitter systems by these two agents
(Jameson et al. 2007; Qiao et al. 2001; Slotkin
et al. 2006a, 2007).
The two specific members of the FGF
superfamily that were most highly affected by
neonatal organophosphate exposure were fgf2
and fgf20, both of which have clearly estab-
lished roles in neurodevelopment, plasticity,
damage/repair, and neurodegenerative dis-
orders. The expression of fgf2 shows spatial
and temporal relationships to the matura-
tional profile of each brain region (Gomez-
Pinilla et al. 1994; Monfils et al. 2006) and
up-regulation of this gene is required for the
recovery from developmental brain injury
(Monﬁls et al. 2005; Yoshimura et al. 2001).
In addition, we recently found that fgf2 is inti-
mately involved in the programming of neural
plasticity associated with less injurious pertur-
bations, such as prenatal stress (Fumagalli
et al. 2005). Accordingly, the robust down-
regulation of this gene caused by neonatal
organophosphate treatment is likely to play an
important role in the neurodevelopmental
outcomes of such exposures; in particular, our
finding of regional selectivity (brain stem >
forebrain) is in keeping with the targeting of a
speciﬁc maturational stage and/or anatomical
location and similarly, the preferential sensi-
tivity to diazinon predicts a potentially wors-
ened outcome with this agent. For fgf2, our
finding of gross suppression by organophos-
phates during the brain growth spurt
(Dobbing and Sands 1979) is highly likely to
have long-term, adverse consequences for
neural development and behavioral function.
Even a brief period of fgf2 down-regulation
interferes directly with neurogenesis (Tao
et al. 1997), and the period of exposure stud-
ied here (first few days after birth) corre-
sponds to the peak proliferation period in a
number of neuronal populations, including
those of the hippocampal dentate gyrus
(Kempermann et al. 1997; Rodier 1988). If
similar effects occur with organophosphate
exposures in earlier or later developmental peri-
ods, this could explain why shifting the expo-
sure window often targets the neural cells and
regions that are undergoing the most rapid
development (Slotkin 1999, 2004, 2005).
In contrast to the organophosphate-
evoked reduction in fgf2, which was more
prominent in the brain stem, the suppression
of fgf20 was selective for the forebrain. What is
particularly notable about the regional differ-
ence is that fgf20 is preferentially expressed in
a subregion of the forebrain, the striatum
(Ohmachi et al. 2000), which contains the
majority of dopamine projections, the loss of
which results in Parkinson disease. There is
growing suspicion that repeated developmen-
tal exposures to pesticides that target striatal
dopamine projections play a signiﬁcant role in
the later emergence of this neurodegenerative
disorder (for review, see Cory-Slechta et al.
2005; Landrigan et al. 2005). Indeed, the rela-
tionship of suppressed fgf20 expression to
dopaminergic deﬁcits and thence to Parkinson
disease is directly supported by human genetic
data (Murase and McKay 2006; Takagi et al.
2005; van der Walt et al. 2004) and by the
speciﬁc role of this neurotrophic factor in pro-
moting survival of the very neurons that are
lost in Parkinson disease (Damier et al. 1999;
Yamada et al. 1990). 
The requirement for fgf20 is similarly
found for development of these neurons and
for preventing their death from apoptosis sec-
ondary to oxidative stress (Murase and
McKay 2006); the striatum is especially sensi-
tive to oxidative damage, in part because
dopamine itself produces oxidative metabo-
lites (Hirsch 1994; Olanow and Arendash
1994). Organophosphates target striatal
dopamine systems by causing release of
dopamine while simultaneously evoking
oxidative stress through other cellular mecha-
nisms (Bloomquist et al. 2002; Gupta 2004;
Jett and Navoa 2000; Karen et al. 2001;
Lazarini et al. 2004; Slotkin et al. 2002, 2005;
Slotkin and Seidler 2007). Consequently,
Organophosphate effects on developing brain FGFs
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Figure 3. Effects of chlorpyrifos or diazinon exposure on expression of genes encoding the FGF receptors,
shown as the percentage change from control values (Table 1). Multivariate ANOVA (all treatments, all
genes, both regions) indicates interactions of treatment × region (p < 0.005) and treatment × region × gene
(p < 0.05). Error bars indicate SE.
*Signiﬁcant main treatment effect. #Signiﬁcant difference from corresponding control region after a treatment × region
difference was detected by ANOVA.
40
30
20
10
0
–10
–20
–30
–40
fgfr1 fgfr2 fgfr3 fgfr4
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
c
o
n
t
r
o
l
Chlorpyrifos 1 mg/kg
#
Brain stem
Forebrain
fgfr1* fgfr4* fgfr2 fgfr3 fgfr4* fgfr3 fgfr2 fgfr1
Diazinon 1 mg/kg Diazinon 2 mg/kg
#
#these neural pathways are among the most
vulnerable to long-term damage after develop-
mental exposure to chlorpyrifos (Aldridge
et al. 2005b; Dam et al. 1999; Slotkin et al.
2002, 2007; Slotkin and Seidler 2007).
Finally, it should be noted that fgf2 is also deﬁ-
cient in dopaminergic neurons in Parkinson
disease (Tooyama et al. 1993) and fgf2 and
fgf20 actually act in concert to protect
dopaminergic neurons from oxidative injury
and to promote their repair (Krieglstein et al.
1998; Ohmachi et al. 2000; Otto and
Unsicker 1990; Shults et al. 2000), so that the
combined deficit in both these neurotrophic
factors, superimposed on organophosphate-
induced oxidative stress, may render striatal
dopamine pathways especially vulnerable. In
particular, in Parkinson disease, degeneration
begins in the brain stem (Braak et al. 2006),
the region in which we found reduced fgf2
expression after neonatal organophosphate
exposure. We therefore anticipate that later in
life, exposed individuals may show a greater
likelihood of neurodegenerative disorders such
as Parkinson disease, which is already known
to be associated with pesticide exposures in
adulthood (Kamel and Hoppin 2004).
In addition to the major changes seen for
fgf2 and fgf20 expression, we found signifi-
cant but smaller effects on other members of
the FGF superfamily, including fgf11, fgf14,
and fgf22, and also on two of the receptor
genes, fgfr1 and fgfr4. Although the roles for
these are less well understood, there is sub-
stantial evidence for involvement of all of
them in neurodevelopment and hence in the
developmental neurotoxicity of the organo-
phosphates. Developing neurons show
particularly high expression of fgf11 and fgf14
(Luo et al. 2002; Wang et al. 2000), and the
latter participates directly in neuronal signal-
ing, axonal trafficking, and development of
sodium channels required for neuronal
excitability (Lou et al. 2005; Wang et al.
2002). Deficits in fgf14 are associated with
the development of movement disorders
(Wang et al. 2002) and it is well established
that early exposure to organophosphates com-
promises the subsequent development of
motor activity (Carr et al. 2001; Dam et al.
2000). Similarly, fgf22, a recently discovered
member of the FGF family, is involved in
neural differentiation of granule cells and acts
as an organizer of presynaptic activity
(Umemori et al. 2004). Again, hippocampal
and cerebellar granule cells are known to be
targeted by developmental exposure to
organophosphates (Abdel-Rahman et al.
2003; Roy et al. 2005) in association with
profound alterations in the patterns of pre-
synaptic neuronal activity and associated
behaviors (Aldridge et al. 2005b; Dam et al.
1999; Icenogle et al. 2004; Levin et al. 2001,
2002; Qiao et al. 2003, 2004; Richardson
and Chambers 2004, 2005; Slotkin et al.
2001, 2002; Slotkin and Seidler 2007). 
Of the two FGF receptor genes for which
we found significant changes, fgfr1 is only
weakly expressed in the developing brain but
probably serves as an organization factor
(Blak et al. 2005); we found only a small
effect on this receptor, restricted to diazinon,
so that this may ultimately contribute to some
differences in outcome between the two
organophosphates. We saw a far more robust
effect on fgf4, again with a greater action of
diazinon as compared to chlorpyrifos. In con-
trast to fgfr1, fgfr4 is highly expressed in devel-
oping brain, especially in the hippocampus
(Cool et al. 2002; Limke et al. 2003; Wright
et al. 2004) and in cholinergic neurons of the
medial habenular nucleus (Miyake and Itoh
1996), and is involved specifically in neurite
outgrowth (Hart et al. 2000). Furthermore,
this receptor binds fgf2, one of the FGF mem-
bers highly affected by organophosphate expo-
sure, reinforcing the greater potential
contribution of this particular signaling path-
way; indeed, the fact that fgf4 was up-regu-
lated suggests that this is a partial, adaptive
response to the suppression of fgf2 expression,
a conclusion reinforced by the fact that diazi-
non was more effective than chlorpyrifos for
both the down-regulation of brain stem fgf2
and the up-regulation of fgfr4. In keeping
with these relationships, developmental expo-
sure to organophosphates especially targets
each of the processes associated with fgfr4:
neurons of the cholinergic phenotype (Slotkin
1999, 2004, 2005), the hippocampus (Abdel-
Rahman et al. 2003; Pung et al. 2006; Roy
et al. 2005; Terry et al. 2003), and neuritic
outgrowth (Axelrad et al. 2003; Das and
Barone 1999; Howard et al. 2005; Slotkin
et al. 2006a; Song et al. 1998).
It is important to note a number of limi-
tations of our approach, which relies on meas-
urement of gene expression at the mRNA
level assessed in two, broadly defined brain
regions. First, the magnitude of changes was
small when compared to the fold-change that
can be obtained with in vitro studies of pesti-
cide neurotoxicity, where typically one
assesses the effects on a single cell type at a
fixed stage of differentiation (Mense et al.
2006). That is hardly surprising, given the
heterogeneity of the brain stem and the fore-
brain, so that even a large change in gene
expression in a speciﬁc cell population would
be “washed out” by mRNA from unaffected
areas. In fact, treatment of animals with
higher doses of organophosphates that pro-
duce outright toxicity or even lethality rarely
produces changes in gene expression exceed-
ing 10–30% in vivo (Betancourt et al. 2006;
Damodaran et al. 2006a, 2006b). 
The second limitation is inherent in any
study of mRNA: this measure by itself does
not provide a definitive answer about the
actual rate of synthesis and degradation of the
encoded protein, the factors that actually con-
trol the concentrations of the corresponding
trophic factors or factors within the cell.
Nevertheless, there are two important aspects
designed into the current study that render
the ﬁndings relevant and interpretable. First,
we included chlorpyrifos as a test compound
whose impact has already been conﬁrmed for
the relevant end points of neural cell differ-
entiation, axonogenesis, and other develop-
mental processes known to be regulated by
FGFs. Second, our interpretations rely on
patterns of changes across multiple regions
and FGF/FGFR subtypes rather than on a
single change in one region. Nevertheless, it
is obvious that a direct mechanistic link
needs to be established between the changes
seen here at the mRNA level and the known
outcomes for chlorpyrifos, or the suspected
outcomes for diazinon. 
Our results are also limited by the fact that
we examined only males, whereas there are
numerous studies showing signiﬁcant sex dif-
ferences in the outcomes of developmental
exposure to organophosphates (Aldridge et al.
2004, 2005a, 2005b; Dam et al. 2000; Levin
et al. 2001; Ricceri et al. 2006; Slotkin 2005;
Slotkin et al. 2001, 2002; Slotkin and Seidler
2007). Here, we were limited primarily by
practical considerations of technical capabilities
and cost. We expect, however, that males and
females will show important differences in
transcriptional proﬁles in accordance with the
sex-selective nature of organophosphate-
induced neurodevelopmental anomalies.
Despite these limitations, though, our results
are likely to be relevant to environmental expo-
sures of fetuses and children to organophos-
phates. Although our studies were modeled
primarily on the upper limits of estimated or
measured exposures after home or agricultural
application (Gurunathan et al. 1998; Ostrea
et al. 2002), recent studies indicate that much
lower, long-term exposures of pregnant women
result in adverse neurodevelopmental outcomes
for their children (Eskenazi et al. 2007; Rauh
et al. 2006; Young et al. 2005). Accordingly,
modeling the potential mechanisms underlying
the adverse effects of these agents at exposures
below the threshold for cholinesterase inhibi-
tion may provide important insights into the
etiology of these orders and thus to potential
strategies for amelioration.
In conclusion, our results show that
neonatal exposure to low doses of organo-
phosphates, below the threshold for any signs
of systemic toxicity and spanning the thresh-
old for any detectable cholinesterase inhibi-
tion, evoke profound and regionally selective
effects on expression of specific members of
the FGF superfamily of neurotrophic factors,
with the largest effects seen for fgf2 and fgf20.
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notable disparities in the responses to chlor-
pyrifos and diazinon, and that robust effects
were seen at a dose of diazinon that does not
inhibit cholinesterase, supports the idea that
organophosphates differ in their propensity to
elicit developmental neurotoxicity, unrelated
to their anticholinesterase activity. Further,
the specific involvement of fgf2 and fgf20 in
development of the hippocampus and stria-
tum matches some of the most sensitive
regional targets for neurodevelopmental dis-
ruption by the organophosphates, reinforcing
the potential mechanistic role of suppression
of these neurotrophic factors in organophos-
phate-induced developmental neurotoxicity. 
The close relationship between deﬁciencies
in these factors and loss of dopamine neurons
in Parkinson disease further indicates the need
for long-term studies of the effects of early
organophosphate exposure, preferably occupy-
ing the entire life span so as to determine
whether developmental exposures lead to later
emergence of neurodegenerative disorders.
Finally, the identification of specific neuro-
trophic factors targeted by organophosphates
may enable the design of targeted, interven-
tional strategies that might prevent or offset
neurodevelopmental damage in cases of
known exposure. For example, increasing the
concentration of FGF2 protein appears to off-
set the functional outcome of neonatal dam-
age to the motor cortex (Monﬁls et al. 2005),
and the neuroprotective effect of nicotine in
animal models of Parkinson disease (Quik and
Di Monte 2001) is associated with its ability
to up-regulate fgf2 expression (Belluardo et al.
2004). The characterization of neurotrophic
factors involved in the developmental neuro-
toxicity of organophosphates thus establishes a
mechanistic link between the initial events in
neural cell damage and the eventual outcome,
while at the same time providing valuable
information to enable discrimination between
the effects of different organophosphates as
well as potential therapeutic interventions to
prevent or offset neural damage.
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Research
Arsenic is abundant in the earth’s crust and
can be released to groundwater under certain
conditions. In many parts of the world where
groundwater is an important source of drink-
ing water, As exposure has been linked to
increased risks of skin lesions, skin cancer,
internal cancers, and cardiovascular diseases
(Chen et al. 1988, 1996; Haque et al. 2003).
Widespread As exposure from drinking water
in Bangladesh and several neighboring coun-
tries, in particular, is presently a public health
emergency (Chakraborti et al. 2003). It has
been estimated that > 50 million people have
been chronically exposed to As by drinking
groundwater with As concentrations exceed-
ing the World Health Organization (WHO)
standard (10 μg/L) in Bangladesh alone
(British Geological Survey 1999). Given the
potential health consequences of As exposure,
there is a need to identify and evaluate an
effective mitigation policy that could poten-
tially be implemented at the national scale. 
Arsenic mitigation in Bangladesh is a
multifaceted public health problem, requir-
ing consideration of geological, engineering,
economical, and cultural constraints. There
still is considerable debate about the technical
advantages and pitfalls of various mitigation
options in Bangladesh. Remediation options
such as piped groundwater, rainwater harvest-
ing, pond-sand ﬁlters, and the use of dug wells
(Anstiss et al. 2001; Berg et al. 2006; Hassan
2005; Hoque et al. 2000, 2004) have been
tested, but the record to date shows that they
may not be safe, affordable, or sufficiently
convenient (Ahmed et al. 2006). These reme-
diation options, all of which require consider-
able maintenance, also deviate from the
currently much more widespread practice of
relying on hand-pumped tube wells, shallow
or deep. This a concern because, from a pub-
lic health standpoint, emergency interventions
are best accomplished through an existing
technology that has already been accepted
(Smith et al. 2000), even if an adjustment to
existing behavior is required. Several studies
have indicated that intervention programs
using health education and/or well labeling
increase the awareness of As-related health
problems (Hadi 2003; Hanchett et al. 2002).
However, the effectiveness of such programs in
reducing As exposure has rarely been evaluated
at a large scale. 
In 2000, researchers from Columbia
University (CU) and partner institutions in
Bangladesh established a large epidemiologic
cohort study of 11,746 men and women to
prospectively evaluate long-term health effects
of As exposure through in-person biennial
follow-up visits. At the same time, a mitiga-
tion program was initiated to promote
switching to safe wells in order to reduce the
continuing As exposure in the population.
The impact of some of the component inter-
ventions evaluated on the basis of interviews
has been reported previously for subsamples
of the cohort (Madajewicz et al. 2006; Opar
et al. 2007; Schoenfeld 2006). In this article
we document for the ﬁrst time the effective-
ness of the mitigation program in terms of As
exposure directly by comparing As concentra-
tion in the urine of cohort members at base-
line and 2 years later. We also assess various
host factors that may further inﬂuence urinary
arsenic reduction in a subpopulation. 
Methods
The Health Effects of Arsenic Longitudinal
Study. The principal aim of the Health Effects
of Arsenic Longitudinal Study (HEALS) is to
investigate health effects of As exposure from
drinking water in a well-defined geographic
area of 25 km2 in Araihazar, Bangladesh.
Details of the study methodologies have been
presented elsewhere (Ahsan et al. 2006a;
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Reduction in Urinary Arsenic Levels in Response to Arsenic Mitigation Efforts
in Araihazar, Bangladesh
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BACKGROUND: There is a need to identify and evaluate an effective mitigation program for arsenic
exposure from drinking water in Bangladesh. 
OBJECTIVE: We evaluated the effectiveness of a multifaceted mitigation program to reduce As expo-
sure among 11,746 individuals in a prospective cohort study initiated in 2000 in Araihazar,
Bangladesh, by interviewing participants and measuring changes in urinary As levels. 
METHODS: The interventions included a) person-to-person reporting of well test results and health
education; b) well labeling and village-level health education; and c) installations of 50 deep, low-As
community wells in villages with the highest As exposure. 
RESULTS: Two years after these interventions, 58% of the 6,512 participants with unsafe wells
(As ≥ 50 µg) at baseline had responded by switching to other wells. Well labeling and village-level
health education was positively related to switching to safe wells (As < 50 µg/L) among participants
with unsafe wells [rate ratio (RR) = 1.84; 95% conﬁdence interval (CI), 1.60–2.11] and inversely
related to any well switching among those with safe wells (RR = 0.80; 95% CI, 0.66–0.98). The
urinary As level in participants who switched to a well identiﬁed as safe (< 50 µg As/L) dropped
from an average of 375 µg As/g creatinine to 200 µg As/g creatinine, a 46% reduction toward the
average urinary As content of 136 µg As/g creatinine for participants that used safe wells through-
out. Urinary As reduction was positively related to educational attainment, body mass index,
never-smoking, absence of skin lesions, and time since switching (p for trend < 0.05). 
CONCLUSIONS: Our study shows that testing of wells and informing households of the consequences
of As exposure, combined with installation of deep community wells where most needed, can effec-
tively address the continuing public health emergency from arsenic in drinking water in Bangladesh.
KEY WORDS: arsenic, Bangladesh, epidemiology, environmental epidemiology, intervention. Environ
Health Perspect 115:917–923 (2007). doi:10.1289/ehp.9833 available via http://dx.doi.org/ [Online
5 February 2007]Parvez et al. 2006; van Geen et al. 2002).
Briefly, before subject recruitment into the
cohort, water samples were collected in two
stages and geographic coordinates were
recorded for each well using handheld global
positioning system (GPS) receivers. During the
ﬁrst stage (Figure 1), 4,999 contiguous wells in
the area were sampled in March–June 2000
(van Geen et al. 2002, 2003b). During the sec-
ond stage, 978 wells were sampled in a con-
tiguous region during November–December
2001 (van Geen et al. 2003b). Demographic
information about the users of the 5,966 wells
was collected during both stages to provide a
sampling framework for HEALS (Parvez et al.
2006).
Eligibility criteria for recruitment in the
cohort study during the baseline visits
included being married (in order to increase
stability of residence), being at least 18 years
of age, and having resided in the study area
for ≥ 5 years. Upon verification of identity
and eligibility of subjects, the interviewers
explained the details of the study objectives
and procedures. Because the average educa-
tional attainment was low in the population
(50% did not have formal education), verbal
consent was obtained from each eligible
respondent who agreed to participate in the
study. Participants were given the option of
participating with or without donating a
blood/urine sample (Ahsan et al. 2006a). A
total of 11,746 men and women (a participa-
tion rate of 97.5%) were recruited at baseline
into the HEALS cohort between October
2000 and May 2002. The HEALS cohort has
since been followed at 2-year intervals. 
The ﬁrst 2-year follow-up visit took place
between June 2002 and June 2004 (Figure 1).
At both baseline and follow-up visits, detailed
information on demographics, lifestyles, and
well-water drinking history was collected with
in-person interviews. Trained physicians who
were blind to participants’ As exposure status
completed a comprehensive physical examina-
tion (Ahsan et al. 2006a). A spot urine sample
was collected in 50-mL acid-washed tubes at
baseline and the follow-up visits for 95.6%
and 94.5% of the cohort participants, respec-
tively. The study protocol and ﬁeld procedures
were approved by theCU Institutional Review
Board and by the Ethical Committee of the
Bangladesh Medical Research Council.
Arsenic mitigation under HEALS. Several
As mitigation programs were implemented by
the HEALS investigators, in part concurrently
with the baseline recruitment of participants
and follow-up (Figure 1).
In-person communication of test results
and health education at baseline. After the
completion of baseline physical examinations
and interviews, all study participants received
an individual health education session from
trained interviewers concerning As concentra-
tions in their well and potential health impacts
related to As exposure. Participants who con-
sumed well water with As concentrations
≥ 50 μg/L were speciﬁcally advised to switch,
if possible, to nearby safer well(s), deﬁned as
wells with As concentrations < 50 μg/L.
Participants who consumed well water with As
concentrations < 50 μg/L were not advised to
switch wells.
Well labeling and education campaign at
the village level. During January–June 2001,
in the area where the ﬁrst stage of well water
sampling took place, metal placards with As
concentrations were posted on each well after
testing. During the same period, an education
campaign was launched at the village level. A
team of three educators traveled from village
to village. Through the use of skits, songs, and
focus-group discussions, they disseminated
information on health problems related to As
exposure in drinking water, the ineffectiveness
of various popular ways of As removal (e.g.,
boiling water), the importance of switching
wells to reduce As exposure, and the meaning
of the metal placards posted on the wells. The
team also advised that people with unsafe wells
should change to a well with a lower level of
As if a safe well (based on the Bangladesh stan-
dard of As < 50 μg/L) was not available in the
vicinity (Madajewicz et al. 2006). There was
no village-level education in the smaller area
where the second stage of well-water sampling
took place, and these wells were not labeled
until 2004 when the follow-up survey was
completed.
Installations of deep low-As community
wells. From 2001 to 2004, but primarily in
2003, a total of 50 deep, low-As community
wells were installed across the 25-km2 study
area, generally in villages where As exposure
was particularly high. A description of house-
hold response to the ﬁrst 7 of these commu-
nity wells has been described elsewhere
(van Geen et al. 2003a). The depths of these
50 low-As wells ranged from 36 to 180 m; all
community wells met the Bangladesh stan-
dard for As of 50 μg/L, and only two did not
also meet the WHO guideline for As of
10 μg/L (Opar et al. 2007).
Independently of CU and its local part-
ners, most wells within the study area were
painted red or green in 2003 after testing with
Hach field kits by NGO (nongovernmental
organization) workers hired under the
Bangladesh Arsenic Mitigation and Water
Supply Program (BAMWSP; 2007). Relative
to the national standard for arsenic in drinking
water of 50 μg/L, these results agreed with our
laboratory tests for 88% of a randomly
selected subset of 799 wells (van Geen et al.
2005). The inconsistencies were primarily
underestimates in the 50–100 μg/L range of
arsenic concentrations that resulted in unsafe
wells being labeled as safe. 
Measurements of As exposure. Water sam-
ples from all 5,966 tube wells in the study area
were collected in 60-mL acid-washed bottles
after pumping each well for 5 min (van Geen
et al. 2003b). Total As concentrations were
first determined by graphite furnace atomic-
absorption spectrometry (GFAA) with a
Hitachi Z-8200 system (Hitachi, Tokyo,
Japan) at the Lamont-Doherty Earth observa-
tory of CU (van Geen et al. 2002). Water
samples found to have As concentrations at or
below the detection limit of GFAA (5 μg/L)
were later reanalyzed by inductively-coupled
plasma-mass spectrometry, which has a detec-
tion limit of 0.1 μg/L (Cheng et al. 2004).
All urine samples collected at baseline and
at follow-up visits were analyzed for total As
concentration by GFAA using the Analyst 600
graphite furnace system (PerkinElmer,
Wellesley, MA, USA), as previously described
(Nixon et al. 1991). Urinary creatinine was
analyzed using a method based on the Jaffe
reaction for adjustment of urinary total As
concentration (Yu et al. 2002). The concen-
tration of total As in urine has often been used
as an indicator of recent exposure because
urine is the main route of excretion of most
arsenic species. Therefore, we consider urinary
As concentration to be a good measure of
changes in As exposure over time.
Statistical analysis. We evaluated the deter-
minants of switching wells in participants with
safe and unsafe wells separately at baseline,
because only the participants with unsafe wells
were advised to switch. We defined a “safe
well” according to the Bangladesh standard of
< 50 μg/L As in drinking water. Because
switching wells is a dichotomized outcome and
Chen et al.
918 VOLUME 115 | NUMBER 6 | June 2007 • Environmental Health Perspectives
Figure 1. Timeline of HEALS activities. Bars indicate time period for activities; black bars indicate collection
of urine samples.
First follow-up visits
Installation of deep, low-As wells
Well labeling and education campaign for stage 1 area
Baseline recruitment and in-person health education
Well testing, stage 2
Well testing, stage 1
2000 2001 2002 2003 2004 2005
Yearthe analysis involved follow-up time, we used
Cox proportional hazard models to compare
the likelihood of switching wells among groups
with different attributes. We computed rate
ratios (RR) for any well switching in partici-
pants with safe wells at baseline, and RRs for
switching to known safe wells in participants
with unsafe wells at baseline. A total of
423 participants had either died (n = 104) or
moved (n = 270) since recruitment or were lost
at the time of the follow-up survey (n = 49);
therefore, their well-switching status was
treated as censored. We calculated person-
years of observation from the date of baseline
visit to the date of well switching (reported at
the follow-up) for those who switched wells, to
the date of follow-up visit for those who did
not switch, to death date and date of move
reported by close relatives or neighbors for
those who had died and moved, respectively.
For the 49 subjects who were lost to follow-up,
person-years of observation were considered
from baseline to the midpoint between base-
line and follow-up. Sensitivity analysis was
conducted by excluding these subjects, and
results did not change appreciably (data not
shown). We included a total of 11,280 partici-
pants in this analysis (96% of the overall par-
ticipants); those with unknown values on any
of the covariates (n = 466) were excluded from
the analysis.
Urinary arsenic is a continuous variable,
and therefore multiple linear regression models
were conducted to assess changes in urinary As
level by baseline well-As level and switching sta-
tus at follow-up. The underlying assumption of
the models was that the relationship between
variables is linear. Models were also run with
log-transformed urinary As values; the results
were similar and therefore are not shown.
Participants with data on urinary As at both vis-
its, known well-switching status, age, body
mass index (BMI), and sex (n = 10,645; 90% of
the overall participants) were considered in this
analysis. Those who were excluded from the
analysis did not differ appreciably from those
included in the analysis with respect to demo-
graphic and lifestyle factors and arsenic expo-
sure attributes (data not shown). To evaluate
host factors that may influence urinary As
reductions, we included participants with
unsafe wells at baseline who switched to known
safe wells (n = 1,517) because well As concen-
tration at baseline and follow-up could be sta-
tistically held constant for this group. All
analyses were performed using SAS, version 8.0
(SAS Institute Inc., Cary, NC, USA).
Results
As previously described (Ahsan et al. 2006b),
the study population in general had a low edu-
cational level and included more females and
middle-aged participants (Table 1). The distri-
bution of sex, age, educational attainment, or
land ownership does not differ appreciably by
baseline well-As categories. Well labeling and
the health education campaign at baseline cov-
ered a greater proportion of participants with
low As exposure. The proportion of partici-
pants with unsafe and safe wells that switched
to a new source of drinking water averaged
58% and 17%, respectively (Table 1). Among
participants with unsafe wells, most partici-
pants that changed their source of water
switched to safe wells that were either labeled
or installed by CU, or installed by an
NGO/DPHE (Department of Public Health
Engineering) (27%). The next largest propor-
tion of participants with unsafe wells switched
to tube wells that had not been sampled at
baseline (23%). Among participants with safe
wells at baseline, the majority of participants
who changed their source of water switched to
a new tube well or another safe well labeled by
CU. The majority (83%) of participants with
unsafe wells at baseline who later switched
wells did so because their wells were unsafe,
whereas the majority (64%) of participants
with safe wells at baseline who later switched
wells stated they did so for convenience.
Among participants with unsafe wells at
baseline, those with 5–9 and ≥ 10 years of edu-
cation were more likely to switch to safe wells
(wells labeled by CU, installed by CU, or
installed by an NGO/DPHE), compared with
those with < 5 years of education; the associ-
ated RRs were 1.36 [95% conﬁdence interval
(CI), 1.17–1.58] and 1.61 (95% CI,
1.36–1.74), respectively (Table 2). Land own-
ership, on the other hand, was inversely related
Effectiveness of arsenic mitigation
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Table 1. Baseline and follow-up characteristics by baseline well As levels.
< 50 µg/L  ≥ 50 µg/L 
Characteristica (n = 5,234) (n = 6,512) p-Value
Baseline characteristics
Percent male 42.8 43.0 0.78
Years of age (%) 
17–39 60.6 60.4
40–59 37.2 37.3
60–75 2.2 2.3
Mean ± SD 37.1 ± 10.1 37.0 ± 10.1 0.58
Health education/well labeling (%) < 0.01
Yes 85.4 78.8
Acres of land owned (%)
0 49.4 51.8 0.08
≤ 1 32.2 30.6
> 1 16.0 15.6
Amount unknown 2.3 2.0
Years of education (%)
0 44.3 44.9 0.58
< 6 29.3 29.8
6–9 15.2 14.7
≥ 10 11.2 10.7
Mean ± SD 3.5 ± 3.9 3.4 ± 3.8 0.09
Mean well As (µg/L) 14.9 171.1 < 0.01
Presence of As-related skin lesions (%) 4.4 9.4 < 0.01
Creatinine-adjusted urinary As [µg/g creatinine (mean ± SD)] 141.7 ± 115.7 397.1 ± 324.0 < 0.01
Distance to the nearest safe well [meters (mean ± SD)] 14.8 ± 13.7 48.5 ± 38.7 < 0.01
Follow-up characteristics
Time since baseline [months (mean ± SD)] 23.5 ± 5.3 25.3 ± 7.0 0.39
Creatinine-adjusted urinary As [µg/g creatinine (mean ± SD)] 136.3 ± 108.1 291.9 ± 265.6 < 0.01
Changes in creatinine-adjusted urinary As –6.2 ± 107.4 –108.6 ± 319.9 < 0.01
[µg/g creatinine (mean ± SD)]b
Switching status (%) < 0.01
Did not switch 82.7 41.9
Switched to a safe well labeled by CU 5.7 20.3
Switched to a community well installed by CU 0.0 4.1
Switched to an NGO well 0.4 2.4
Switched to an unsafe well labeled by CU 0.9 8.7
Switched to new tube wells 10.4 22.6
Reasons for switching, within those who switched (%)
Well not safe  5.8 83.4 < 0.01
Smell/taste not good 5.7 1.5
Deleterious relations with neighbor/owner 5.7 0.8
Well no longer exists 4.2 1.3
Well does not work 14.7 3.2
For convenience 63.8 9.7
aData on education level were missing for 5 subjects with safe wells (< 50 µg/L As) and for 4 subjects with unsafe wells
(≥ 50 µg/L As) at baseline; data were unknown on baseline skin lesion status for 138 and 75 subjects, respectively; data
were missing for baseline urinary As for 378 and 148 subjects; data were missing on distance to the nearest safe well for
136 and 101 subjects; data were missing on follow-up urinary As for 340 and 299 subjects; and data were missing on well-
switching status for 314 and 271 subjects, respectively. bChanges in creatinine-adjusted urinary As = follow-up – baseline. to switching to safe wells, although not at the
statistically signiﬁcant level of p < 0.05. Well
labeling and the village-level health campaign
were positively associated with subsequent
switching to safe wells (RR = 1.84; 95% CI,
1.60–2.11). Higher baseline As concentration
was also positively related to the likelihood of
switching to safe wells. An estimate of the dis-
tance from each unsafe well to the nearest safe
well was calculated on the basis of the available
GPS data (van Geen et al. 2002). Participants
with unsafe wells located within 50 m of a safe
well were approximately 4 times more likely to
switch to safe wells compared with participants
with an unsafe well located ≥ 100 m from a
safe well. Among participants with safe wells
at baseline, well labeling and the village-
level health campaign were inversely related
to switching wells (RR = 0.80; 95% CI,
0.66–0.98) (Table 2). In this group, no appar-
ent relationships were observed between
switching wells and educational attainment,
baseline well As level, or distance to the nearest
safe well among participants with safe wells. In
both groups, the presence of lesions led to a
somewhat higher proportion of switching wells
(Table 2).
At baseline, urinary As concentration was
on average nearly 3 times higher for partici-
pants using unsafe wells (397 μg As/g creati-
nine) compared with those using safe wells
(141 μg As/g creatinine; Table 1). Average
concentrations of As in unsafe and safe well
water differed by more than an order of mag-
nitude (171 and 15 μg/L, respectively). At
follow-up, urinary As levels in participants
with unsafe wells at baseline dropped by
109 μg As/g creatinine (Table 1). This reduc-
tion is attributable to switching wells
(Figure 2). The average drop of urinary As in
participants who switched to a safe well ranged
from 29 to 65%, according to the types of
wells participants switched to, with an overall
average drop of 46% from 375 to 200 μg As/g
creatinine. Most signiﬁcantly, the urinary As
level dropped from 491 to 172 μg As/g creati-
nine in participants who indicated that they
had switched to deep, low-As community wells
(Figure 2). The urinary As level in participants
who switched to a new well or another unsafe
well also decreased. Urinary As levels did not
change appreciably in the population that con-
tinued to rely on a safe well or in participants
with an unsafe well at baseline who had not
switched to a different well (Figure 2). 
The determinants of changes in urinary As
were examined in greater detail for the 1,517
participants with unsafe wells who switched to
known safe wells. We controlled for baseline
urinary As level, baseline well As level, and well
As level at the time of follow-up in the analysis
to evaluate the influences of host factors on
changes in urinary As in excess of what can be
explained by differences in As exposure. The
Chen et al.
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Table 2. Associations of switching wells with sociodemographics and As-related variables.
Participants with a safe  Participants with an unsafe 
well at baselinea well at baselinea
Switched to  Switched to 
any well a safe well
Yes (%  RR for  Yes (%  RR for switching to
Baseline characteristic of total)b Totalb switching (95% CI) of total)b Totalb a safe well (95% CI)
Education (years)
0 16.3 2,241 1.00 23.4 2,777 1.00
1–4 18.6  1,485 1.17 (0.98–1.37) 25.1  1,867 1.14 (1.01–1.28)
5–9 15.1  768 0.96 (0.77–1.19) 28.2  916 1.36 (1.17–1.58)
≥ 10 13.7  554 0.92 (0.71–1.19) 30.1  672 1.61 (1.36–1.92)
Land owned (acres)
0 17.8 2,505 1.00 25.3 3,216 1.00
≤ 1 16.2 1,616 0.92 (0.78–1.07) 25.9 1,920 0.93 (0.83–1.04)
> 1 14.0 813 0.83 (0.67–1.04) 24.8 977 0.83 (0.71–1.01)
Amount unknown  9.7 114 0.53 (0.29–0.97) 21.9 119 0.75 (0.51–1.11)
Baseline skin lesion status
No 16.2 4,828 1.00 25.0 5,656 1.00
Yes 22.7  220 1.56 (1.16–2.10) 28.5 576 1.15 (0.99–1.38)
Health education and well labeling
No 17.1 756 1.00 16.8  1,338 1.00
Yes 16.4  4,292 0.80 (0.66–0.98) 27.7  4,894 1.84 (1.60–2.11)
Baseline well As (µg/L)
< 10 16.1  2,631 1.00
10–24 17.5 1,006 1.07  (0.90–1.28)
25–49 16.6 1,411 0.97  (0.82–1.14)
50–99 23.0 1,988 1.00
100–299 25.6 3,433 1.38  (1.23–1.55)
300–499 29.3 724 1.62 (1.37–1.90)
≥ 500 34.5 87 1.85  (1.26–2.72)
Distance to nearest safe well (m)
≥ 100 0.0 10 1.00 11.3  648 1.00
50–99 13.2 211 20.8  1,691 2.22  (1.72–2.86)
25–49 18.5  552 1.38 (0.90–2.09) 30.0  1,886 3.71 (2.90–4.73)
< 25 16.4  4,275 1.22 (0.83–1.78) 29.2  2,007 3.95 (3.09–5.06)
aRRs were adjusted for all variables in the table and additionally for age and sex. A total of 11,280 subjects were included
in the analysis; participants with unknown information for any of the covariates were excluded from the analysis. b“Total”
indicates the number of participants with the attribute, and “% of total” indicates the percentage of persons with that
attribute that switched wells.
Figure 2. Mean urinary creatinine-adjusted As levels for participants with an unsafe well at baseline (A)
and for those with a safe well at baseline (B). Additional adjustments were made for age, sex, and BMI.
Values above the bars are average baseline well As concentration and number.
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Baseline
Follow-up 154 μg/L
(n = 2,442)
262 μg/L
(n = 242)
160 μg/L
(n = 1,207)
236 μg/L
(n = 134)
181 μg/L
(n = 1,300)
205 μg/L
(n = 506)
15 μg/L
(n = 3,990)
17 μg/L
(n = 275)
17 μg/L
(n = 20)
14 μg/L
(n = 486)
20 μg/L
(n = 43)reduction in urinary creatinine-adjusted As
was significantly greater in men (p for trend
= 0.01) and in participants who had never
smoked (p for trend = 0.03), had a higher
BMI (p for trend = 0.01), had higher educa-
tion (p for trend = 0.01), and had no skin
lesions at baseline (p = 0.04) (Table 3). The
drop in urinary As increased with time elapsed
since switching (p for trend = 0.02) but
reached a plateau after a duration of
≥ 12 months since switching wells. Within
participants who switched from an unsafe to a
safe well, the reduction in urinary As did not
differ signiﬁcantly by the distance to the near-
est safe well, land ownership, or the status of
well labeling and village-level health education. 
Discussion
The high proportion of the Bangladesh popu-
lation that is exposed to arsenic by drinking
water from tube wells remains a public health
emergency. The present study is the ﬁrst large
prospective analysis to examine the effective-
ness of an As intervention program in terms
of well-switching behavior and changes in uri-
nary As concentrations. 
Among participants with unsafe wells at
baseline, 58% switched to other wells at 
follow-up. The extent of well switching we
recorded in the study area for the entire
2002–2004 period is consistent with smaller
but more rapid surveys conducted in the same
study area in 2002 (Madajewicz et al. 2006)
and in 2004 (Opar et al. 2007). In a portion
of Araihazar adjacent to the study area, where
wells were tested under BAMWSP but the
message was not reinforced through addi-
tional health education, only 27% of house-
holds stopped using 1,870 wells that had been
tested to be unsafe (Schoenfeld 2006). In
other parts of Bangladesh where blanket
testing was conducted by UNICEF, 38% of
the test population switched from 6,359
unsafe wells (Sarker et al. 2005). These com-
parisons suggest that our team’s continued
presence in the study area significantly
encourages switching of wells. The signiﬁcant
positive association between well labeling/vil-
lage-level health campaigns and switching to
safe wells among participants with unsafe
wells (Table 2) conﬁrms the reinforcing effect
of these additional efforts. 
Participants with unsafe wells who
switched to new wells that were not tested by
CU, but were possibly tested by BAMWSP, on
average did not increase their exposure to As
(Figure 2). However, the urinary As levels of
these participants indicate that a significant
number of these wells probably contain
> 50 μg/L As. These data emphasize that well
testing should be made available on demand at
the village level. The drop in urinary As among
participants with unsafe wells who switched to
a different unsafe well suggests that they sought
wells with a lower As content than their own,
albeit still unsafe. This is an argument for not
only labeling wells as safe or unsafe but also for
indicating each well’s actual As level, as was
done in our study area. The dose–response
relationship between baseline well As level and
switching behavior among participants with
unsafe wells at baseline (Table 2) also suggests
that participants take into account the actual
As concentration that was measured and not
only its safe/unsafe status. 
Consistent with previous analyses of sub-
population in the study area (Madajewicz et al.
2006; Opar et al. 2007; Schoenfeld 2006), we
found that switching wells drops off rapidly
when safe wells are located ≥ 100 m away. The
largest drop in urinary As observed in those vil-
lages where participants benefited from the
installation of a community well is consistent
with the consumption of water with high As
(mean 258 μg/L) at baseline and < 10 μg/L at
follow-up (van Geen et al. 2006). In view of
the particularly beneﬁcial effect of community
wells that are periodically monitored
(van Geen et al. 2006), the spatial density of
such wells in different villages should be calcu-
lated to minimize the number of households
that live > 100 m from a safe water source. The
large existing database of close to 5 million well
tests compiled under BAMWSP could be used
effectively to produce such estimates and help
target those aquifers that are systematically low
in As (van Geen et al. 2006).
We observed positive relationships of
switching to safe wells and urinary As reduc-
tion with educational attainment but not with
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Table 3. Determinants of urinary As changes (follow-up – baseline) among participants with an unsafe
baseline well who switched to a safe well (n = 1,517).
Adjusted changes in urinary
creatinine-adjusted Asa p-Values for 
Characteristics No. Mean SD trend tests 
Sex
Female 885 –171.4 13.0 0.01
Male 632 –186.4 12.4
Education (years)
0 621 –159.2 13.6 0.02
1–4 451 –170.1 13.7
5–9 249 –165.0 15.2
≥ 10 196 –200.6 16.6
Land owned (acres)
0 790 –162.0 11.0 0.93
≤ 1 470 –160.3 11.8
> 1 234 –155.6 13.9
Amount unknown 23 –216.9 33.0
Age (years)
< 30 385 –166.2 15.0 0.45
30–39 511 –175.9 14.1
40–49 403 –165.5 13.8
≥ 50 218 –187.2 15.7
BMI
< 17.6 402 –155.5 14.2 0.02
17.6–19.2 401 –172.9 14.6
19.3–21.5 349 –186.3 14.4
≥ 21.6 365 –180.1 14.3
Baseline smoking status
Never-smokers 999 –189.6 13.0 0.03
Past smokers 93 –171.2 19.3
Current smokers 425 –160.3 14.7
Baseline skin lesion status
No 1,357 –186.8 11.8 0.04
Yes 160 –160.6 16.4
Health education and well labeling
No 217 –172.7 15.4 0.73
Yes 1,300 –174.7 12.1
Time since switching wells (months)
< 6 126 –160.3 17.0 0.03
6–11 117 –156.2 18.4
12–17 364 –180.1 14.2
18–23 507 –185.1 13.9
≥ 24 403 –186.8 15.0
Distance to the nearest safe well (m)
< 25 560 –166.1 13.0 0.44
25–49 548 –180.9 12.9
50–99 339 –171.8 14.4
≥ 100 70 –176.0 21.7
aFollow-up – baseline; means were adjusted for all variables in the table and baseline urinary creatinine-adjusted As,
baseline well As, and well As level in the wells participants switched to.land ownership (Tables 2 and 3). Persons with
higher educational attainment may be more
responsive to health education and interven-
tion. On the other hand, persons who own
land may be less likely to switch wells because
they may tend to use their own well located in
the property. Such relationships between well
switching and different indicators of socio-
economic status need to be considered in the
plan and design of intervention programs. 
BMI was positively related to urinary As
reduction. A high BMI in Bangladesh is an
indicator of a better nutrition status, which
may inﬂuence the excretion of As. Smoking of
tobacco products and presence of skin lesions
were inversely associated with the reduction of
total urinary As, indicating that these factors
may be related to a higher body burden of As
or a reduced clearance of As from the body.
These observations are consistent with our
previous ﬁndings of a synergistic effect of high
level of As exposure with tobacco smoking and
low BMI on the risk of skin lesions (Ahsan
et al. 2006b; Chen et al. 2006).
It is worth noting that there was consider-
able overlap between the timing of the various
interventions and when the baseline data were
collected (Figure 1). Wells were labeled and
participants were exposed to village-level
health education before collection of the
majority of baseline urine samples. The instal-
lation of most of the deep community wells
took place in 2003, after the follow-up survey
for a considerable number of participants, and
the associated change in behavior and reduc-
tion in urinary As level may not have been
fully captured. In addition, although the ini-
tial half-life of As is short (Buchet et al. 1981;
Pomroy et al. 1980), the literature has docu-
mented that the human body storessubstantial
amounts of As (Farmer and Johnson 1990)
and may excrete it in urine over a period of
time, even after the exposure has ceased
(Aposhian et al. 1997). Therefore, the urinary
As level in persons with high exposure who
switched to safe wells may not immediately
respond to a drop in well As level. Together,
these considerations suggest that the effective-
ness of the intervention in reducing urinary
As level may therefore be somewhat under-
estimated in the present study.
Switching to a safe well can reduce urinary
As to levels almost as low as that observed in
residents consuming water with < 50 μg/L.
The large drop in urinary As for participants
who switched from an unsafe well to a known
safe well, almost to levels in the control popu-
lation, is very encouraging. On the basis of
these observations, we urge a revision of the
governmental policy to reinforce the effective-
ness of a community-based mitigation pro-
gram that relies on deeper, low-As aquifers
(Ahmed et al. 2006). Signiﬁcant As contami-
nation in deep aquifers is unlikely unless large
amounts of water are withdrawn for irrigation
(Zheng et al. 2005). Additional governmental
efforts may therefore have to be considered to
manage irrigation (Ahmed et al. 2006). 
Our findings not only indicate that
response surveys based on interviews are reliable
but they also suggest a decrease in an internal
biomarker of exposure that may lead to future
health beneﬁts. Several studies have suggested
that As mitigation eventually reduces As-associ-
ated morbidity. Pi et al. (2005) found that a
13-month period of consuming low-As water
improved the vascular response to cold stress in
Inner Mongolia, China. Another study in
Chile found that provision of water with low
As (45 μg/L) for 8 weeks was associated with a
decrease in micronucleated cells in exfoliated
bladder cells (Moore et al. 1997). On the other
hand, a reduction in ischemic heart disease
mortality and kidney cancer mortality was
observed only decades after tap water (As free)
was provided in an arseniasis-endemic area in
Taiwan (Chang et al. 2004; Yang et al. 2004).
We recently described a dose–response rela-
tionship between prevalence of As-related skin
lesions and As exposure at baseline even at
water As levels < 50 μg/L (Ahsan et al. 2006b).
The average time of exposure to baseline wells
(8 years) was relatively longer than the average
duration of switching wells (1.9 years). The
extent to which As-related morbidity and
mortality in this population is reversible by
the reduction of As exposure awaits further
examination with a longer follow-up of the
population. The cost-effectiveness or cost–
beneﬁt issues also need to be addressed to eval-
uate the overall impact on the society when
such data are available in the future. 
Removal of As from groundwater, or
human pathogens from surface water, is eco-
nomically and culturally challenging, particu-
larly on a large scale (Ahmed et al. 2006).
Based on the quantitative evidence presented
here, it appears that testing and monitoring of
wells managed at the village level, combined
with judicious installation of low-As deep
community wells in high exposure areas,
could rapidly reduce As exposure at the
national scale.
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